[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Wilson-Cook Medical Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":375},{"warningLetters":4,"total":374},[5,31,48,66,87,107,125,147,170,187,203,222,244,265,282,299,319,336,354],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},778,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-07-15T04:00:00Z\">07\u002F15\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-09T04:00:00Z\">07\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcovalent-medical-695839-07092025\">Covalent Medical \u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Nonprescription\u002FOTC","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Clint Worley, COO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Covalent Medical \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>24600 Millstream Drive, Ste 410\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Aldie\u003C\u002Fspan>, \u003Cspan>VA\u003C\u002Fspan> \u003Cspan>20105\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:CWORLEY@focusvitamins.com\"> CWORLEY@focusvitamins.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>July 9, 2025\u003C\u002Fp>\u003Cp>RE: 695839\u003C\u002Fp>\u003Cp>Dear Mr. Worley:\u003C\u002Fp>\u003Cp>This letter is to advise you that on September 27, 2024 the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including on your website at the internet address, www.focusvitamins.com, where your FOCUS PI Post-Injection Eye Drops product is available for purchase in the United States without a prescription. We also reviewed your social media sites on Instagram (https:\u002F\u002Fwww.instagram.com\u002Ffocus_vitamins\u002F) and Facebook (https:\u002F\u002Fwww.facebook.com\u002Ffocusvitamins), both of which direct consumers to your website to purchase your product(s).\u003C\u002Fp>\u003Cp>Based on our review, your FOCUS PI Post-Injection Eye Drops product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). In addition, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your FOCUS PI Post-Injection Eye Drops product is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples of claims from the product labeling, your website, and your social media posts that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>“FOCUS PI … Post-Injection Eye Drops” [product name on principal display panel (PDP) of product carton labeling and product label]\u003C\u002Fp>\u003Cp>“Long Lasting Relief, Clinically proven to lubricate, hydrate, &amp; relieve the eyes from irritation” [from PDP on product carton labeling]\u003C\u002Fp>\u003Cp>“\u003Cstrong>Use\u003C\u002Fstrong> ▪ For use as a lubricant to prevent further irritation or to relieve dryness of the eye” [from Drug Facts panel on product carton labeling]\u003C\u002Fp>\u003Cp>\u003Cstrong>“Designed for Post-injection Irritation Relief”\u003C\u002Fstrong> [from your website https:\u002F\u002Ffocusvitamins.com\u002Fproducts\u002Ffocus-pi (last visited September 2024)]\u003C\u002Fp>\u003Cp>\u003Cstrong>“Focus PI (Post-injection) eye drops provide relief from irritation associated with eye injections.\u003C\u002Fstrong> As the first product of its kind, Focus Vitamins and founding ophthalmologists formulated Focus PI to help soothe any eye discomfort patients might experience, including irritation and dry eye symptoms after eye injections.” [from your website https:\u002F\u002Ffocusvitamins.com\u002Fproducts\u002Ffocus-pi (last visited September 2024)]\u003C\u002Fp>\u003Cp>“Focus PI is formulated and safe for use immediately after eye injections and\u002For during the following days when your eyes are irritated.” [from your website under FAQS: When should I use Focus PI? https:\u002F\u002Ffocusvitamins.com\u002Fproducts\u002Ffocus-pi (last visited September 2024)]\u003C\u002Fp>\u003Cp>“If you get eye injections, Focus PI is for you! Focus PI are post-injection eye drops that are clinically proven to lubricate, hydrate, &amp; relieve the eyes from irritation that comes after ocular injections.” [from Instagram post with 2 likes on January 23, 2023 https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCn0P_CpMZJM\u002F (last visited September 2024)]\u003C\u002Fp>\u003Cp>“Searching for post-injection relief for your eyes? Focus PI eye drops are clinically proven to lubricate, hydrate, and relieve the eyes from irritation following ocular injections. Shop now…” [from Facebook post on August 15, 2023 https:\u002F\u002Fwww.facebook.com\u002Ffocusvitamins (last visited September 2024)]\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the above evidence of intended use, your FOCUS PI Post-Injection Eye Drops product is intended for use as an ophthalmic demulcent (lubricant) drug product. As described below, this drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for your FOCUS PI Post-Injection Eye Drops drug product.\u003C\u002Fp>\u003Cp>Your drug product is marketed as an ophthalmic demulcent drug product and is subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which generally governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. With respect to nonprescription ophthalmic drug products, such as your FOCUS PI Post-Injection Eye Drops drug product, in order to be GRASE and not a new drug, the product must, among other things, conform to the conditions in the applicable OTC monograph, here OTC Monograph M018: Ophthalmic Drug Products for Over-the-Counter Human Use (hereinafter M018).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, your FOCUS PI Post-Injection Eye Drops drug product does not conform to the conditions specified in M018 for the reasons described below.\u003C\u002Fp>\u003Cp>Specifically, the statements made in your product labeling on your website and social media sites include claims for relief of post-injection irritation, which are not permitted indications for ophthalmic demulcent drug products in monograph M018.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Thus, your FOCUS PI Post-Injection Eye Drops drug product does not comply with the applicable conditions specified in Monograph M018 and has not otherwise been found GRASE.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, this product is a new drug within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which this product would be legally marketed without an approved application. Because there is no approved application in effect for this product, this product is an unapproved new drug. The introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Additionally, your FOCUS PI Post-Injection Eye Drops drug product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your product(s). You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your product(s) are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “695839” in the subject line of your email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\u003Cp>_____________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> M018 reflects the monograph conditions as set forth in the relevant final order(s) established and in effect under section 505G; see Order ID OTC000023, available at FDA’s website OTC Monographs@FDA.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Under M018.60, “Labeling of ophthalmic demulcent drug products”, the permitted indications are listed in M018.60(b).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that the FOCUS PI Post-Injection Eye Drops drug product is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b) of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nClint Worley, COO\n\nCovalent Medical\n\n24600 Millstream Drive, Ste 410\n\nAldie, VA 20105\n\nUnited States\n\nCWORLEY@focusvitamins.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nJuly 9, 2025\nRE: 695839\nDear Mr. Worley:\nThis letter is to advise you that on September 27, 2024 the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including on your website at the internet address, www.focusvitamins.com, where your FOCUS PI Post-Injection Eye Drops product is available for purchase in the United States without a prescription. We also reviewed your social media sites on Instagram (https:\u002F\u002Fwww.instagram.com\u002Ffocus_vitamins\u002F) and Facebook (https:\u002F\u002Fwww.facebook.com\u002Ffocusvitamins), both of which direct consumers to your website to purchase your product(s).\nBased on our review, your FOCUS PI Post-Injection Eye Drops product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). In addition, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\nUnapproved New Drug and Misbranded Drug Violations\nYour FOCUS PI Post-Injection Eye Drops product is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body.\nExamples of claims from the product labeling, your website, and your social media posts that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\n“FOCUS PI … Post-Injection Eye Drops” [product name on principal display panel (PDP) of product carton labeling and product label]\n“Long Lasting Relief, Clinically proven to lubricate, hydrate, & relieve the eyes from irritation” [from PDP on product carton labeling]\n“Use ▪ For use as a lubricant to prevent further irritation or to relieve dryness of the eye” [from Drug Facts panel on product carton labeling]\n“Designed for Post-injection Irritation Relief” [from your website https:\u002F\u002Ffocusvitamins.com\u002Fproducts\u002Ffocus-pi (last visited September 2024)]\n“Focus PI (Post-injection) eye drops provide relief from irritation associated with eye injections. As the first product of its kind, Focus Vitamins and founding ophthalmologists formulated Focus PI to help soothe any eye discomfort patients might experience, including irritation and dry eye symptoms after eye injections.” [from your website https:\u002F\u002Ffocusvitamins.com\u002Fproducts\u002Ffocus-pi (last visited September 2024)]\n“Focus PI is formulated and safe for use immediately after eye injections and\u002For during the following days when your eyes are irritated.” [from your website under FAQS: When should I use Focus PI? https:\u002F\u002Ffocusvitamins.com\u002Fproducts\u002Ffocus-pi (last visited September 2024)]\n“If you get eye injections, Focus PI is for you! Focus PI are post-injection eye drops that are clinically proven to lubricate, hydrate, & relieve the eyes from irritation that comes after ocular injections.” [from Instagram post with 2 likes on January 23, 2023 https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCn0P_CpMZJM\u002F (last visited September 2024)]\n“Searching for post-injection relief for your eyes? Focus PI eye drops are clinically proven to lubricate, hydrate, and relieve the eyes from irritation following ocular injections. Shop now…” [from Facebook post on August 15, 2023 https:\u002F\u002Fwww.facebook.com\u002Ffocusvitamins (last visited September 2024)]\nUnapproved New Drug Violations\nBased on the above evidence of intended use, your FOCUS PI Post-Injection Eye Drops product is intended for use as an ophthalmic demulcent (lubricant) drug product. As described below, this drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for your FOCUS PI Post-Injection Eye Drops drug product.\nYour drug product is marketed as an ophthalmic demulcent drug product and is subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which generally governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. With respect to nonprescription ophthalmic drug products, such as your FOCUS PI Post-Injection Eye Drops drug product, in order to be GRASE and not a new drug, the product must, among other things, conform to the conditions in the applicable OTC monograph, here OTC Monograph M018: Ophthalmic Drug Products for Over-the-Counter Human Use (hereinafter M018).1 However, your FOCUS PI Post-Injection Eye Drops drug product does not conform to the conditions specified in M018 for the reasons described below.\nSpecifically, the statements made in your product labeling on your website and social media sites include claims for relief of post-injection irritation, which are not permitted indications for ophthalmic demulcent drug products in monograph M018.2\nThus, your FOCUS PI Post-Injection Eye Drops drug product does not comply with the applicable conditions specified in Monograph M018 and has not otherwise been found GRASE.3 Accordingly, this product is a new drug within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which this product would be legally marketed without an approved application. Because there is no approved application in effect for this product, this product is an unapproved new drug. The introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nMisbranded Drug Violations\nAdditionally, your FOCUS PI Post-Injection Eye Drops drug product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your product(s). You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your product(s) are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “695839” in the subject line of your email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration\n_____________________________\n1 M018 reflects the monograph conditions as set forth in the relevant final order(s) established and in effect under section 505G; see Order ID OTC000023, available at FDA’s website OTC Monographs@FDA.\n2 Under M018.60, “Labeling of ophthalmic demulcent drug products”, the permitted indications are listed in M018.60(b).\n3 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that the FOCUS PI Post-Injection Eye Drops drug product is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b) of the FD&C Act.","Covalent Medical","covalent-medical-695839-07092025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcovalent-medical-695839-07092025","2026-10-26T08:08:18.901487+00:00","Warning Letter","Issued","2025-07-15","695839","Drugs Over-the-Counter Drugs","Clint Worley, COO","2026-08-19T16:35:27.665+00:00","Via Email","2025-07-09",{"id":32,"raw":33,"subject":12,"body_html":36,"body_text":37,"firm_name":38,"letter_id":39,"created_at":18,"fei_number":19,"letter_url":40,"updated_at":41,"action_type":22,"case_status":23,"posted_date":42,"marcs_cms_no":43,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":44,"body_fetched_at":45,"delivery_method":46,"recipient_title":19,"reference_number":47,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},762,[34,9,35,11,12,13,13,13],"\u003Ctime datetime=\"2025-07-22T04:00:00Z\">07\u002F22\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-chemical-corporation-706007-07092025\">Medical Chemical Corporation\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-91\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Emmanuel R. Didier\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Medical Chemical Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>19250 Van Ness Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Torrance\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90501-1102\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-91\u003C\u002Fp>\u003Cp>July 9, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Didier:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Medical Chemical Corporation, FEI 2013736, at 19430 Van Ness Avenue, Torrance, from February 12 to 18, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>In addition, “MED CHEM Tincture Green Soap” drug product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>Furthermore, we reviewed your firm’s drug listing submissions in FDA’s electronic Drug Registration and Listing System (eDRLS) and found that your drug products, Tincture Green, NDC 12745-041, and Isopropyl Alcohol, NDC 12745-105, are not properly listed as required by section 510(j) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Your firm has not fulfilled its listing obligations under 510(j) of the FD&amp;C Act and 21 CFR 207, which is prohibited under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p), and will render a drug misbranded under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o). The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We reviewed your February 28, 2025 response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures over-the-counter (OTC) topical drug products, including hand sanitizers, Tincture Green Soap USP, and Isopropyl Alcohol 70% v\u002Fv. You failed to adequately perform identity testing on each shipment of each lot of incoming components (e.g., ethanol, glycerin) used in the manufacture of your OTC topical drug products. In addition, you relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\u003C\u002Fp>\u003Cp>Products Containing Ethyl Alcohol and Isopropyl Alcohol\u003C\u002Fp>\u003Cp>You failed to adequately test your incoming component ethyl alcohol (ethanol), used as an active pharmaceutical ingredient (API), for methanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\u003C\u002Fp>\u003Cp>Furthermore, you failed to demonstrate that the component alcohol (“C40B \u003Cstrong>(b)(4)\u003C\u002Fstrong> PROOF SDA 40B ETHYL ALCOHOL BULK”), used to manufacture your drug product Tincture Green Soap USP, meets United States Pharmacopoeia (USP) monograph specifications. For example, we reviewed your raw material specification for your component alcohol and note that the specifications failed to demonstrate performance of the USP monograph identification parts A, B, and C.\u003C\u002Fp>\u003Cp>\u003Cem>Products Containing Ingredients at Risk for Diethylene Glycol or Ethylene Glycol (DEG or EG) Contamination\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You also failed to adequately test your incoming components at high risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination for identity before using them to manufacture your drug products. This includes, but is not limited to, testing of glycerin to determine its appropriate identity, prior to use in manufacturing your OTC topical drug products.\u003C\u002Fp>\u003Cp>Identity testing for glycerin and certain other high-risk drug components includes a limit test in the USP to ensure the component meets the relevant safety limits for DEG or EG levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\u003Cp>In your response, you state that you perform identity testing, use raw materials certified by trusted suppliers, and have added or will add certain assays to your specifications. Your response is inadequate because you do not provide adequate details to demonstrate identity testing meets all compendial requirements. Furthermore, your response does not address testing your high-risk drug components for DEG or EG contamination, or test ethanol for the presence of methanol contamination. Also, you do not address the potential impact on drug products in the U.S. market within expiry.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications before use in the manufacture of your drug products. You are responsible for sampling, testing, and examining drug components before use in production to ensure acceptable quality parameters are met.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of alcohol, isopropyl alcohol, glycerin, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\u003Cli>A commitment to provide methanol test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of components within expiry of manufactured drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of methanol.\u003C\u002Fli>\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You used “\u003Cstrong>(b)(4)\u003C\u002Fstrong> water” as a component to manufacture your OTC topical drug products. However, you have not established that the water system is adequately designed, maintained, and monitored to ensure that it consistently produces water suitable for its intended use. You lacked water system validation and failed to conduct total organic carbon (TOC) testing to ensure that your component water met \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water United States Pharmacopeia (USP) monograph specifications.\u003C\u002Fp>\u003Cp>Additionally, you obtained excessive microbial growth from the point of use, “\u003Cstrong>(b)(4)\u003C\u002Fstrong> (No hose)” location, following \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system maintenance sanitization cycles. The inadequate control of your water system poses a potential risk for objectionable microbiological contamination into your drug products.\u003C\u002Fp>\u003Cp>In your response, you state that you will “revalidate” your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system and include TOC testing in your water specification. Your response is inadequate because you do not provide your initial water system validation, nor do you provide adequate details regarding your plan for performing water system validation, maintenance, and testing of the water system. Furthermore, you do not provide a timeline for the validation of your methods, nor do you consider retrospective testing of retained finished drug products that used water.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> water for pharmaceutical use must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes. Routine monitoring of microbial counts and identity of contamination in the system is integral to ensuring oversight of ongoing state of control and suitability of water for use in manufacturing operations.\u003C\u002Fp>\u003Cp>Furthermore, test methods must be validated to show they are suitable for their intended use, and equivalent or better than applicable USP compendial methods. The reproducibility of your test methods is essential to determine if your drug products meet established specifications for microbial attributes. The ability of microbial testing methods to detect objectionable microorganisms in the presence of each drug product must be established.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system. Ensure that the total count limits for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water are appropriately stringent in view of the intended use of each of the products produced by your firm. Total microbial count limits for \u003Cstrong>(b)(4)\u003C\u002Fstrong> water systems are generally tighter than your proposed action limits for the topical liquid dosage forms produced by your firm.\u003C\u002Fli>\u003Cli>A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the system consistently produces water that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\u003Cli>Validation of your microbiological test methods, including growth promotion testing, demonstrating they are equivalent to, or better than USP compendial methods, and suitable for their intended use.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) failed to perform adequate oversight for the manufacture and testing of your OTC topical drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\u003Cul>\u003Cli>Establishment and review of adequate batch production and control records for each batch of drug product which include complete information regarding each significant step in the manufacture, processing, packing, or holding of the batch (21 CFR 211.188(b)).\u003C\u002Fli>\u003Cli>Establishment and review of adequate laboratory records which include all data obtained during testing (21 CFR 211.194(a)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you state that you have added the mixing time to the batch record, and you maintain a temperature log of your incubator. Your response is inadequate because you do not provide sufficient details to demonstrate your QU will ensure the establishment and review of manufacturing records.\u003C\u002Fp>\u003Cp>Complete and accurate batch production and control records are necessary to ensure that manufacturing processes are consistently followed and reproducible. Additionally, complete manufacturing records are necessary to reliably conduct batch record review, adequately investigate deviations and batch failures, and to ensure a continued state of validation processes.\u003C\u002Fp>\u003Cp>An adequate QU overseeing all CGMP operations is necessary to ensure consistent drug quality. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\u003Cli>A list of chemical and microbial test methods and specifications used to analyze each of your drug product before making a disposition decision, and the associated written procedures.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“MED CHEM Tincture Green Soap” is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples of claims observed on the “MED CHEM Tincture Green Soap” product labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>&nbsp; “Drug Facts Active Ingredients Ethyl Alcohol, 30% Purpose Antiseptic Uses Intended for . . . mild antisepsis of skin . . . Directions Mix with water. Lather and rinse” [from the product label]\u003C\u002Fp>\u003Cp>Based on the above labeling claims, “MED CHEM Tincture Green Soap” is intended for use as a topical antiseptic drug product. This topical antiseptic product is a new drug within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your “MED CHEM Tincture Green Soap” drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\u003Cp>Over-the-Counter (OTC) topical and oral antiseptic drug products have been the subject of rulemakings under the Agency’s OTC Drug Review. In particular, consumer topical antiseptics were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use”, Proposed Rule, 78 FR 76444 (December 17, 2013) (Consumer Antiseptic Washes Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, benzethonium chloride, and chloroxylenol) were classified as Category III for use in consumer antiseptic wash products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic wash.\u003C\u002Fp>\u003Cp>Section 505G of the FD&amp;C Act governs nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330—and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\u003Cp>However, “MED CHEM Tincture Green Soap” does not conform to the 1994 TFM, as further amended by the Consumer Antiseptic Washes Proposed Rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505. The “MED CHEM Tincture Green Soap” product labeling states that its active ingredient is “Ethyl Alcohol, 30%” and provides the following directions for use: “Mix with water. Lather and rinse.” Your “MED CHEM Tincture Green Soap” product does not conform to the 1994 TFM as further amended or any other TFM or proposed or final rule. As noted above, ethyl alcohol is not one of the three active ingredients classified as Category III for use in consumer antiseptic wash products.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>&nbsp;\u003C\u002Fp>\u003Cp>Accordingly, your product does not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003Cbr>The introduction or delivery for introduction of this unapproved new drug product into interstate commerce violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>Additionally, “MED CHEM Tincture Green Soap” is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violations section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Listing Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Section 510(j) of the FD&amp;C Act, 21 U.S.C. 360(j), and 21 CFR Part 207 outline the requirements for establishment registration and listing of drug products. Under 21 CFR 207.57(b), registrants are required to update drug listing information twice each year, in June and December. Under 21 CFR 207.57(b)(2) registrants may satisfy the listing update requirement with respect to unchanged listing information by making a single “no changes” certification during the October 1st through December 31st annual registration period. If the drug listing data is not updated or certified, the outdated listing data will get inactivated at the next scheduled FDA inactivation period.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Your products, Tincture Green, NDC 12745-041, and Isopropyl Alcohol, NDC 12745-105, were not certified as required, thus they were inactivated by FDA in January 2024.\u003C\u002Fp>\u003Cp>Therefore, your products Tincture Green and Isopropyl Alcohol are not properly listed under section 510(j) of the FD&amp;C Act, rendering these drugs to be misbranded under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o). The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). In addition, failure to provide listing information in accordance with 510(j) of the FD&amp;C Act is prohibited under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p).\u003C\u002Fp>\u003Cp>Complete, accurate, and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing, electronic health records, insurance reimbursement, and patient education.\u003C\u002Fp>\u003Cp>We note that several of your firm’s drug listings are inactivated\u002Funcertified. Firms must discontinue listed products when manufacturing and commercial distribution cease by adding an end marketing date which corresponds to the expiration date of the last lot in commercial distribution. It is your responsibility to ensure that all products manufactured at your establishment comply with all establishment registration and drug listing requirements under section 510 of the FD&amp;C Act, 21 U.S.C. 360, 21 CFR Part 207, and all other applicable FDA regulations. Registration and listing information and instructions on how to properly register an establishment or submit drug listings can be found at \u003Cem>Electronic Drug Registration and Listing Instructions.\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2013736 and ATTN: Sena G. Dissmeyer.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>&nbsp;\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We note that “tincture of green soap” was not evaluated as part of the consumer antiseptic wash rulemaking and was not one of the three active ingredients classified as Category III for use in consumer antiseptic wash products. On June 19, 2008, FDA issued a proposed rule that would determine that there were inadequate data to establish general recognition of safety and effectiveness for tincture of green soap for use as the active ingredient in a nonantimicrobial skin wound cleanser product. “Status of Certain Additional Over-the-Counter Drug Category II Active Ingredients,” Proposed Rule, 73 FR 34895, 34901 (June 19, 2008).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See 84 FR 40417 (https:\u002F\u002Fwww.regulations.gov\u002Fdocument\u002FFDA-2019-N-2374-0001).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-25-91\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Emmanuel R. Didier\n\nRecipient Title\n\nPresident and CEO\n\nMedical Chemical Corporation\n\n19250 Van Ness Avenue\n\nTorrance, CA 90501-1102\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-91\nJuly 9, 2025\nDear Mr. Didier:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Medical Chemical Corporation, FEI 2013736, at 19430 Van Ness Avenue, Torrance, from February 12 to 18, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nIn addition, “MED CHEM Tincture Green Soap” drug product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\nFurthermore, we reviewed your firm’s drug listing submissions in FDA’s electronic Drug Registration and Listing System (eDRLS) and found that your drug products, Tincture Green, NDC 12745-041, and Isopropyl Alcohol, NDC 12745-105, are not properly listed as required by section 510(j) of the FD&C Act.\nYour firm has not fulfilled its listing obligations under 510(j) of the FD&C Act and 21 CFR 207, which is prohibited under section 301(p) of the FD&C Act, 21 U.S.C. 331(p), and will render a drug misbranded under section 502(o) of the FD&C Act, 21 U.S.C. 352(o). The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\nCGMP Violations\nWe reviewed your February 28, 2025 response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm manufactures over-the-counter (OTC) topical drug products, including hand sanitizers, Tincture Green Soap USP, and Isopropyl Alcohol 70% v\u002Fv. You failed to adequately perform identity testing on each shipment of each lot of incoming components (e.g., ethanol, glycerin) used in the manufacture of your OTC topical drug products. In addition, you relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\nProducts Containing Ethyl Alcohol and Isopropyl Alcohol\nYou failed to adequately test your incoming component ethyl alcohol (ethanol), used as an active pharmaceutical ingredient (API), for methanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\nFurthermore, you failed to demonstrate that the component alcohol (“C40B (b)(4) PROOF SDA 40B ETHYL ALCOHOL BULK”), used to manufacture your drug product Tincture Green Soap USP, meets United States Pharmacopoeia (USP) monograph specifications. For example, we reviewed your raw material specification for your component alcohol and note that the specifications failed to demonstrate performance of the USP monograph identification parts A, B, and C.\nProducts Containing Ingredients at Risk for Diethylene Glycol or Ethylene Glycol (DEG or EG) Contamination\nYou also failed to adequately test your incoming components at high risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination for identity before using them to manufacture your drug products. This includes, but is not limited to, testing of glycerin to determine its appropriate identity, prior to use in manufacturing your OTC topical drug products.\nIdentity testing for glycerin and certain other high-risk drug components includes a limit test in the USP to ensure the component meets the relevant safety limits for DEG or EG levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\nIn your response, you state that you perform identity testing, use raw materials certified by trusted suppliers, and have added or will add certain assays to your specifications. Your response is inadequate because you do not provide adequate details to demonstrate identity testing meets all compendial requirements. Furthermore, your response does not address testing your high-risk drug components for DEG or EG contamination, or test ethanol for the presence of methanol contamination. Also, you do not address the potential impact on drug products in the U.S. market within expiry.\nWithout adequate testing, you do not have scientific evidence that the components conform to appropriate specifications before use in the manufacture of your drug products. You are responsible for sampling, testing, and examining drug components before use in production to ensure acceptable quality parameters are met.\nIn response to this letter, provide:\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of alcohol, isopropyl alcohol, glycerin, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\nA commitment to provide methanol test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of components within expiry of manufactured drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of methanol.\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYou used “(b)(4) water” as a component to manufacture your OTC topical drug products. However, you have not established that the water system is adequately designed, maintained, and monitored to ensure that it consistently produces water suitable for its intended use. You lacked water system validation and failed to conduct total organic carbon (TOC) testing to ensure that your component water met (b)(4) Water United States Pharmacopeia (USP) monograph specifications.\nAdditionally, you obtained excessive microbial growth from the point of use, “(b)(4) (No hose)” location, following (b)(4) water system maintenance sanitization cycles. The inadequate control of your water system poses a potential risk for objectionable microbiological contamination into your drug products.\nIn your response, you state that you will “revalidate” your (b)(4) water system and include TOC testing in your water specification. Your response is inadequate because you do not provide your initial water system validation, nor do you provide adequate details regarding your plan for performing water system validation, maintenance, and testing of the water system. Furthermore, you do not provide a timeline for the validation of your methods, nor do you consider retrospective testing of retained finished drug products that used water.\n(b)(4) water for pharmaceutical use must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes. Routine monitoring of microbial counts and identity of contamination in the system is integral to ensuring oversight of ongoing state of control and suitability of water for use in manufacturing operations.\nFurthermore, test methods must be validated to show they are suitable for their intended use, and equivalent or better than applicable USP compendial methods. The reproducibility of your test methods is essential to determine if your drug products meet established specifications for microbial attributes. The ability of microbial testing methods to detect objectionable microorganisms in the presence of each drug product must be established.\nIn response to this letter, provide:\nA (b)(4) water system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\nA detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\nThe current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4) water system. Ensure that the total count limits for your (b)(4) water are appropriately stringent in view of the intended use of each of the products produced by your firm. Total microbial count limits for (b)(4) water systems are generally tighter than your proposed action limits for the topical liquid dosage forms produced by your firm.\nA procedure governing your program for ongoing control, maintenance, and monitoring that ensures the system consistently produces water that meets (b)(4) Water, USP monograph specifications and appropriate microbial limits.\nValidation of your microbiological test methods, including growth promotion testing, demonstrating they are equivalent to, or better than USP compendial methods, and suitable for their intended use.\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) failed to perform adequate oversight for the manufacture and testing of your OTC topical drug products. For example, your QU failed to ensure the following:\nEstablishment and review of adequate batch production and control records for each batch of drug product which include complete information regarding each significant step in the manufacture, processing, packing, or holding of the batch (21 CFR 211.188(b)).\nEstablishment and review of adequate laboratory records which include all data obtained during testing (21 CFR 211.194(a)).\nIn your response, you state that you have added the mixing time to the batch record, and you maintain a temperature log of your incubator. Your response is inadequate because you do not provide sufficient details to demonstrate your QU will ensure the establishment and review of manufacturing records.\nComplete and accurate batch production and control records are necessary to ensure that manufacturing processes are consistently followed and reproducible. Additionally, complete manufacturing records are necessary to reliably conduct batch record review, adequately investigate deviations and batch failures, and to ensure a continued state of validation processes.\nAn adequate QU overseeing all CGMP operations is necessary to ensure consistent drug quality. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn response to this letter, provide:\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\nA list of chemical and microbial test methods and specifications used to analyze each of your drug product before making a disposition decision, and the associated written procedures.\nUnapproved New Drug and Misbranded Drug Violations\n“MED CHEM Tincture Green Soap” is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body.\nExamples of claims observed on the “MED CHEM Tincture Green Soap” product labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product as a drug include, but may not be limited to, the following:\n“Drug Facts Active Ingredients Ethyl Alcohol, 30% Purpose Antiseptic Uses Intended for . . . mild antisepsis of skin . . . Directions Mix with water. Lather and rinse” [from the product label]\nBased on the above labeling claims, “MED CHEM Tincture Green Soap” is intended for use as a topical antiseptic drug product. This topical antiseptic product is a new drug within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your “MED CHEM Tincture Green Soap” drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\nOver-the-Counter (OTC) topical and oral antiseptic drug products have been the subject of rulemakings under the Agency’s OTC Drug Review. In particular, consumer topical antiseptics were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use”, Proposed Rule, 78 FR 76444 (December 17, 2013) (Consumer Antiseptic Washes Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, benzethonium chloride, and chloroxylenol) were classified as Category III for use in consumer antiseptic wash products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic wash.\nSection 505G of the FD&C Act governs nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330—and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\nHowever, “MED CHEM Tincture Green Soap” does not conform to the 1994 TFM, as further amended by the Consumer Antiseptic Washes Proposed Rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505. The “MED CHEM Tincture Green Soap” product labeling states that its active ingredient is “Ethyl Alcohol, 30%” and provides the following directions for use: “Mix with water. Lather and rinse.” Your “MED CHEM Tincture Green Soap” product does not conform to the 1994 TFM as further amended or any other TFM or proposed or final rule. As noted above, ethyl alcohol is not one of the three active ingredients classified as Category III for use in consumer antiseptic wash products.1\nAccordingly, your product does not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\nThe introduction or delivery for introduction of this unapproved new drug product into interstate commerce violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nAdditionally, “MED CHEM Tincture Green Soap” is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violations section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nDrug Listing Violations\nSection 510(j) of the FD&C Act, 21 U.S.C. 360(j), and 21 CFR Part 207 outline the requirements for establishment registration and listing of drug products. Under 21 CFR 207.57(b), registrants are required to update drug listing information twice each year, in June and December. Under 21 CFR 207.57(b)(2) registrants may satisfy the listing update requirement with respect to unchanged listing information by making a single “no changes” certification during the October 1st through December 31st annual registration period. If the drug listing data is not updated or certified, the outdated listing data will get inactivated at the next scheduled FDA inactivation period.2 Your products, Tincture Green, NDC 12745-041, and Isopropyl Alcohol, NDC 12745-105, were not certified as required, thus they were inactivated by FDA in January 2024.\nTherefore, your products Tincture Green and Isopropyl Alcohol are not properly listed under section 510(j) of the FD&C Act, rendering these drugs to be misbranded under section 502(o) of the FD&C Act, 21 U.S.C. 352(o). The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). In addition, failure to provide listing information in accordance with 510(j) of the FD&C Act is prohibited under section 301(p) of the FD&C Act, 21 U.S.C. 331(p).\nComplete, accurate, and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing, electronic health records, insurance reimbursement, and patient education.\nWe note that several of your firm’s drug listings are inactivated\u002Funcertified. Firms must discontinue listed products when manufacturing and commercial distribution cease by adding an end marketing date which corresponds to the expiration date of the last lot in commercial distribution. It is your responsibility to ensure that all products manufactured at your establishment comply with all establishment registration and drug listing requirements under section 510 of the FD&C Act, 21 U.S.C. 360, 21 CFR Part 207, and all other applicable FDA regulations. Registration and listing information and instructions on how to properly register an establishment or submit drug listings can be found at Electronic Drug Registration and Listing Instructions.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2013736 and ATTN: Sena G. Dissmeyer.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\n\u002FS\u002F\nTina Smith\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_________________________\n1 We note that “tincture of green soap” was not evaluated as part of the consumer antiseptic wash rulemaking and was not one of the three active ingredients classified as Category III for use in consumer antiseptic wash products. On June 19, 2008, FDA issued a proposed rule that would determine that there were inadequate data to establish general recognition of safety and effectiveness for tincture of green soap for use as the active ingredient in a nonantimicrobial skin wound cleanser product. “Status of Certain Additional Over-the-Counter Drug Category II Active Ingredients,” Proposed Rule, 73 FR 34895, 34901 (June 19, 2008).\n2 See 84 FR 40417 (https:\u002F\u002Fwww.regulations.gov\u002Fdocument\u002FFDA-2019-N-2374-0001).","Medical Chemical Corporation","medical-chemical-corporation-706007-07092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-chemical-corporation-706007-07092025","2026-10-26T08:09:22.922674+00:00","2025-07-22","706007","Mr. Emmanuel R. Didier","2026-08-19T16:34:05.655+00:00","VIA UPS","320-25-91",{"id":49,"raw":50,"subject":12,"body_html":54,"body_text":55,"firm_name":56,"letter_id":57,"created_at":58,"fei_number":19,"letter_url":59,"updated_at":60,"action_type":22,"case_status":23,"posted_date":61,"marcs_cms_no":62,"product_type":63,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":64,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":65,"medical_device_id":19,"response_letter_date":19},472,[51,52,53,11,12,13,13,13],"\u003Ctime datetime=\"2025-11-18T05:00:00Z\">11\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-13T05:00:00Z\">11\u002F13\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mega-717840-11132025\">Medical Mega\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Medical Mega\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>208 Fairmont Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jersey City\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07306\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Sales@medicalmega.com\"> Sales@medicalmega.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 13, 2025\u003C\u002Fp>\u003Cp>RE: 717840\u003C\u002Fp>\u003Cp>Medical Mega:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fwww.medicalmega.com. The FDA has observed that your website offers the following triclosan-containing consumer and health care antiseptic nonprescription drug products: “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 800 mL,” “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1 Gallon,” and “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1000 mL” (hereinafter “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”) for sale in United States. Based on our review, these products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301 (d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” product labeling, including your website, https:\u002F\u002Fwww.medicalmega.com, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“Anti-microbial…Kills bacteria on contact…” [from your https:\u002F\u002Fmedicalmega.com\u002FAmeriWash-Antimicrobial-Lotion-Soap-with-Triclosan-1000-mL product page]\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are intended for use as triclosan-containing consumer and health care antiseptic nonprescription drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\u003C\u002Fp>\u003Cp>With respect to triclosan-containing consumer and health care antiseptic nonprescription drug products, such as the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan,” such products are subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these products fall under section 505G(a)(5) of the FD&amp;C Act, 21 U.S.C. 355h(a)(5), because FDA has determined that topical consumer and health care antiseptic nonprescription drug products formulated with triclosan as an active ingredient are not GRASE under a final determination issued under 21 CFR part 330.1\u003C\u002Fp>\u003Cp>Therefore, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&amp;C Act is in effect for these drug products. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\u003Cp>In addition, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov, please include your firm name and the unique identifier “717840” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> On September 6, 2017, FDA issued a final rule establishing that certain ingredients for OTC topical consumer antiseptic wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (81 FR 61106). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(iii). On December 20, 2018, FDA issued a final rule establishing that certain ingredients for OTC health care antiseptic hand wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (82 FR 60474). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(vi). Under section 505G(k)(2)(A) of the FD&amp;C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) were deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC 000007, available at OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nMedical Mega\n\n208 Fairmont Ave\n\nJersey City, NJ 07306\n\nUnited States\n\nSales@medicalmega.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nNovember 13, 2025\nRE: 717840\nMedical Mega:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fwww.medicalmega.com. The FDA has observed that your website offers the following triclosan-containing consumer and health care antiseptic nonprescription drug products: “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 800 mL,” “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1 Gallon,” and “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1000 mL” (hereinafter “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”) for sale in United States. Based on our review, these products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301 (d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\nUnapproved New Drug and Misbranded Drug Violations\n“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples from the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” product labeling, including your website, https:\u002F\u002Fwww.medicalmega.com, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\n“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”\n“Anti-microbial…Kills bacteria on contact…” [from your https:\u002F\u002Fmedicalmega.com\u002FAmeriWash-Antimicrobial-Lotion-Soap-with-Triclosan-1000-mL product page]\nBased on the above labeling evidence, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are intended for use as triclosan-containing consumer and health care antiseptic nonprescription drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\nWith respect to triclosan-containing consumer and health care antiseptic nonprescription drug products, such as the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan,” such products are subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these products fall under section 505G(a)(5) of the FD&C Act, 21 U.S.C. 355h(a)(5), because FDA has determined that topical consumer and health care antiseptic nonprescription drug products formulated with triclosan as an active ingredient are not GRASE under a final determination issued under 21 CFR part 330.1\nTherefore, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&C Act is in effect for these drug products. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\nIn addition, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov, please include your firm name and the unique identifier “717840” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_________________\n1 On September 6, 2017, FDA issued a final rule establishing that certain ingredients for OTC topical consumer antiseptic wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (81 FR 61106). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(iii). On December 20, 2018, FDA issued a final rule establishing that certain ingredients for OTC health care antiseptic hand wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (82 FR 60474). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(vi). Under section 505G(k)(2)(A) of the FD&C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) were deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC 000007, available at OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F).","Medical Mega","medical-mega-717840-11132025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mega-717840-11132025","2026-10-26T08:09:22.956521+00:00","2025-11-18","717840","Drugs","2026-08-19T14:27:25.954+00:00","2025-11-13",{"id":67,"raw":68,"subject":73,"body_html":74,"body_text":75,"firm_name":76,"letter_id":77,"created_at":78,"fei_number":19,"letter_url":79,"updated_at":80,"action_type":22,"case_status":23,"posted_date":81,"marcs_cms_no":82,"product_type":83,"closeout_date":19,"issuing_office":72,"recipient_name":84,"body_fetched_at":85,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":86,"medical_device_id":19,"response_letter_date":19},3235,[69,70,71,72,73,13,13,13],"\u003Ctime datetime=\"2021-08-03T13:20:00Z\">08\u002F03\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-07-26T04:00:00Z\">07\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flexion-medical-llc-613588-07262021\">Lexion Medical LLC\u003C\u002Fa>","Center for Devices and Radiological Health","Adulterated and Misbranded Products, including Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Patrick Spearman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Lexion Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>545 Atwater Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint Paul\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55103\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:pspearman@lexionmedical.com\"> pspearman@lexionmedical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>July 26, 2021\u003C\u002Fp>\n\n\u003Cp>RE: Adulterated and Misbranded Products, including Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>Dear Patrick Spearman:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) has learned that your firm is marketing the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE Gas Evacuation Cannula (Pneuview XE) in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act).\u003C\u002Fp>\n\n\u003Cp>Under section 201(h) of the Act, 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. We also note that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. As recent as June 22, 2021, FDA reviewed your website, https:\u002F\u002Fwww.lexionmedical.com\u002F and information posted to social media platforms (https:\u002F\u002Ftwitter.com\u002FLexionMedical\u002Fstatus\u002F1245400259888582656, https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=NEhxp1fgewA&amp;feature=emb_logo) and determined that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the devices as described and marketed. The AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of the product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>AP 50\u002F30 Insufflator and Insuflow Port\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The AP 50\u002F30 Insufflator was cleared under K191780 for use during diagnostic and\u002For therapeutic endoscopic procedures to distend a cavity by filling it with gas. The Insuflow Port was also cleared under K191780 for having applications in thoracic, abdominal and gynecologic minimally invasive endoscopic surgical procedures to establish a path of entry for endoscopic instruments and to heat, humidify, filter and introduce a CO2 gas stream for insufflation of the surgical cavity. However, your firm’s promotion of these devices provides evidence that they are intended for uses such as reduction of cell desiccation, hypothermia, post-operative pain and subcutaneous emphysema, which would constitute major changes or modifications to their intended uses, for which your firm lacks clearance or approval. Any therapeutic, treatment, or prevention effectiveness claims beyond the cleared indication for use constitute a new intended use and requires a premarket submission prior to marketing.\u003C\u002Fp>\n\n\u003Cp>For example, your website, www.Lexion.com, contains the following promotional claims for the AP 50\u002F30 Insufflator and Insuflow Port:\u003C\u002Fp>\n\n\u003Cp>• Under the sections of your website titled, “Gas Delivery” (https:\u002F\u002Fwww.lexionmedical.com\u002Fgas-delivery) and “Testimonials” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews)\u003Cbr>\n “Less hypothermia”\u003Cbr>\n “Less peritoneal damage”\u003Cbr>\n “Less postoperative pain”\u003Cbr>\n “Decreased amount of pain medication”\u003Cbr>\n “Shortened recovery room stay”\u003Cbr>\n “Less tissue dessication”\u003Cbr>\n• Under the section of your website titled, “Pneumostability” (https:\u002F\u002Fwww.lexionmedical.com\u002Fpneumostability)“reduce the incidence of subcutaneous emphysema”\u003C\u002Fp>\n\n\u003Cp>There are many factors that may contribute to the health risks listed above. FDA is not aware of evidence demonstrating that the AP 50\u002F30 Insufflator and Insuflow Port are effective in the reduction of these risks. Such promotion of your devices for unsupported and uncleared indications, and statements about demonstrating improved safety outcomes, may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps, which may lead to patient harm. If you have data to support these statements, please submit that data to FDA for review. FDA informed your firm in written communications following the submission of 510(k) notifications for a different accessory device that certain claims, such as those listed above, required the submission of clinical data and that literature reviews provided were not adequate to support these indications. The respective submissions were not cleared, were withdrawn, or were cleared without these indications.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Pneuview XE\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The Pneuview XE was cleared under K132203 for having applications in thoracic, abdominal, and gynecologic minimally invasive endoscopic surgical procedures to establish a path of entry for endoscopic instruments and to evacuate smoke and plume generated during minimally invasive surgery from the surgical cavity to aid visualization. However, your firm’s promotion of this device provides evidence that it is intended for the elimination of all plume, gases, particles, contaminants, viruses and unsafe negative pressure which would constitute major changes or modifications to its intended use, for which your firm lacks clearance or approval. Any therapeutic, treatment, or prevention effectiveness claims beyond the cleared indication for use constitute a new intended use and requires a premarket submission prior to marketing. For example, the Smoke Evacuation section of your website (https:\u002F\u002Fwww.lexionmedical.com\u002Fsmoke-evacuation) includes the following promotional claims for the Pneuview XE:\u003C\u002Fp>\n\n\u003Cp>• “Eliminate \u003Cem>all\u003C\u002Fem> plume, gases, and particles” [emphasis added]\u003Cbr>\n• “…eliminating \u003Cem>all\u003C\u002Fem> harmful contaminants associated with combustion, including viral particles” [emphasis added]\u003Cbr>\n• “actively evacuates and removes \u003Cem>all \u003C\u002Fem>smoke plume including hazardous gas” [emphasis added]\u003Cbr>\n• “…a patented vacuum break which eliminates the ability of any suction system to pull an unsafe negative pressure on the patient”\u003C\u002Fp>\n\n\u003Cp>The cleared indication for use of this device includes only evacuation of smoke and plume. FDA is not aware of evidence, and no data have been provided in your 510(k), demonstrating that the Pneuview XE is effective in the removal of all harmful gases, vapors, particulates, or viruses. We note that leakage of gases, vapors, and particulates through the cannula when devices are inserted and removed occurs, regardless of filtration within the system. Therefore, statements including the word “all” or any statements implying 100% removal of vapors, gases, particulates, or viruses are misleading. Misleading claims may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps. Medical practitioners may also overestimate the amount of protection provided them by use of your device in the operating room (OR), which has the potential to lead to patient and practitioner harm. Additionally, FDA is not aware of evidence, and no data has been submitted in your 510(k), demonstrating that the Pneuview XE is effective in eliminating unsafe negative pressure on the patient. Such promotion of your device for unsupported and uncleared indications may lead to patient harm.\u003Cbr>\n\u003Cbr>\nThe Pneuview XE is further misbranded under § 502(a) of the Act, 21 U.S.C. § 352(a), because there are statements on your website and social media sites that, under 21 CFR § 801.6, constitute false or misleading representations with respect to another device. Specifically, the information makes misleading comparisons between your device, a one-way insufflator, and competing devices, two-way insufflators. For example, relevant pictures, illustrations, videos, literature, and written\u002Fverbal statements include the following:\u003C\u002Fp>\n\n\u003Cp>• A picture of smoke venting out of the patient into the OR in the two-way insufflator and a picture showing that all the smoke is vented outside the OR by one-way insufflator on your website page titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it fails to recognize the smoke reduction characteristics contained in two-way insufflators.\u003Cbr>\n• Stating, with respect to two-way insufflators, that, “Smoke particulates and some gases are removed however toxic [gas] is vented into the OR” on your website page titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it minimizes the smoke reduction characteristics contained in two-way insufflators.\u003Cbr>\n• Stating that the recirculating system of two-way insufflators “[c]ycles contaminated gases through insufflator potentially increasing the risk of cross contamination and build-up of toxic gas”, under the section on your website titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it fails to recognize that both one-way and two-way systems carry these risks and contain filtration capabilities to mitigate these risks.\u003Cbr>\n• Referencing a limited selection of journal articles about competing devices under the section on your website titled, “Resources”\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> (https:\u002F\u002Fwww.lexionmedical.com\u002Finsights) and “Testimonials” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews). This information is misleading in that it may cause medical practitioners to overestimate the type of protection provided to their patients by use of your device in the OR.\u003Cbr>\n• Stating in videos and literature on social media platforms, including YouTube, that there is “constant venting of gas into the atmosphere” which increases the risk of cross-contamination and colonization of pathogens in two-way insufflators and referencing a limited selection of journal articles, as described above. This information is misleading in that it mischaracterizes two-way devices by failing to recognize their smoke reduction characteristics.\u003C\u002Fp>\n\n\u003Cp>We are not aware of any new data supporting such claims. Such claims are false or misleading because data do not demonstrate that the Pneuview XE is superior to other insufflator devices. These comparisons may mislead consumers about the effectiveness of the Pneuview XE by implying less effectiveness of other devices. Misleading information may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps, which may lead to practitioner and patient harm. These claims therefore constitute misleading representations with respect to another device. If you do have data demonstrating that Pneuview XE is more effective than other insufflation devices, please provide that information to the agency.\u003C\u002Fp>\n\n\u003Cp>Additionally, the FDA has observed that your website currently offers the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE for sale in the United States as being intended to mitigate, prevent, treat, diagnose or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. Promoting these devices as an effective prevention method against COVID-19 constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval, and requires premarket submission prior to marketing. For example, in videos under the sections on your website titled, “COVID-19” (https:\u002F\u002Fwww.lexionmedical.com\u002Fcovid-19) and “Testimonials,” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews) several statements are made about how your devices provide safety against COVID-19. Some of those statements include the following:\u003C\u002Fp>\n\n\u003Cp>• The video titled, “How Does Lexion Compare with other Insufflation Systems for COVID-19?” provides a testimonial that states in part:\u003Cbr>\n “This COVID crisis has brought a lot of focus on how we work in the operating room and particularly the risks to us and our patients that could come from some of the laparoscopic insufflation devices [used]…to perform procedures.” (minute 0:23)\u003Cbr>\n In the context of COVID-19, the video goes on to compare two-way systems, and how they remove “a lot of raw gas out of the patient and straight into the room…dumping the gas back into the OR room and the OR atmosphere… [potentially] contaminating the device itself [leading to contamination] into the patient or the next patient.” (minute 2:32) to traditional one-way systems and leakage of gas that “escape[s] through any variety of ways” (minute 2:45)\u003Cbr>\n The video clip then describes the advantages of the AP 50\u002F30 Insufflator which include, “The Lexion is a valved system [that has] minimal spillage of gas out of the port and into the [OR] room during the procedure.” (minute 6:03)\u003Cbr>\n The video concludes that “[a] lot of the different surgical societies have been making recommendations in the midst of this COVID crisis about ways we can try to protect ourselves and those we work with, and … [based on those recommendations] the Lexion AP 50 seems to checks all those boxes for us.” (minute 6:50) [https:\u002F\u002Fwww.lexionmedical.com\u002Fcovid-19].\u003Cbr>\n• In the video titled, “Why this Oncology GYN Robotic Surgeon switched to the Lexion System,” the testimonial states, “…but lately, mainly due to COVID-19… I’m using the system by Lexion which to me is the safest and best system out there… It’s just so much safer with the current climate… I would just hate to have a patient who turns COVID-19 positive.” (minute 0:23)\u003C\u002Fp>\n\n\u003Cp>Taken together, the statements exemplified above imply that traditional one-way insufflators and two-way insufflators potentially contaminate the OR or lead to contamination to other patients, whereas, the AP 50\u002F30 Insufflator and accessories are recommended for and may be used to mitigate and\u002For prevent the spread of COVID-19. FDA is not aware of evidence demonstrating that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are effective in the reduction of the spread of COVID-19. If you have data to support these statements, please submit that data to FDA for review.\u003C\u002Fp>\n\n\u003Cp>In combination with information displayed on your COVID-19 webpage, as well as other areas of your website, as referenced above, where your firm claims that these devices can remove viral particles, these statements and information indicate that the AP 50\u002F30 Insufflator and its accessories are intended for use to protect OR staff or patients against COVID-19. Such promotion of your device for unsupported and uncleared indications may cause medical practitioners to overestimate the type of protection provided them and their patients by use of your device in the OR, which has the potential to lead to patient and practitioner harm.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you sell a product that is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved, uncleared, and unauthorized product for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of unapproved, uncleared, and unauthorized product(s) for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\">http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\u003C\u002Fa>. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>FDA requests that Lexion Medical LLC immediately cease activities that result in the misbranding or adulteration of the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE, such as the commercial distribution of the device for the uses discussed above.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to correct the violations addressed in this letter. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your product(s) as safe and\u002For effective for indications outside the cleared indications, including for COVID-19-related uses, for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the product(s) in violation of the Act. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts.\u003C\u002Fp>\n\n\u003Cp>Note, there are two response time frames specified. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address the COVID-19 related violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. For all other claims, please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Please include documentation of any corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, please state the reason for the delay and the time within which these activities will be completed. Your firm’s responses should be comprehensive and address all violations included in this Warning Letter. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response to address all other violations, should be sent to: Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, Rm 3572, 10903 New Hampshire Ave, Silver Spring, Maryland 20993 or emailed to CDRHWarningLetterResponses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Please refer to the identification numbers CMS 613588 and CPT2001060 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Jason Roberts, Ph.D., Assistant Director for the Gynecological and Surgical Devices Team, at Jason.Roberts@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, this letter is not meant to be an all-inclusive list of the violations that exist in connection with the product(s) at your firm or in your promotional materials including your website. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. Failure to adequately address any violations may result in legal action, including without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>\nOffice Director\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\nGeneral Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC\u003Cbr>\nShelly Amann, Owner\u003Cbr>\nLexion Medical LLC\u003Cbr>\n545 Atwater Circle\u003Cbr>\nSaint Paul, MN 55103\u003Cbr>\nsamann@lexionmedical.com\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> While earlier journal articles dated 2009 -2013 cite some cases of subcutaneous emphysema with AirSeal, later articles show no significant difference in subcutaneous emphysema for AirSeal and standard CO2 insufflator. The 2020 Feng et al article even notes a significantly lesser risk of subcutaneous emphysema with the AirSeal at 12mmHg and the transperitoneal approach. Feng TS, Heulitt G, Islam A, Porter JR. Comparison of valve-less and standard insufflation on pneumoperitoneum-related complications in robotic partial nephrectomy: a prospective randomized trial [published online ahead of print, 2020 Jul 6]. \u003Cem>J Robot Surg\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), \u003Cem>available\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nPatrick Spearman\n\nRecipient Title\n\nOwner\n\nLexion Medical LLC\n\n545 Atwater Circle\n\nSaint Paul, MN 55103\n\nUnited States\n\npspearman@lexionmedical.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nJuly 26, 2021\n\nRE: Adulterated and Misbranded Products, including Products Related to Coronavirus Disease 2019 (COVID-19)\n\nDear Patrick Spearman:\n\nThe United States Food and Drug Administration (FDA) has learned that your firm is marketing the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE Gas Evacuation Cannula (Pneuview XE) in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act).\n\nUnder section 201(h) of the Act, 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. We also note that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people. As recent as June 22, 2021, FDA reviewed your website, https:\u002F\u002Fwww.lexionmedical.com\u002F and information posted to social media platforms (https:\u002F\u002Ftwitter.com\u002FLexionMedical\u002Fstatus\u002F1245400259888582656, https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=NEhxp1fgewA&feature=emb_logo) and determined that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the devices as described and marketed. The AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of the product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nAP 50\u002F30 Insufflator and Insuflow Port\n\nThe AP 50\u002F30 Insufflator was cleared under K191780 for use during diagnostic and\u002For therapeutic endoscopic procedures to distend a cavity by filling it with gas. The Insuflow Port was also cleared under K191780 for having applications in thoracic, abdominal and gynecologic minimally invasive endoscopic surgical procedures to establish a path of entry for endoscopic instruments and to heat, humidify, filter and introduce a CO2 gas stream for insufflation of the surgical cavity. However, your firm’s promotion of these devices provides evidence that they are intended for uses such as reduction of cell desiccation, hypothermia, post-operative pain and subcutaneous emphysema, which would constitute major changes or modifications to their intended uses, for which your firm lacks clearance or approval. Any therapeutic, treatment, or prevention effectiveness claims beyond the cleared indication for use constitute a new intended use and requires a premarket submission prior to marketing.\n\nFor example, your website, www.Lexion.com, contains the following promotional claims for the AP 50\u002F30 Insufflator and Insuflow Port:\n\n• Under the sections of your website titled, “Gas Delivery” (https:\u002F\u002Fwww.lexionmedical.com\u002Fgas-delivery) and “Testimonials” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews)\n\n “Less hypothermia”\n\n “Less peritoneal damage”\n\n “Less postoperative pain”\n\n “Decreased amount of pain medication”\n\n “Shortened recovery room stay”\n\n “Less tissue dessication”\n\n• Under the section of your website titled, “Pneumostability” (https:\u002F\u002Fwww.lexionmedical.com\u002Fpneumostability)“reduce the incidence of subcutaneous emphysema”\n\nThere are many factors that may contribute to the health risks listed above. FDA is not aware of evidence demonstrating that the AP 50\u002F30 Insufflator and Insuflow Port are effective in the reduction of these risks. Such promotion of your devices for unsupported and uncleared indications, and statements about demonstrating improved safety outcomes, may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps, which may lead to patient harm. If you have data to support these statements, please submit that data to FDA for review. FDA informed your firm in written communications following the submission of 510(k) notifications for a different accessory device that certain claims, such as those listed above, required the submission of clinical data and that literature reviews provided were not adequate to support these indications. The respective submissions were not cleared, were withdrawn, or were cleared without these indications.\n\nPneuview XE\n\nThe Pneuview XE was cleared under K132203 for having applications in thoracic, abdominal, and gynecologic minimally invasive endoscopic surgical procedures to establish a path of entry for endoscopic instruments and to evacuate smoke and plume generated during minimally invasive surgery from the surgical cavity to aid visualization. However, your firm’s promotion of this device provides evidence that it is intended for the elimination of all plume, gases, particles, contaminants, viruses and unsafe negative pressure which would constitute major changes or modifications to its intended use, for which your firm lacks clearance or approval. Any therapeutic, treatment, or prevention effectiveness claims beyond the cleared indication for use constitute a new intended use and requires a premarket submission prior to marketing. For example, the Smoke Evacuation section of your website (https:\u002F\u002Fwww.lexionmedical.com\u002Fsmoke-evacuation) includes the following promotional claims for the Pneuview XE:\n\n• “Eliminate all plume, gases, and particles” [emphasis added]\n\n• “…eliminating all harmful contaminants associated with combustion, including viral particles” [emphasis added]\n\n• “actively evacuates and removes all smoke plume including hazardous gas” [emphasis added]\n\n• “…a patented vacuum break which eliminates the ability of any suction system to pull an unsafe negative pressure on the patient”\n\nThe cleared indication for use of this device includes only evacuation of smoke and plume. FDA is not aware of evidence, and no data have been provided in your 510(k), demonstrating that the Pneuview XE is effective in the removal of all harmful gases, vapors, particulates, or viruses. We note that leakage of gases, vapors, and particulates through the cannula when devices are inserted and removed occurs, regardless of filtration within the system. Therefore, statements including the word “all” or any statements implying 100% removal of vapors, gases, particulates, or viruses are misleading. Misleading claims may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps. Medical practitioners may also overestimate the amount of protection provided them by use of your device in the operating room (OR), which has the potential to lead to patient and practitioner harm. Additionally, FDA is not aware of evidence, and no data has been submitted in your 510(k), demonstrating that the Pneuview XE is effective in eliminating unsafe negative pressure on the patient. Such promotion of your device for unsupported and uncleared indications may lead to patient harm.\n\nThe Pneuview XE is further misbranded under § 502(a) of the Act, 21 U.S.C. § 352(a), because there are statements on your website and social media sites that, under 21 CFR § 801.6, constitute false or misleading representations with respect to another device. Specifically, the information makes misleading comparisons between your device, a one-way insufflator, and competing devices, two-way insufflators. For example, relevant pictures, illustrations, videos, literature, and written\u002Fverbal statements include the following:\n\n• A picture of smoke venting out of the patient into the OR in the two-way insufflator and a picture showing that all the smoke is vented outside the OR by one-way insufflator on your website page titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it fails to recognize the smoke reduction characteristics contained in two-way insufflators.\n\n• Stating, with respect to two-way insufflators, that, “Smoke particulates and some gases are removed however toxic [gas] is vented into the OR” on your website page titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it minimizes the smoke reduction characteristics contained in two-way insufflators.\n\n• Stating that the recirculating system of two-way insufflators “[c]ycles contaminated gases through insufflator potentially increasing the risk of cross contamination and build-up of toxic gas”, under the section on your website titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it fails to recognize that both one-way and two-way systems carry these risks and contain filtration capabilities to mitigate these risks.\n\n• Referencing a limited selection of journal articles about competing devices under the section on your website titled, “Resources”2 (https:\u002F\u002Fwww.lexionmedical.com\u002Finsights) and “Testimonials” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews). This information is misleading in that it may cause medical practitioners to overestimate the type of protection provided to their patients by use of your device in the OR.\n\n• Stating in videos and literature on social media platforms, including YouTube, that there is “constant venting of gas into the atmosphere” which increases the risk of cross-contamination and colonization of pathogens in two-way insufflators and referencing a limited selection of journal articles, as described above. This information is misleading in that it mischaracterizes two-way devices by failing to recognize their smoke reduction characteristics.\n\nWe are not aware of any new data supporting such claims. Such claims are false or misleading because data do not demonstrate that the Pneuview XE is superior to other insufflator devices. These comparisons may mislead consumers about the effectiveness of the Pneuview XE by implying less effectiveness of other devices. Misleading information may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps, which may lead to practitioner and patient harm. These claims therefore constitute misleading representations with respect to another device. If you do have data demonstrating that Pneuview XE is more effective than other insufflation devices, please provide that information to the agency.\n\nAdditionally, the FDA has observed that your website currently offers the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE for sale in the United States as being intended to mitigate, prevent, treat, diagnose or cure COVID-193 in people. Promoting these devices as an effective prevention method against COVID-19 constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval, and requires premarket submission prior to marketing. For example, in videos under the sections on your website titled, “COVID-19” (https:\u002F\u002Fwww.lexionmedical.com\u002Fcovid-19) and “Testimonials,” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews) several statements are made about how your devices provide safety against COVID-19. Some of those statements include the following:\n\n• The video titled, “How Does Lexion Compare with other Insufflation Systems for COVID-19?” provides a testimonial that states in part:\n\n “This COVID crisis has brought a lot of focus on how we work in the operating room and particularly the risks to us and our patients that could come from some of the laparoscopic insufflation devices [used]…to perform procedures.” (minute 0:23)\n\n In the context of COVID-19, the video goes on to compare two-way systems, and how they remove “a lot of raw gas out of the patient and straight into the room…dumping the gas back into the OR room and the OR atmosphere… [potentially] contaminating the device itself [leading to contamination] into the patient or the next patient.” (minute 2:32) to traditional one-way systems and leakage of gas that “escape[s] through any variety of ways” (minute 2:45)\n\n The video clip then describes the advantages of the AP 50\u002F30 Insufflator which include, “The Lexion is a valved system [that has] minimal spillage of gas out of the port and into the [OR] room during the procedure.” (minute 6:03)\n\n The video concludes that “[a] lot of the different surgical societies have been making recommendations in the midst of this COVID crisis about ways we can try to protect ourselves and those we work with, and … [based on those recommendations] the Lexion AP 50 seems to checks all those boxes for us.” (minute 6:50) [https:\u002F\u002Fwww.lexionmedical.com\u002Fcovid-19].\n\n• In the video titled, “Why this Oncology GYN Robotic Surgeon switched to the Lexion System,” the testimonial states, “…but lately, mainly due to COVID-19… I’m using the system by Lexion which to me is the safest and best system out there… It’s just so much safer with the current climate… I would just hate to have a patient who turns COVID-19 positive.” (minute 0:23)\n\nTaken together, the statements exemplified above imply that traditional one-way insufflators and two-way insufflators potentially contaminate the OR or lead to contamination to other patients, whereas, the AP 50\u002F30 Insufflator and accessories are recommended for and may be used to mitigate and\u002For prevent the spread of COVID-19. FDA is not aware of evidence demonstrating that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are effective in the reduction of the spread of COVID-19. If you have data to support these statements, please submit that data to FDA for review.\n\nIn combination with information displayed on your COVID-19 webpage, as well as other areas of your website, as referenced above, where your firm claims that these devices can remove viral particles, these statements and information indicate that the AP 50\u002F30 Insufflator and its accessories are intended for use to protect OR staff or patients against COVID-19. Such promotion of your device for unsupported and uncleared indications may cause medical practitioners to overestimate the type of protection provided them and their patients by use of your device in the OR, which has the potential to lead to patient and practitioner harm.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.4 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.5 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you sell a product that is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved, uncleared, and unauthorized product for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of unapproved, uncleared, and unauthorized product(s) for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nFDA requests that Lexion Medical LLC immediately cease activities that result in the misbranding or adulteration of the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE, such as the commercial distribution of the device for the uses discussed above.\n\nYour firm should take prompt action to correct the violations addressed in this letter. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your product(s) as safe and\u002For effective for indications outside the cleared indications, including for COVID-19-related uses, for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the product(s) in violation of the Act. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts.\n\nNote, there are two response time frames specified. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address the COVID-19 related violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. For all other claims, please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Please include documentation of any corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, please state the reason for the delay and the time within which these activities will be completed. Your firm’s responses should be comprehensive and address all violations included in this Warning Letter. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration.\n\nYour firm’s response to address all other violations, should be sent to: Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, Rm 3572, 10903 New Hampshire Ave, Silver Spring, Maryland 20993 or emailed to CDRHWarningLetterResponses@fda.hhs.gov.\n\nPlease refer to the identification numbers CMS 613588 and CPT2001060 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Jason Roberts, Ph.D., Assistant Director for the Gynecological and Surgical Devices Team, at Jason.Roberts@fda.hhs.gov.\n\nFinally, this letter is not meant to be an all-inclusive list of the violations that exist in connection with the product(s) at your firm or in your promotional materials including your website. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. Failure to adequately address any violations may result in legal action, including without limitation, seizure and injunction.\n\nSincerely yours,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nOffice Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC\n\nShelly Amann, Owner\n\nLexion Medical LLC\n\n545 Atwater Circle\n\nSaint Paul, MN 55103\n\nsamann@lexionmedical.com\n\n______________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 While earlier journal articles dated 2009 -2013 cite some cases of subcutaneous emphysema with AirSeal, later articles show no significant difference in subcutaneous emphysema for AirSeal and standard CO2 insufflator. The 2020 Feng et al article even notes a significantly lesser risk of subcutaneous emphysema with the AirSeal at 12mmHg and the transperitoneal approach. Feng TS, Heulitt G, Islam A, Porter JR. Comparison of valve-less and standard insufflation on pneumoperitoneum-related complications in robotic partial nephrectomy: a prospective randomized trial [published online ahead of print, 2020 Jul 6]. J Robot Surg.\n\n3 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n4 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n5 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","Lexion Medical LLC","lexion-medical-llc-613588-07262021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flexion-medical-llc-613588-07262021","2026-10-26T08:09:14.12601+00:00","2021-08-03","613588","Medical Devices","Patrick Spearman","2026-08-20T02:44:07.37+00:00","2021-07-26",{"id":88,"raw":89,"subject":94,"body_html":95,"body_text":96,"firm_name":97,"letter_id":98,"created_at":58,"fei_number":19,"letter_url":99,"updated_at":100,"action_type":22,"case_status":23,"posted_date":101,"marcs_cms_no":102,"product_type":83,"closeout_date":19,"issuing_office":72,"recipient_name":103,"body_fetched_at":104,"delivery_method":105,"recipient_title":19,"reference_number":19,"action_taken_date":106,"medical_device_id":19,"response_letter_date":19},63,[90,91,92,72,93,13,13,13],"\u003Ctime datetime=\"2026-06-30T04:00:00Z\">06\u002F30\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-20T04:00:00Z\">05\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbmc-medical-co-ltd-725759-05202026\">BMC Medical Co., Ltd.\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jian Xu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BMC Medical Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 16 Lize Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Room 10, 17F Building 4, Huiya Plaza\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fengtai Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Beijing Shi\u003C\u002Fspan>, \u003Cspan>100073\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 725759\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>May 20, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Xu:\u003C\u002Fp>\u003Cp>During an inspection of 3B Medical, Inc. (d.b.a. React Health, Inc.) located at 5475 Rings Road, Dublin, OH 43017 from December 1, 2025 through December 10, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is the specification developer and 510(k) owner of various ventilator devices that are imported to the United States by 3B Medical, Inc. This includes Auto-Adjusting Positive Airway Pressure (Auto-CPAP or APAP) ventilator devices, intended for the treatment of obstructive sleep apnea in adults, under the brand name of G3X APAP (G4600). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection revealed that your G3X APAP devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with significant changes or modifications without submitting a new premarket notification to FDA, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>Your firm has made significant changes or modifications to the design of the Luna® CPAP and Auto CPAP System which was granted clearance on September 8, 2016 under 510(k) number K153387. The inspection at 3B Medical, Inc. established that you are the design change authority and 510(k) owner of the device. For example, FDA has reviewed your firm’s nP3_Product System Verification Report_G3-2.11.01 and Design change evaluation report, Project code: nP3 for the Luna G3 APAP, Model LG3600, approved on March 12, 2025, which revealed that the firmware\u002Fsoftware was updated with additional recognition features, i.e., (1) Flow Limitation, (2) Respiratory Effort-Related Arousals (RERA), and (3) Periodic breathing, to distinguish between central hypopnea and obstructive hypopnea events.\u003C\u002Fp>\u003Cp>Furthermore, the sound abatement system of the cleared Luna APAP devices was modified to ‘\u003Cstrong>(b)(4)\u003C\u002Fstrong>’ or ‘\u003Cstrong>(b)(4)\u003C\u002Fstrong>’ and a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> was added to the cleared Luna APAP device to match the sound reduction as a result of the material change. Additionally, the Printed Circuit Board Assembly (PCBA) includes a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> chip compatible with the new algorithm and new data structure master control software. These design modifications to the cleared Luna APAP appear to have given rise to a new model branded as G3X APAP. These changes could significantly affect safety or effectiveness because they are significant changes in the design and materials of these devices. The firmware update introduced new detection algorithms capable of distinguishing between central and obstructive hypopnea events, which affects the accuracy of event classification and the data available to clinicians for evaluating therapy effectiveness and informing future therapy adjustments. The removal of \u003Cstrong>(b)(4)\u003C\u002Fstrong> represents a material change to the gas pathway that raises biocompatibility concerns, and when combined with the addition of a new \u003Cstrong>(b)(4)\u003C\u002Fstrong>, these changes could affect the overall pressure and flow profile of the device, thereby impacting therapy delivery. The addition of a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> PCBA chip and updated master control software introduces potential implications for electrical safety and overall device performance. Collectively, these changes represent significant modifications in device design, materials, and software that could significantly affect the safety and effectiveness of the device.\u003C\u002Fp>\u003Cp>FDA’s regulations at 21 CFR 807.81(a)(3)(i) provide that submission of a 510(k) is required for “a change or modification in the device that could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process.” Thus, the G3X APAP is misbranded under 502(o) because of your failure to submit the required premarket notification for the modifications. FDA requests that your firm cease any activities that result in the misbranding or adulteration of your devices.\u003C\u002Fp>\u003Cp>For further explanation on the need for a new premarket notification, or \"510(k),\" for changes to the intended use or design affecting safety and effectiveness, consult the guidance document \"Deciding When to Submit a 510(k) for a Change to an Existing Device — Guidance for Industry and Food and Drug Administration Staff (fda.gov).\" The “Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program Guidance for Industry and Food and Drug Administration Staff,” is also recommended for obtaining FDA feedback on the 510(k) submission for the G3 X APAP devices.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Correction and Removals Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection also revealed that your firm’s Luna G3 APAP devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals.\u003C\u002Fp>\u003Cp>Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to submit a Report required by 21 CFR 806.10 to FDA, within 10 working days of initiating the correction or removal. For example: your Luna G3 APAP devices with firmware G3-2.00.76 could cause the Luna G3 APAP device to unexpectedly shut down during use, which causes loss of therapy for patients with obstructive sleep apnea. You communicated with 3B (React Health) in \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The action of updating the firmware to G3-2.00.77 is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA.\u003C\u002Fp>\u003Cp>Your firm has not submitted a Report of Correction or Removal to FDA for the firmware update to G3-2.00.77 as of May 19, 2026.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts.\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. The inspection of 3B Medical on December 1, 2025 to December 10, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, should any corrective actions you propose or implement relate to device current good manufacturing practice (CGMP) requirements, they must be made pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 725759” when replying. If you have any questions about the contents of this letter, please contact: Sargum Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara A. Marsden\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>\u003Cstrong>(b)(4), (b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJian Xu\n\nRecipient Title\n\nPresident\n\nBMC Medical Co., Ltd.\n\nNo. 16 Lize Road\n\nRoom 10, 17F Building 4, Huiya Plaza\n\nFengtai Qu\n\nBeijing Shi, 100073\n\nChina\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 725759\nMay 20, 2026\nDear Mr. Xu:\nDuring an inspection of 3B Medical, Inc. (d.b.a. React Health, Inc.) located at 5475 Rings Road, Dublin, OH 43017 from December 1, 2025 through December 10, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is the specification developer and 510(k) owner of various ventilator devices that are imported to the United States by 3B Medical, Inc. This includes Auto-Adjusting Positive Airway Pressure (Auto-CPAP or APAP) ventilator devices, intended for the treatment of obstructive sleep apnea in adults, under the brand name of G3X APAP (G4600). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nUnapproved Device Violations\nOur inspection revealed that your G3X APAP devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with significant changes or modifications without submitting a new premarket notification to FDA, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nYour firm has made significant changes or modifications to the design of the Luna® CPAP and Auto CPAP System which was granted clearance on September 8, 2016 under 510(k) number K153387. The inspection at 3B Medical, Inc. established that you are the design change authority and 510(k) owner of the device. For example, FDA has reviewed your firm’s nP3_Product System Verification Report_G3-2.11.01 and Design change evaluation report, Project code: nP3 for the Luna G3 APAP, Model LG3600, approved on March 12, 2025, which revealed that the firmware\u002Fsoftware was updated with additional recognition features, i.e., (1) Flow Limitation, (2) Respiratory Effort-Related Arousals (RERA), and (3) Periodic breathing, to distinguish between central hypopnea and obstructive hypopnea events.\nFurthermore, the sound abatement system of the cleared Luna APAP devices was modified to ‘(b)(4)’ or ‘(b)(4)’ and a new (b)(4) was added to the cleared Luna APAP device to match the sound reduction as a result of the material change. Additionally, the Printed Circuit Board Assembly (PCBA) includes a new (b)(4) chip compatible with the new algorithm and new data structure master control software. These design modifications to the cleared Luna APAP appear to have given rise to a new model branded as G3X APAP. These changes could significantly affect safety or effectiveness because they are significant changes in the design and materials of these devices. The firmware update introduced new detection algorithms capable of distinguishing between central and obstructive hypopnea events, which affects the accuracy of event classification and the data available to clinicians for evaluating therapy effectiveness and informing future therapy adjustments. The removal of (b)(4) represents a material change to the gas pathway that raises biocompatibility concerns, and when combined with the addition of a new (b)(4), these changes could affect the overall pressure and flow profile of the device, thereby impacting therapy delivery. The addition of a new (b)(4) PCBA chip and updated master control software introduces potential implications for electrical safety and overall device performance. Collectively, these changes represent significant modifications in device design, materials, and software that could significantly affect the safety and effectiveness of the device.\nFDA’s regulations at 21 CFR 807.81(a)(3)(i) provide that submission of a 510(k) is required for “a change or modification in the device that could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process.” Thus, the G3X APAP is misbranded under 502(o) because of your failure to submit the required premarket notification for the modifications. FDA requests that your firm cease any activities that result in the misbranding or adulteration of your devices.\nFor further explanation on the need for a new premarket notification, or \"510(k),\" for changes to the intended use or design affecting safety and effectiveness, consult the guidance document \"Deciding When to Submit a 510(k) for a Change to an Existing Device — Guidance for Industry and Food and Drug Administration Staff (fda.gov).\" The “Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program Guidance for Industry and Food and Drug Administration Staff,” is also recommended for obtaining FDA feedback on the 510(k) submission for the G3 X APAP devices.\nCorrection and Removals Violations\nOur inspection also revealed that your firm’s Luna G3 APAP devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals.\nSignificant violations include, but are not limited to, the following:\n1. Failure to submit a Report required by 21 CFR 806.10 to FDA, within 10 working days of initiating the correction or removal. For example: your Luna G3 APAP devices with firmware G3-2.00.76 could cause the Luna G3 APAP device to unexpectedly shut down during use, which causes loss of therapy for patients with obstructive sleep apnea. You communicated with 3B (React Health) in (b)(4) to (b)(4). The action of updating the firmware to G3-2.00.77 is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA.\nYour firm has not submitted a Report of Correction or Removal to FDA for the firmware update to G3-2.00.77 as of May 19, 2026.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. The inspection of 3B Medical on December 1, 2025 to December 10, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, should any corrective actions you propose or implement relate to device current good manufacturing practice (CGMP) requirements, they must be made pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 725759” when replying. If you have any questions about the contents of this letter, please contact: Sargum Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara A. Marsden\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\n(b)(4), (b)(6)","BMC Medical Co., Ltd.","bmc-medical-co-ltd-725759-05202026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbmc-medical-co-ltd-725759-05202026","2026-10-26T08:08:06.951272+00:00","2026-06-30","725759","Jian Xu","2026-08-19T04:32:13.877+00:00","VIA Electronic Mail","2026-05-20",{"id":108,"raw":109,"subject":94,"body_html":113,"body_text":114,"firm_name":115,"letter_id":116,"created_at":18,"fei_number":19,"letter_url":117,"updated_at":118,"action_type":22,"case_status":23,"posted_date":119,"marcs_cms_no":120,"product_type":83,"closeout_date":19,"issuing_office":72,"recipient_name":121,"body_fetched_at":122,"delivery_method":123,"recipient_title":19,"reference_number":19,"action_taken_date":124,"medical_device_id":19,"response_letter_date":19},954,[110,111,112,72,94,13,13,13],"\u003Ctime datetime=\"2025-04-22T04:00:00Z\">04\u002F22\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-04-04T04:00:00Z\">04\u002F04\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ficu-medical-702535-04042025\">ICU Medical\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Vivek Jain\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>ICU Medical\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>951 Calle Amanecer\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Clemente\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92673\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS 702535\u003C\u002Fp>\u003Cp>April 04, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Jain:\u003C\u002Fp>\u003Cp>During an inspection of Smiths Medical ASD (acquired by your firm ICU Medical in January 2022) FEI: 3012307300 located at 6000 Nathan Lane N., Minneapolis, Minnesota on July 23, 2024, through August 9, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), each of these products is a device because it is an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, which is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Our inspection revealed that the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not for these devices have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\u003Cbr>http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>You currently have clearance, dated August 29, 2011, for a version of the Medfusion® Model 4000 Syringe Infusion Pump which was cleared under K111386 as a Class II device under 21 CFR 880.5725. You also currently have clearance, dated February 1, 2013, for a version of the CADD® Solis VIP Ambulatory Infusion Pump which was cleared under K111275 as a Class II device under 21 CFR 880.5725. However, your firm has failed to submit a premarket notification submission to FDA for significant changes or modifications that could significantly affect the safety or effectiveness of these devices, as required by 21 CFR 807.81(a)(3)(i).\u003C\u002Fp>\u003Cp>In particular, since their last respective clearances, you made multiple changes to the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump that could significantly affect the safety or effectiveness of these devices, including the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the Medfusion® Model 4000 Syringe Infusion Pump as well as \u003Cstrong>(b)(4)\u003C\u002Fstrong> changes for both the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Specifically, these modifications included \u003Cstrong>(b)(4)\u003C\u002Fstrong> changes to address \u003Cstrong>(b)(4)\u003C\u002Fstrong> identified via adverse event reports and \u003Cstrong>(b)(4)\u003C\u002Fstrong> changes to \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Such modifications can significantly impact the functionality of the device with respect to the infusion pumps delivery profile, alarm functionality, etc., and affect the device’s risk profile for risks related to under- or over-infusion, delay in therapy, incomplete therapy, or false alarms leading to adverse health effects for patients such as overdose, volume overload, or cardiorespiratory compromise. Your documentation collected during the recent inspection describing the 510(k) risk-benefit analysis for the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump indicates that these changes were implemented after the most recent clearances of the devices as noted above. Further, you have disseminated updated software \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which includes the changes described above, in response to a Class I recall intended to remediate the cause(s) of the recall impacting delivery of fluids, false alarms, therapy interruption, etc. However, you have not yet submitted 510(k)s as required by 21 CFR 807.81(a)(3)(i). Adding a statement to your labeling that the device software has not undergone FDA review is not sufficient.\u003C\u002Fp>\u003Cp>Furthermore, in the regulatory change impact assessment for the Medfusion® Model 4000 Syringe Infusion Pump software update dated April 28, 2023, you identified that a risk-based assessment of the changed device identified new risks or significantly modified risks. Further, you identified that the change either creates or necessitates a new risk control measure or modification of an existing risk control measure for a hazardous situation that could result in significant harm. The changes that you made to the risk control measures in an effort to mitigate the hazards that were the basis for a Class I recall were not submitted to FDA in a required 510(k) even though your own procedure indicates that submission of a 510(k) would be required in this situation. However, you only documented to the file that you had made the change and did not submit the required 510(k).\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address the violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent to: Melissa Michurski, Assistant Director at CDRHenforcement@fda.hhs.gov. Please include in the subject line, CMS case # 702535 when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, Compliance Officer at Demetria.Lueneburg@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nVivek Jain\n\nRecipient Title\n\nCEO\n\nICU Medical\n\n951 Calle Amanecer\n\nSan Clemente, CA 92673\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS 702535\nApril 04, 2025\nDear Mr. Jain:\nDuring an inspection of Smiths Medical ASD (acquired by your firm ICU Medical in January 2022) FEI: 3012307300 located at 6000 Nathan Lane N., Minneapolis, Minnesota on July 23, 2024, through August 9, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), each of these products is a device because it is an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, which is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nOur inspection revealed that the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not for these devices have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\nhttp:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nYou currently have clearance, dated August 29, 2011, for a version of the Medfusion® Model 4000 Syringe Infusion Pump which was cleared under K111386 as a Class II device under 21 CFR 880.5725. You also currently have clearance, dated February 1, 2013, for a version of the CADD® Solis VIP Ambulatory Infusion Pump which was cleared under K111275 as a Class II device under 21 CFR 880.5725. However, your firm has failed to submit a premarket notification submission to FDA for significant changes or modifications that could significantly affect the safety or effectiveness of these devices, as required by 21 CFR 807.81(a)(3)(i).\nIn particular, since their last respective clearances, you made multiple changes to the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump that could significantly affect the safety or effectiveness of these devices, including the (b)(4) for the Medfusion® Model 4000 Syringe Infusion Pump as well as (b)(4) changes for both the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Specifically, these modifications included (b)(4) changes to address (b)(4) identified via adverse event reports and (b)(4) changes to (b)(4) and (b)(4). Such modifications can significantly impact the functionality of the device with respect to the infusion pumps delivery profile, alarm functionality, etc., and affect the device’s risk profile for risks related to under- or over-infusion, delay in therapy, incomplete therapy, or false alarms leading to adverse health effects for patients such as overdose, volume overload, or cardiorespiratory compromise. Your documentation collected during the recent inspection describing the 510(k) risk-benefit analysis for the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump indicates that these changes were implemented after the most recent clearances of the devices as noted above. Further, you have disseminated updated software (b)(4), which includes the changes described above, in response to a Class I recall intended to remediate the cause(s) of the recall impacting delivery of fluids, false alarms, therapy interruption, etc. However, you have not yet submitted 510(k)s as required by 21 CFR 807.81(a)(3)(i). Adding a statement to your labeling that the device software has not undergone FDA review is not sufficient.\nFurthermore, in the regulatory change impact assessment for the Medfusion® Model 4000 Syringe Infusion Pump software update dated April 28, 2023, you identified that a risk-based assessment of the changed device identified new risks or significantly modified risks. Further, you identified that the change either creates or necessitates a new risk control measure or modification of an existing risk control measure for a hazardous situation that could result in significant harm. The changes that you made to the risk control measures in an effort to mitigate the hazards that were the basis for a Class I recall were not submitted to FDA in a required 510(k) even though your own procedure indicates that submission of a 510(k) would be required in this situation. However, you only documented to the file that you had made the change and did not submit the required 510(k).\nYour firm should take prompt action to address the violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent to: Melissa Michurski, Assistant Director at CDRHenforcement@fda.hhs.gov. Please include in the subject line, CMS case # 702535 when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, Compliance Officer at Demetria.Lueneburg@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","ICU Medical","icu-medical-702535-04042025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ficu-medical-702535-04042025","2026-10-26T08:08:57.251119+00:00","2025-04-22","702535","Vivek Jain","2026-08-19T16:52:11.735+00:00","VIA UNITED PARCEL SERVICE","2025-04-04",{"id":126,"raw":127,"subject":131,"body_html":133,"body_text":134,"firm_name":135,"letter_id":136,"created_at":137,"fei_number":19,"letter_url":138,"updated_at":139,"action_type":22,"case_status":140,"posted_date":141,"marcs_cms_no":142,"product_type":83,"closeout_date":143,"issuing_office":72,"recipient_name":144,"body_fetched_at":145,"delivery_method":105,"recipient_title":19,"reference_number":19,"action_taken_date":146,"medical_device_id":19,"response_letter_date":19},2483,[128,129,130,72,131,13,132,13],"\u003Ctime datetime=\"2022-08-30T13:20:00Z\">08\u002F30\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-03T04:00:00Z\">08\u002F03\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-08032022\">USA Medical LLC\u003C\u002Fa>","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-02062023\">\u003Ctime datetime=\"2023-02-09T05:00:00Z\">02\u002F09\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Damon H. Roberts\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FOwner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>USA Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1220 Texan Trail, Suite 205\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Grapevine\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76051-4164\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:damon@USAMedicalllc.com\"> damon@USAMedicalllc.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 631500\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 3, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Roberts:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at USA Medical LLC (USA Medical), located at 1220 Texan Trail, Suite 205, Grapevine, TX from February 28 through March 15, 2022. During the inspection, FDA investigators determined that your firm is a medical device manufacturer and distributor of SARS-CoV-2 Antigen Rapid Test kits distributed under the names SARS-COV-2 Antigen Rapid Test, \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID-19 Ag Rapid Test\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> (hereafter, collectively referred to as “COVID-19 Tests”). Based on our review, your COVID-19 Tests are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that the COVID-19 Tests have been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated within the meaning of section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>Your products are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because labeling distributed with these products included statements that the products are authorized for use under an Emergency Use Authorization (EUA). These statements create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, none of your COVID-19 Test Kits have been approved, cleared, or authorized for emergency use by FDA.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed products that are intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent the distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that these COVID-19 Tests are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, in manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We note that you have not responded to the Form FDA 483, List of Inspectional Observations issued to your firm initially on March 15, 2022, and, again in annotated form, on March 17, 2022. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish procedures for acceptance activities, as required by 21 CFR § 820.80(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm distributed at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> SARS-CoV-2 Antigen Rapid Test kits from 9\u002F30\u002F2021 – 2\u002F24\u002F2022 without establishing procedures for incoming product and finished device acceptance activities to ensure the device(s) conform to specified requirements and meet acceptance criteria, and acceptance records are maintained.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures to ensure that nonconforming product is identified, documented, evaluated, segregated, and dispositioned. As you repackage and relabel tests and you do not have an authorized Emergency Use Authorization for those products, you do not have procedures regarding these nonconforming products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR § 820.160(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established and maintained procedures for the control and distribution of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure only devices approved for release are distributed, and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. You distributed more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> test kits from 9\u002F30\u002F2021 - 2\u002F24\u002F2022 to customers in the United States and did not review and approve the products prior to release\u002Fdistribution.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for evaluation of suppliers, including the quality requirements that must be met by suppliers, to ensure that received products and services conform to specified requirements. The firm did not evaluate the manufacturers of the SARS-CoV-2 Antigen Rapid Test kits based on their ability to meet specified requirements, including quality requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish procedures for corrective and preventative action, as required by 21 CFR § 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for implementing and documenting corrective and preventive action, including requirements for: 1) analyzing quality data sources; 2) investigating the cause of nonconformities; 3) identifying the actions needed to prevent occurrence or recurrence of nonconformities; 4) ensuring actions implemented are effective; 5) documenting changes in methods and procedures; 6) disseminating information related to quality problems to appropriate individuals; and 7) submitting relevant information on quality problems for management review.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for complaint handling and documentation to ensure that complaints are: 1) processed in a uniform and timely manner, 2) oral complaints are documented upon receipt, 3) complaints are evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to establish procedures to control environmental conditions as required by 21 CFR § 820.70(c).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures to control environmental conditions to ensure that the SARS-CoV-2 Antigen Rapid Test products (raw materials and finished devices) are stored within the required temperature range(s) and monitored to ensure that any deviations are noted and addressed. Your firm was found to be storing test kits in its loading dock and administrative areas without procedures\u002Frequirements\u002Fmonitoring. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> kit has defined storage requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to establish and maintain adequate procedures to ensure that mix-ups, damage, deterioration, contamination, or other adverse effects to product do not occur during handling as required by 21 CFR § 820.140.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, \u003Cstrong>(b)(4)\u003C\u002Fstrong> boxes containing \u003Cstrong>(b)(4)\u003C\u002Fstrong> Diagnostic Kit SARS-CoV-2 Antigen Rapid Test kits (no batch\u002Flot number identification) of products returned on 2\u002F16\u002F2022 in the common administrative area were observed that had not been identified, documented, or segregated as returned product.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>9. Failure to establish procedures for quality audits as required by 21 CFR § 820.22.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for quality audits to ensure that the quality system complies with the quality system requirements and to determine the effectiveness of the quality system. Quality audits have not been performed since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>10. Failure to establish procedures for management review as required by 21 CFR § 820.20(c).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for management review of the suitability and effectiveness of the quality system. Management reviews have not been conducted since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>11. Failure to establish procedures for training and identifying training needs as required by 21 CFR § 820.25(b).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established training procedures to identify training needs and to ensure that all personnel are trained to adequately perform their responsibilities. Training records are not maintained.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>12. Failure to establish a policy, and objectives for, and commitment to, quality as required by 21 CFR § 820.20(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your Management with executive responsibility has not established it policy and objectives for, and commitment to, quality.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your COVID-19 Tests are misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Failure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations. Other federal agencies may take your compliance history into account when considering the award of contracts. Should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices such devices will not be approved until the violations have been corrected. Should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-%20fdas-decision-not-issue-certain-export-certificates-devices\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-fdas-decision-not-issue-certain-export-certificates-devices\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Note, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test Kits and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>Please also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter related to Quality Systems and MDR reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\u003C\u002Fp>\n\n\u003Cp>This response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS Case # 631500.\u003C\u002Fp>\n\n\u003Cp>If you have questions about the contents of this letter, please contact Compliance Officer Raymond W. Brullo at 949-608-2918, or via email at raymond.brullo@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to correct any violations and bring your products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTimothy T. Stenzel, M.D., Ph.D. Director\u003Cbr>\nOHT7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 3\u003Cbr>\nOffice of Regulatory Affairs\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The “\u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Ag Rapid Test” distributed by your firm appears to be the \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Ag Rapid Test manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. On \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FDA reissued an Emergency Use Authorization (EUA) pursuant to section 564 of the Act, 21 U.S.C § 360bbb‐3, to permit emergency use of \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>COVID‐19 Ag Rapid Test. The test is indicated for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet the requirements to perform high complexity, moderate complexity, or waived tests and in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. However, the EUA does not authorize the distribution of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Rapid Test for use outside of these specified settings.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID‐19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential%E2%80%90actions\u002Fproclamation%E2%80%90declaring%E2%80%90national%E2%80%90%20emergency-concerning%E2%80%90novel%E2%80%90coronavirus%E2%80%90disease%E2%80%90covid%E2%80%9019%E2%80%90outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential‐actions\u002Fproclamation‐declaring‐national‐ emergency-concerning‐novel‐coronavirus‐disease‐covid‐19‐outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Accessible at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDamon H. Roberts\n\nRecipient Title\n\nPresident\u002FOwner\n\nUSA Medical LLC\n\n1220 Texan Trail, Suite 205\n\nGrapevine, TX 76051-4164\n\nUnited States\n\ndamon@USAMedicalllc.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS # 631500\n\nAugust 3, 2022\n\nDear Mr. Roberts:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at USA Medical LLC (USA Medical), located at 1220 Texan Trail, Suite 205, Grapevine, TX from February 28 through March 15, 2022. During the inspection, FDA investigators determined that your firm is a medical device manufacturer and distributor of SARS-CoV-2 Antigen Rapid Test kits distributed under the names SARS-COV-2 Antigen Rapid Test, (b)(4) COVID-19 Ag Rapid Test1 (hereafter, collectively referred to as “COVID-19 Tests”). Based on our review, your COVID-19 Tests are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-192 in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nOur inspection revealed that the COVID-19 Tests have been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated within the meaning of section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nYour products are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because labeling distributed with these products included statements that the products are authorized for use under an Emergency Use Authorization (EUA). These statements create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, none of your COVID-19 Test Kits have been approved, cleared, or authorized for emergency use by FDA.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.3 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.4 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed products that are intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent the distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”5 provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nOur inspection also revealed that these COVID-19 Tests are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, in manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We note that you have not responded to the Form FDA 483, List of Inspectional Observations issued to your firm initially on March 15, 2022, and, again in annotated form, on March 17, 2022. These violations include, but are not limited to, the following:\n\n1. Failure to establish procedures for acceptance activities, as required by 21 CFR § 820.80(a).\n\nSpecifically, your firm distributed at least (b)(4) SARS-CoV-2 Antigen Rapid Test kits from 9\u002F30\u002F2021 – 2\u002F24\u002F2022 without establishing procedures for incoming product and finished device acceptance activities to ensure the device(s) conform to specified requirements and meet acceptance criteria, and acceptance records are maintained.\n\n2. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a).\n\nSpecifically, your firm has not established procedures to ensure that nonconforming product is identified, documented, evaluated, segregated, and dispositioned. As you repackage and relabel tests and you do not have an authorized Emergency Use Authorization for those products, you do not have procedures regarding these nonconforming products.\n\n3. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR § 820.160(a).\n\nSpecifically, your firm has not established and maintained procedures for the control and distribution of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure only devices approved for release are distributed, and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. You distributed more than (b)(4) test kits from 9\u002F30\u002F2021 - 2\u002F24\u002F2022 to customers in the United States and did not review and approve the products prior to release\u002Fdistribution.\n\n4. Failure to establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50.\n\nSpecifically, your firm has not established procedures for evaluation of suppliers, including the quality requirements that must be met by suppliers, to ensure that received products and services conform to specified requirements. The firm did not evaluate the manufacturers of the SARS-CoV-2 Antigen Rapid Test kits based on their ability to meet specified requirements, including quality requirements.\n\n5. Failure to establish procedures for corrective and preventative action, as required by 21 CFR § 820.100(a).\n\nSpecifically, your firm has not established procedures for implementing and documenting corrective and preventive action, including requirements for: 1) analyzing quality data sources; 2) investigating the cause of nonconformities; 3) identifying the actions needed to prevent occurrence or recurrence of nonconformities; 4) ensuring actions implemented are effective; 5) documenting changes in methods and procedures; 6) disseminating information related to quality problems to appropriate individuals; and 7) submitting relevant information on quality problems for management review.\n\n6. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\n\nSpecifically, your firm has not established procedures for complaint handling and documentation to ensure that complaints are: 1) processed in a uniform and timely manner, 2) oral complaints are documented upon receipt, 3) complaints are evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report.\n\n7. Failure to establish procedures to control environmental conditions as required by 21 CFR § 820.70(c).\n\nSpecifically, your firm has not established procedures to control environmental conditions to ensure that the SARS-CoV-2 Antigen Rapid Test products (raw materials and finished devices) are stored within the required temperature range(s) and monitored to ensure that any deviations are noted and addressed. Your firm was found to be storing test kits in its loading dock and administrative areas without procedures\u002Frequirements\u002Fmonitoring. The (b)(4) kit has defined storage requirements.\n\n8. Failure to establish and maintain adequate procedures to ensure that mix-ups, damage, deterioration, contamination, or other adverse effects to product do not occur during handling as required by 21 CFR § 820.140.\n\nSpecifically, (b)(4) boxes containing (b)(4) Diagnostic Kit SARS-CoV-2 Antigen Rapid Test kits (no batch\u002Flot number identification) of products returned on 2\u002F16\u002F2022 in the common administrative area were observed that had not been identified, documented, or segregated as returned product.\n\n9. Failure to establish procedures for quality audits as required by 21 CFR § 820.22.\n\nSpecifically, your firm has not established procedures for quality audits to ensure that the quality system complies with the quality system requirements and to determine the effectiveness of the quality system. Quality audits have not been performed since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\n\n10. Failure to establish procedures for management review as required by 21 CFR § 820.20(c).\n\nSpecifically, your firm has not established procedures for management review of the suitability and effectiveness of the quality system. Management reviews have not been conducted since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\n\n11. Failure to establish procedures for training and identifying training needs as required by 21 CFR § 820.25(b).\n\nSpecifically, your firm has not established training procedures to identify training needs and to ensure that all personnel are trained to adequately perform their responsibilities. Training records are not maintained.\n\n12. Failure to establish a policy, and objectives for, and commitment to, quality as required by 21 CFR § 820.20(a).\n\nSpecifically, your Management with executive responsibility has not established it policy and objectives for, and commitment to, quality.\n\nOur inspection also revealed that your COVID-19 Tests are misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting.\n\nFailure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\n\nSpecifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\n\nYour firm should take prompt action to address any violations. Other federal agencies may take your compliance history into account when considering the award of contracts. Should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices such devices will not be approved until the violations have been corrected. Should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-fdas-decision-not-issue-certain-export-certificates-devices.\n\nNote, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test Kits and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nPlease also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter related to Quality Systems and MDR reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\n\nThis response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS Case # 631500.\n\nIf you have questions about the contents of this letter, please contact Compliance Officer Raymond W. Brullo at 949-608-2918, or via email at raymond.brullo@fda.hhs.gov\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to correct any violations and bring your products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D. Director\n\nOHT7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 3\n\nOffice of Regulatory Affairs\n\n___________________________\n\n1 The “(b)(4) COVID‐19 Ag Rapid Test” distributed by your firm appears to be the (b)(4) COVID‐19 Ag Rapid Test manufactured by (b)(4). On (b)(4), FDA reissued an Emergency Use Authorization (EUA) pursuant to section 564 of the Act, 21 U.S.C § 360bbb‐3, to permit emergency use of (b)(4) COVID‐19 Ag Rapid Test. The test is indicated for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet the requirements to perform high complexity, moderate complexity, or waived tests and in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. However, the EUA does not authorize the distribution of the (b)(4) COVID‐19 Rapid Test for use outside of these specified settings.\n\n2 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\n\n3 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n4 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID‐19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential‐actions\u002Fproclamation‐declaring‐national‐ emergency-concerning‐novel‐coronavirus‐disease‐covid‐19‐outbreak\u002F.\n\n5 Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.","USA Medical LLC","usa-medical-llc-631500-08032022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-08032022","2026-10-26T08:10:18.402099+00:00","Closed Out","2022-08-30","631500","2023-02-09","Damon H. Roberts","2026-08-20T01:37:57.067+00:00","2022-08-03",{"id":148,"raw":149,"subject":154,"body_html":155,"body_text":156,"firm_name":157,"letter_id":158,"created_at":159,"fei_number":19,"letter_url":160,"updated_at":161,"action_type":22,"case_status":23,"posted_date":162,"marcs_cms_no":163,"product_type":164,"closeout_date":19,"issuing_office":153,"recipient_name":165,"body_fetched_at":166,"delivery_method":167,"recipient_title":19,"reference_number":168,"action_taken_date":169,"medical_device_id":19,"response_letter_date":19},21646,[150,151,152,153,154,13,13,13],"\u003Ctime datetime=\"2026-08-25T04:00:00Z\">08\u002F25\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-14T04:00:00Z\">08\u002F14\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fr3-medical-companies-726330-08142026\">R3 Medical Companies\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Unapproved New Drugs\u002FUnlicensed Biological Product Violations","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via UPS and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 26-726330\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>David L. Greene, M.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>R3 Medical Companies\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>10045 E. Dynamite Blvd., Suite 260\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Scottsdale\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85262\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:dgreene@bello.bio\"> dgreene@bello.bio\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:dgreene@regensuppliers.com\"> dgreene@regensuppliers.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>August 14, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>CBER 26-726330\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Dr. Greene:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your facilities, Bello Bio, LLC (herein referred to as “Bello”) and Regen Suppliers, LLC (herein referred to as “Regen”) co-located at 10045 E. Dynamite Blvd., Suite 260, Scottsdale, AZ 85262, between November 17, 2025, and December 16, 2025.\u003Cem>\u003Cstrong>\u003Csup>1,2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> During the inspections, FDA documented that Bello contract manufactures and labels umbilical cord derived products, ReBellaWJ, ReBellaXO, and ReBellaXOL, for private label distribution by Regen.\u003Cem>\u003Cstrong>\u003Csup>3,4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Regen approves, labels, stores, and distributes the aforementioned products as well as an umbilical cord blood derived product, ReBellaCB, contract manufactured under private label by \u003Cstrong>(b)(4)\u003C\u002Fstrong> ReBellaWJ, ReBellaXO, and ReBellaXOL will herein be referred to as “your umbilical cord derived products.” These three products, together with ReBellaCB, will be referred to collectively as “your products.”\u003C\u002Fp>\u003Cp>This letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&amp;C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).\u003C\u002Fp>\u003Cp>This warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211, in the manufacture of your products. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B). Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. § 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Unlicensed Biological Product Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, including, but not limited to, your YouTube channel, @R3StemCell www.youtube.com\u002F@R3StemCell, TikTok @R3StemCell www.tiktok.com\u002F@r3stemcell, Instagram @R3stemcellofficial, www.instagram.com\u002Fr3stemcellofficial, Facebook page R3 Stem Cell www.facebook.com\u002Fr3stemcelltherapyofficial, and websites, www.r3stemcell.com, www.bello.bio, and www.regensuppliers.com5, (last visited August 2026), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans, and\u002For are intended to affect the structure or function of the body. For example:\u003C\u002Fp>\u003Cul>\u003Cli>ReBellaWJ:\u003Cbr>o R3 Stem Cell, LLC website (www.r3stemcell.com\u002F):\u003Cbr> In a November 15, 2020, blog post entitled “\u003Cem>What is Umbilical Cord Wharton’s Jelly\u003C\u002Fem>?” (https:\u002F\u002Fr3stemcell.com\u002Fwhat-is-umbilical-cord-whartons-jelly\u002F):\u003Cbr>• “One of the major effects is the reduction of inflammation. Chronic inflammation has been shown to be present in the body and is a known precursor to many medical conditions including organ failure, arthritis, several types of cancer and more. The biologic’s cells are able to systemically reduce this inflammation…”\u003Cbr>• “…The top wharton’s jelly stem cell product being offered is ReBellaWJ…To find out more information and to place an order, visit and call Regen Suppliers at (888) 568-6909.”\u003Cbr> Under a title of “What conditions benefit from their use?” on Umbilical Cord Stem Cell Therapy tab: “In the research literature and from our provider’s experience, there are benefits being shown for: Neurologic Conditions…Heart\u002FKidney\u002FLung Failure (e.g. Cardiomyopathy, COPD)…Autism…Cerebral Palsy…Diabetes…Lyme Disease...SI Joint Pain...Erectile Dysfunction..”\u003Cbr>o R3 Anti-Aging website (https:\u002F\u002Fr3antiaging.com):\u003Cbr> Under the “Umbilical Cord Allograft” tab within your “Regenerative Therapies” page: “R3 Anti-Aging and Medspa in Scottsdale and Nashville offers umbilical cord allograft therapy for patients who have joint or soft tissue pain...In addition, the umbilical cord tissue contains a significant amount of growth factors, exosomes, mesenchymal stem cells and cytokines as well. These facilitate one's body to amp up the repair and regeneration activities to reduce pain from joint degeneration, tendonitis, bursitis...and neuropathy.”\u003C\u002Fli>\u003Cli>ReBellaXO and ReBellaXOL:\u003Cbr>o Regen website (https:\u002F\u002Fwww.regensuppliers.com):\u003Cbr> Until recently, within the “ReBellaXO 1.0mL - B” product page: “ReBellaXO an exosome allograft derived from Wharton's Jelly MSCs... For your procedures involving IV's, joints, soft tissue, hair, facial or sexual rejuvenation, ReBellaXO represents your most cost effective and safe option for fitting regenerative biologics into your patient care!”\u003Cbr> Until recently, under the “About” tab: “ReBellaXOL Lyophilized Exosomes… produces collagenesis, anti-scar, pro-angiogenesis, &amp; anti-apoptosis. BelloXO intensely stimulates regeneration…”\u003Cbr>o R3 Stem Cell, LLC website (www.r3stemcell.com\u002F):\u003Cbr> Under the Exosome Therapy tab: “Can exosomes help with neurodegenerative conditions? Research has shown that exosomes can penetrate the blood-brain barrier and stimulate neuronal differentiation, growth of neurons, and reduce inflammatory processes within the brain tissue. This may result in future benefit to neurodegenerative conditions such as Alzheimer’s, Parkinson’s, Post Stroke and other issues.”\u003Cbr>o R3 Anti-Aging website (https:\u002F\u002Fr3antiaging.com):\u003Cbr> The \"Exosome therapy\" page within your \"Treatments\" tab under \"Regenerative Therapies,\"\u003Cbr>• “Exosome Therapy for Joint Pain… Exosome therapy is getting great results for joint pain relief:… Rebuilding cartilage: Exosomes help fix damaged cartilage… Reducing inflammation: They calm the swelling in your joints.”\u003Cbr>• Listing “Wound Healing” and “Anti-Inflammation” in a chart titled “Benefits of Exosome Therapy”\u003C\u002Fli>\u003Cli>ReBellaCB:\u003Cbr>o Until recently, the product page for ReBellaCB on your Regen website, (www.regensuppliers.com), states, “REBELLACB is an Umbilical Cord Blood Stem Cell Allograft” and links to an R3 Stem Cell YouTube video, https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=sZeux0WXsUU&amp;feature=youtu.be, titled “\u003Cem>Is Umbilical Cord Blood Safe for Regenerative Procedures?\u003C\u002Fem>” with the video description stating, “For years now, umbilical cord blood has been used increasingly for non-malignant conditions such as arthritis, neurological conditions, autism, diabetes, liver\u002Fkidney failure and much more. Umbilical cord tissue has a ton of hematopoietic and mesenchymal stem cells along with cytokines, growth factors, and exosomes. All of this makes it very effective for these conditions.”\u003C\u002Fli>\u003Cli>ReBellaCB and ReBellaXO:\u003Cbr>o In a video posted on your R3 Stem Cell YouTube Channel on March 5, 2026 (https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=L0QlPvhdjds) titled “\u003Cem>Elite Football Player Talks to His Stem Cells (844) GET-STEM\u003C\u002Fem>,” an employee is seen showing vials of ReBellaCB and ReBellaXO to a patient and states: “These are your stem cells. There’s 30 million in each vial... This is ReBellaXO. These are your exosomes… Those are very anti-inflammatory...” [0.00-0.24] so should help a lot…” The video description states, “When receiving stem cell therapy to help with injuries, athletes should talk to their cells.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your ReBellaWJ, ReBellaXO, ReBellaXOL, and ReBellaCB products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, your firm does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your ReBellaWJ, ReBellaXO, ReBellaXOL and ReBellaCB products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only.” Homologous use means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). Your products are not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord or forming and replenishing the lymphohematopoietic system for umbilical cord blood). Rather, your products are intended for use in the treatment of various diseases and conditions, such as, but not limited to, arthritis and inflammation, which is not a basic function of umbilical cord or umbilical cord blood in the donor.\u003C\u002Fp>\u003Cp>Moreover, your ReBellaCB product fails to meet the criterion in 21 CFR 1271.10(a)(4) because it is manufactured from allogeneic umbilical cord blood, is dependent on the metabolic activity of living cells for its primary function, and is not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.\u003C\u002Fp>\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.6 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your products are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA’s inspections of your Bello and Regen facilities documented evidence of significant CGMP violations. At the conclusion of the inspections, FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483), to each of Bello and Regen. FDA also identified additional significant violations upon further review of the evidence collected during the inspection, as set forth below.\u003C\u002Fp>\u003Cp>The CGMP violations applicable to your Bello facility pertaining to your umbilical cord derived products include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes, as required by 21 CFR 211.113(b).\u003C\u002Fstrong> For example, your firm has not validated the aseptic processes used to manufacture your umbilical cord derived products. Your umbilical cord derived products purport to be sterile and are expected to be sterile.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity that they are purported or represented to possess, as required by 21 CFR 211.100(a).\u003C\u002Fstrong> For example, your firm has not validated the manufacturing processes for your umbilical cord derived products with respect to identity, strength, quality, and purity.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity, as required by 21 CFR 211.160(b).\u003C\u002Fstrong> For example, samples of your umbilical cord derived products are frozen and thawed prior to sterility testing. Freezing samples has the potential to destroy or compromise any microbial content in the samples before testing, if present; therefore, any contamination that was present prior to freezing may not be reliably detected.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions, as required by 21 CFR 211.42(c)(10)(v).\u003C\u002Fstrong> For example, you have not validated your processes for cleaning and disinfecting the ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> biological safety cabinet (BSC) where your products are exposed to the environment during aseptic processing.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use results of such stability testing to determine appropriate storage conditions and expiration dates, as required by 21 CFR 211.166(a).\u003C\u002Fstrong> For example, your firm assigns a 24-month expiration date to your products without supporting stability testing data.\u003C\u002Fp>\u003Cp>The CGMP violations applicable to your Bello and Regen facilities pertaining to your products include, but are not limited to, the following:\u003Cem>\u003Cstrong>\u003Csup>7\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>6. The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed, as required by 21 CFR 211.22(d).\u003C\u002Fstrong> For example, at the time of the inspection, written procedures describing the responsibilities of the quality unit had not been established, including but not limited to, procedures for the approval or rejection of drug products (21 CFR 211.22(a)) and the handling of all written and oral complaints regarding a drug product (21 CFR 211.198(a)).\u003C\u002Fp>\u003Cp>\u003Cstrong>Responses to the Form FDA-483\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We have reviewed your responses to the Form FDA-483s issued to each of your Bello and Regen facilities dated January 08, 2026 and January 06, 2026, as well as your correspondence dated November 20, 2025, in detail. While you represented that you have implemented or plan to implement certain corrective actions, the described corrective actions are not adequate to remedy the violations noted above. For example, your responses do not address your continued distribution of your products or specific plans for disposition of the remaining inventory manufactured under the violative conditions outlined above. We note that certain corrective actions cannot be evaluated because they lack supporting documentation.\u003C\u002Fp>\u003Cp>Further, for your previously distributed products, you do not describe actions you have taken or plan to take that adequately address the impact of the above-noted deficiencies on your distributed products that are still within expiry and were manufactured under the above-described violative conditions.\u003C\u002Fp>\u003Cp>We acknowledge your commitment to temporarily suspend manufacturing operations until you have made corrections to the observations listed on the Form FDA-483 issued to each of your Bello and Regen facilities. However, this does not resolve the violations outlined in this letter because your responses do not adequately address your failure to have an Investigational New Drug (IND) in effect to study your products addressed in this letter or your lack of an approved BLA to lawfully market your products.\u003C\u002Fp>\u003Cp>FDA has previously provided notice to you, David Greene, in a letter dated May 28, 2019, that based on a review of your website for R3 Stem Cell, LLC (www.r3stemcell.com) at that time, your firm appeared to offer “regenerative stem cell therapies” while promoting these stem cell therapies for numerous diseases or conditions, such as amyotrophic lateral sclerosis (ALS), diabetes, kidney failure, Lyme disease, Parkinson’s disease, and stroke. Based on that review, R3 Stem Cell, LLC did not appear to qualify for any exception under 21 CFR 1271.15; the “regenerative stem cell therapies” were intended for nonhomologous uses and thus would be regulated as drugs as defined in section 201(g) of the FD&amp;C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)]. However, our review of your current websites and various social media accounts, which are also linked to your websites, indicates umbilical stem cell therapy and exosome therapy continue to be offered by R3 Stem Cell, LLC for treatment of various diseases and conditions, as described above.\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Concerns\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition to the violations described above, we have the following concerns:\u003C\u002Fp>\u003Cul>\u003Cli>FDA’s review of information and records collected during the inspections documented Bello also manufactures the following umbilical cord derived\u003Cem>\u003Cstrong>\u003Csup>8\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> products: BelloWJ, BelloXO, and BelloXOL. Your response dated January 08, 2026 asserts that Bello is a manufacturer of HCT\u002FPs and is subject only to current good tissue practice (CGTP) requirements of 21 CFR Part 1271 and is regulated solely under section 361 of the PHS Act); however, review of the evidence collected shows these products do not appear to meet the relevant criteria to be regulated solely under section 361 of the PHS Act, for the reasons discussed above. These products appear to be drugs and\u002For biological products, which are subject to premarket review and approval requirements.\u003C\u002Fli>\u003Cli>FDA review of Bello’s manufacturing records revealed that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is a component of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used during Bello’s manufacturing process of products derived from umbilical cord tissue; however, there did not appear to be evidence that testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> had been performed prior to the release of these products, as required by \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>Bello determines donor eligibility upon review of relevant medical records per your contract agreement with \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The “\u003Cem>Donor Eligibility Criteria\u003C\u002Fem>” documents (effective date 08\u002F15\u002F2023) submitted with your January 8, 2026, response and also collected during the inspection do not include “qualifiers\u002Fcomments” for Transmissible Spongiform Encephalopathy (TSE). In accordance with 21 CFR 1271.75(a)(1)(iv), all donors of cells or tissues, except as provided under 1271.90, must be screened by reviewing the donor’s relevant medical records for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases, including human transmissible spongiform encephalopathy, including Creutzfeldt-Jakob disease. Additionally, FDA Guidance for Industry: \u003Cem>Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products\u003C\u002Fem> (August 2007)\u003Cem>\u003Cstrong>\u003Csup>9\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> recommends screening donors for TSE, including Creutzfeldt-Jakob disease (CJD) and variant CJD (vCJD), by asking if donors have been diagnosed with dementia or any degenerative or demyelinating diseases of the central nervous system or other neurological disease of unknown etiology. For additional information and recommendations intended to assist establishments with complying with all requirements in 21 CFR part 1271, subpart C, please refer to the guidance.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Neither this letter nor the observations noted on the Form FDA-483s for both Bello and Regen, which were discussed with you at the conclusion of the inspections, are intended to be all-inclusive lists of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Vincent Amatrudo\u003Cbr>Acting Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>Cc: \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> During the inspections, you informed FDA that R3 Medical Companies is the parent company of these companies co-located at the same business address: Bello, Regen, R3 Stem Cell, LLC and R3 Anti-Aging Scottsdale LLC. You bear primary responsibility for the business operations at each of the aforementioned entities.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Greene Technologies, LLC, for which you are the co-owner and majority holder, along with Ms. Deborah Greene, invests in the referenced entities and other R3 Anti-Aging LLC clinics located at 5020 Thoroughbred Lane, Brentwood, TN 37027 and 9301 Wilshire Boulevard Penthouse, Beverly Hills, CA 90210. The referenced entities function together with Bello as the manufacturer and Regen as the private label distributor to the three R3 Anti-Aging clinics, healthcare professionals, and other clinics as direct-to-customers and through R3 Stem Cell’s partnership program, R3 Alliance Partner. We note you are also the current Chief Executive Officer (CEO) of R3 Anti-Aging &amp; MedSpa Nashville, LLC (located at 5020 Thoroughbred Lane, Brentwood, TN 37027) and R3 Anti-Aging Beverly Hills, LLC (located at 9301 Wilshire Boulevard Penthouse, Beverly Hills, CA 90210).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Regen markets ReBellaXO and ReBellaXOL as exosome products; however, products manufactured by Bello use the same starting material and manufacturing process (with the exception of an added lyophilization step for ReBellaXOL), which does not appear would isolate exosomes.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> ReBellaXOL was also labeled as ReBellaGF by Bello at the time of the inspections.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> As of August 14, 2026, it appears that the Regen Suppliers website www.regensuppliers.com is no longer accessible with a “404, Not Found.” message displayed.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a) for each product.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> Although products are contract manufactured for Regen, Regen’s activities, as described above, constitute manufacturing under 21 CFR 210.3(b)(12). Regen is therefore subject to CGMP requirements.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem> Bello markets BelloXO and BelloXOL as exosome products; however, it does not appear that the manufacturing process would isolate exosomes.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>9\u003C\u002Fstrong>\u003C\u002Fem> See https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Feligibility-determination-donors-human-cells-tissues-and-cellular-and-tissue-based-products.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia UPS and EMAIL\n\nReference #:\n\nCBER 26-726330\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nDavid L. Greene, M.D.\n\nRecipient Title\n\nChief Executive Officer\n\nR3 Medical Companies\n\n10045 E. Dynamite Blvd., Suite 260\n\nScottsdale, AZ 85262\n\nUnited States\n\ndgreene@bello.bio\n\ndgreene@regensuppliers.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nAugust 14, 2026\nCBER 26-726330\nDear Dr. Greene:\nThe United States Food and Drug Administration (FDA) inspected your facilities, Bello Bio, LLC (herein referred to as “Bello”) and Regen Suppliers, LLC (herein referred to as “Regen”) co-located at 10045 E. Dynamite Blvd., Suite 260, Scottsdale, AZ 85262, between November 17, 2025, and December 16, 2025.1,2 During the inspections, FDA documented that Bello contract manufactures and labels umbilical cord derived products, ReBellaWJ, ReBellaXO, and ReBellaXOL, for private label distribution by Regen.3,4 Regen approves, labels, stores, and distributes the aforementioned products as well as an umbilical cord blood derived product, ReBellaCB, contract manufactured under private label by (b)(4) ReBellaWJ, ReBellaXO, and ReBellaXOL will herein be referred to as “your umbilical cord derived products.” These three products, together with ReBellaCB, will be referred to collectively as “your products.”\nThis letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nThis warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211, in the manufacture of your products. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B). Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. § 331(a).\nUnapproved New Drug and Unlicensed Biological Product Violations\nBased on information and records reviewed by FDA, including, but not limited to, your YouTube channel, @R3StemCell www.youtube.com\u002F@R3StemCell, TikTok @R3StemCell www.tiktok.com\u002F@r3stemcell, Instagram @R3stemcellofficial, www.instagram.com\u002Fr3stemcellofficial, Facebook page R3 Stem Cell www.facebook.com\u002Fr3stemcelltherapyofficial, and websites, www.r3stemcell.com, www.bello.bio, and www.regensuppliers.com5, (last visited August 2026), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans, and\u002For are intended to affect the structure or function of the body. For example:\nReBellaWJ:\no R3 Stem Cell, LLC website (www.r3stemcell.com\u002F):\n In a November 15, 2020, blog post entitled “What is Umbilical Cord Wharton’s Jelly?” (https:\u002F\u002Fr3stemcell.com\u002Fwhat-is-umbilical-cord-whartons-jelly\u002F):\n• “One of the major effects is the reduction of inflammation. Chronic inflammation has been shown to be present in the body and is a known precursor to many medical conditions including organ failure, arthritis, several types of cancer and more. The biologic’s cells are able to systemically reduce this inflammation…”\n• “…The top wharton’s jelly stem cell product being offered is ReBellaWJ…To find out more information and to place an order, visit and call Regen Suppliers at (888) 568-6909.”\n Under a title of “What conditions benefit from their use?” on Umbilical Cord Stem Cell Therapy tab: “In the research literature and from our provider’s experience, there are benefits being shown for: Neurologic Conditions…Heart\u002FKidney\u002FLung Failure (e.g. Cardiomyopathy, COPD)…Autism…Cerebral Palsy…Diabetes…Lyme Disease...SI Joint Pain...Erectile Dysfunction..”\no R3 Anti-Aging website (https:\u002F\u002Fr3antiaging.com):\n Under the “Umbilical Cord Allograft” tab within your “Regenerative Therapies” page: “R3 Anti-Aging and Medspa in Scottsdale and Nashville offers umbilical cord allograft therapy for patients who have joint or soft tissue pain...In addition, the umbilical cord tissue contains a significant amount of growth factors, exosomes, mesenchymal stem cells and cytokines as well. These facilitate one's body to amp up the repair and regeneration activities to reduce pain from joint degeneration, tendonitis, bursitis...and neuropathy.”\nReBellaXO and ReBellaXOL:\no Regen website (https:\u002F\u002Fwww.regensuppliers.com):\n Until recently, within the “ReBellaXO 1.0mL - B” product page: “ReBellaXO an exosome allograft derived from Wharton's Jelly MSCs... For your procedures involving IV's, joints, soft tissue, hair, facial or sexual rejuvenation, ReBellaXO represents your most cost effective and safe option for fitting regenerative biologics into your patient care!”\n Until recently, under the “About” tab: “ReBellaXOL Lyophilized Exosomes… produces collagenesis, anti-scar, pro-angiogenesis, & anti-apoptosis. BelloXO intensely stimulates regeneration…”\no R3 Stem Cell, LLC website (www.r3stemcell.com\u002F):\n Under the Exosome Therapy tab: “Can exosomes help with neurodegenerative conditions? Research has shown that exosomes can penetrate the blood-brain barrier and stimulate neuronal differentiation, growth of neurons, and reduce inflammatory processes within the brain tissue. This may result in future benefit to neurodegenerative conditions such as Alzheimer’s, Parkinson’s, Post Stroke and other issues.”\no R3 Anti-Aging website (https:\u002F\u002Fr3antiaging.com):\n The \"Exosome therapy\" page within your \"Treatments\" tab under \"Regenerative Therapies,\"\n• “Exosome Therapy for Joint Pain… Exosome therapy is getting great results for joint pain relief:… Rebuilding cartilage: Exosomes help fix damaged cartilage… Reducing inflammation: They calm the swelling in your joints.”\n• Listing “Wound Healing” and “Anti-Inflammation” in a chart titled “Benefits of Exosome Therapy”\nReBellaCB:\no Until recently, the product page for ReBellaCB on your Regen website, (www.regensuppliers.com), states, “REBELLACB is an Umbilical Cord Blood Stem Cell Allograft” and links to an R3 Stem Cell YouTube video, https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=sZeux0WXsUU&feature=youtu.be, titled “Is Umbilical Cord Blood Safe for Regenerative Procedures?” with the video description stating, “For years now, umbilical cord blood has been used increasingly for non-malignant conditions such as arthritis, neurological conditions, autism, diabetes, liver\u002Fkidney failure and much more. Umbilical cord tissue has a ton of hematopoietic and mesenchymal stem cells along with cytokines, growth factors, and exosomes. All of this makes it very effective for these conditions.”\nReBellaCB and ReBellaXO:\no In a video posted on your R3 Stem Cell YouTube Channel on March 5, 2026 (https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=L0QlPvhdjds) titled “Elite Football Player Talks to His Stem Cells (844) GET-STEM,” an employee is seen showing vials of ReBellaCB and ReBellaXO to a patient and states: “These are your stem cells. There’s 30 million in each vial... This is ReBellaXO. These are your exosomes… Those are very anti-inflammatory...” [0.00-0.24] so should help a lot…” The video description states, “When receiving stem cell therapy to help with injuries, athletes should talk to their cells.”\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nYour ReBellaWJ, ReBellaXO, ReBellaXOL, and ReBellaCB products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, your firm does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\nFor example, your ReBellaWJ, ReBellaXO, ReBellaXOL and ReBellaCB products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only.” Homologous use means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). Your products are not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord or forming and replenishing the lymphohematopoietic system for umbilical cord blood). Rather, your products are intended for use in the treatment of various diseases and conditions, such as, but not limited to, arthritis and inflammation, which is not a basic function of umbilical cord or umbilical cord blood in the donor.\nMoreover, your ReBellaCB product fails to meet the criterion in 21 CFR 1271.10(a)(4) because it is manufactured from allogeneic umbilical cord blood, is dependent on the metabolic activity of living cells for its primary function, and is not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.6 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your products are regulated as drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\nCGMP Violations\nFDA’s inspections of your Bello and Regen facilities documented evidence of significant CGMP violations. At the conclusion of the inspections, FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483), to each of Bello and Regen. FDA also identified additional significant violations upon further review of the evidence collected during the inspection, as set forth below.\nThe CGMP violations applicable to your Bello facility pertaining to your umbilical cord derived products include, but are not limited to, the following:\n1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes, as required by 21 CFR 211.113(b). For example, your firm has not validated the aseptic processes used to manufacture your umbilical cord derived products. Your umbilical cord derived products purport to be sterile and are expected to be sterile.\n2. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity that they are purported or represented to possess, as required by 21 CFR 211.100(a). For example, your firm has not validated the manufacturing processes for your umbilical cord derived products with respect to identity, strength, quality, and purity.\n3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity, as required by 21 CFR 211.160(b). For example, samples of your umbilical cord derived products are frozen and thawed prior to sterility testing. Freezing samples has the potential to destroy or compromise any microbial content in the samples before testing, if present; therefore, any contamination that was present prior to freezing may not be reliably detected.\n4. Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions, as required by 21 CFR 211.42(c)(10)(v). For example, you have not validated your processes for cleaning and disinfecting the ISO (b)(4) biological safety cabinet (BSC) where your products are exposed to the environment during aseptic processing.\n5. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use results of such stability testing to determine appropriate storage conditions and expiration dates, as required by 21 CFR 211.166(a). For example, your firm assigns a 24-month expiration date to your products without supporting stability testing data.\nThe CGMP violations applicable to your Bello and Regen facilities pertaining to your products include, but are not limited to, the following:7\n6. The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed, as required by 21 CFR 211.22(d). For example, at the time of the inspection, written procedures describing the responsibilities of the quality unit had not been established, including but not limited to, procedures for the approval or rejection of drug products (21 CFR 211.22(a)) and the handling of all written and oral complaints regarding a drug product (21 CFR 211.198(a)).\nResponses to the Form FDA-483\nWe have reviewed your responses to the Form FDA-483s issued to each of your Bello and Regen facilities dated January 08, 2026 and January 06, 2026, as well as your correspondence dated November 20, 2025, in detail. While you represented that you have implemented or plan to implement certain corrective actions, the described corrective actions are not adequate to remedy the violations noted above. For example, your responses do not address your continued distribution of your products or specific plans for disposition of the remaining inventory manufactured under the violative conditions outlined above. We note that certain corrective actions cannot be evaluated because they lack supporting documentation.\nFurther, for your previously distributed products, you do not describe actions you have taken or plan to take that adequately address the impact of the above-noted deficiencies on your distributed products that are still within expiry and were manufactured under the above-described violative conditions.\nWe acknowledge your commitment to temporarily suspend manufacturing operations until you have made corrections to the observations listed on the Form FDA-483 issued to each of your Bello and Regen facilities. However, this does not resolve the violations outlined in this letter because your responses do not adequately address your failure to have an Investigational New Drug (IND) in effect to study your products addressed in this letter or your lack of an approved BLA to lawfully market your products.\nFDA has previously provided notice to you, David Greene, in a letter dated May 28, 2019, that based on a review of your website for R3 Stem Cell, LLC (www.r3stemcell.com) at that time, your firm appeared to offer “regenerative stem cell therapies” while promoting these stem cell therapies for numerous diseases or conditions, such as amyotrophic lateral sclerosis (ALS), diabetes, kidney failure, Lyme disease, Parkinson’s disease, and stroke. Based on that review, R3 Stem Cell, LLC did not appear to qualify for any exception under 21 CFR 1271.15; the “regenerative stem cell therapies” were intended for nonhomologous uses and thus would be regulated as drugs as defined in section 201(g) of the FD&C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)]. However, our review of your current websites and various social media accounts, which are also linked to your websites, indicates umbilical stem cell therapy and exosome therapy continue to be offered by R3 Stem Cell, LLC for treatment of various diseases and conditions, as described above.\nAdditional Concerns\nIn addition to the violations described above, we have the following concerns:\nFDA’s review of information and records collected during the inspections documented Bello also manufactures the following umbilical cord derived8 products: BelloWJ, BelloXO, and BelloXOL. Your response dated January 08, 2026 asserts that Bello is a manufacturer of HCT\u002FPs and is subject only to current good tissue practice (CGTP) requirements of 21 CFR Part 1271 and is regulated solely under section 361 of the PHS Act); however, review of the evidence collected shows these products do not appear to meet the relevant criteria to be regulated solely under section 361 of the PHS Act, for the reasons discussed above. These products appear to be drugs and\u002For biological products, which are subject to premarket review and approval requirements.\nFDA review of Bello’s manufacturing records revealed that (b)(4) is a component of the (b)(4) used during Bello’s manufacturing process of products derived from umbilical cord tissue; however, there did not appear to be evidence that testing for (b)(4) had been performed prior to the release of these products, as required by (b)(4).\nBello determines donor eligibility upon review of relevant medical records per your contract agreement with (b)(4). The “Donor Eligibility Criteria” documents (effective date 08\u002F15\u002F2023) submitted with your January 8, 2026, response and also collected during the inspection do not include “qualifiers\u002Fcomments” for Transmissible Spongiform Encephalopathy (TSE). In accordance with 21 CFR 1271.75(a)(1)(iv), all donors of cells or tissues, except as provided under 1271.90, must be screened by reviewing the donor’s relevant medical records for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases, including human transmissible spongiform encephalopathy, including Creutzfeldt-Jakob disease. Additionally, FDA Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (August 2007)9 recommends screening donors for TSE, including Creutzfeldt-Jakob disease (CJD) and variant CJD (vCJD), by asking if donors have been diagnosed with dementia or any degenerative or demyelinating diseases of the central nervous system or other neurological disease of unknown etiology. For additional information and recommendations intended to assist establishments with complying with all requirements in 21 CFR part 1271, subpart C, please refer to the guidance.\nConclusion\nNeither this letter nor the observations noted on the Form FDA-483s for both Bello and Regen, which were discussed with you at the conclusion of the inspections, are intended to be all-inclusive lists of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nVincent Amatrudo\nActing Director\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\nCc: (b)(4)\n________________________\n1 During the inspections, you informed FDA that R3 Medical Companies is the parent company of these companies co-located at the same business address: Bello, Regen, R3 Stem Cell, LLC and R3 Anti-Aging Scottsdale LLC. You bear primary responsibility for the business operations at each of the aforementioned entities.\n2 Greene Technologies, LLC, for which you are the co-owner and majority holder, along with Ms. Deborah Greene, invests in the referenced entities and other R3 Anti-Aging LLC clinics located at 5020 Thoroughbred Lane, Brentwood, TN 37027 and 9301 Wilshire Boulevard Penthouse, Beverly Hills, CA 90210. The referenced entities function together with Bello as the manufacturer and Regen as the private label distributor to the three R3 Anti-Aging clinics, healthcare professionals, and other clinics as direct-to-customers and through R3 Stem Cell’s partnership program, R3 Alliance Partner. We note you are also the current Chief Executive Officer (CEO) of R3 Anti-Aging & MedSpa Nashville, LLC (located at 5020 Thoroughbred Lane, Brentwood, TN 37027) and R3 Anti-Aging Beverly Hills, LLC (located at 9301 Wilshire Boulevard Penthouse, Beverly Hills, CA 90210).\n3 Regen markets ReBellaXO and ReBellaXOL as exosome products; however, products manufactured by Bello use the same starting material and manufacturing process (with the exception of an added lyophilization step for ReBellaXOL), which does not appear would isolate exosomes.\n4 ReBellaXOL was also labeled as ReBellaGF by Bello at the time of the inspections.\n5 As of August 14, 2026, it appears that the Regen Suppliers website www.regensuppliers.com is no longer accessible with a “404, Not Found.” message displayed.\n6 Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a) for each product.\n7 Although products are contract manufactured for Regen, Regen’s activities, as described above, constitute manufacturing under 21 CFR 210.3(b)(12). Regen is therefore subject to CGMP requirements.\n8 Bello markets BelloXO and BelloXOL as exosome products; however, it does not appear that the manufacturing process would isolate exosomes.\n9 See https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Feligibility-determination-donors-human-cells-tissues-and-cellular-and-tissue-based-products.","R3 Medical Companies","r3-medical-companies-726330-08142026","2026-09-07T05:14:13.57002+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fr3-medical-companies-726330-08142026","2026-10-26T08:09:46.375146+00:00","2026-08-25","726330","Biologics","David L. Greene, M.D.","2026-09-07T05:15:14.733+00:00","Via UPS and EMAIL","CBER 26-726330","2026-08-14",{"id":171,"raw":172,"subject":176,"body_html":177,"body_text":178,"firm_name":179,"letter_id":180,"created_at":58,"fei_number":19,"letter_url":181,"updated_at":182,"action_type":22,"case_status":23,"posted_date":183,"marcs_cms_no":184,"product_type":83,"closeout_date":19,"issuing_office":72,"recipient_name":19,"body_fetched_at":185,"delivery_method":105,"recipient_title":19,"reference_number":19,"action_taken_date":186,"medical_device_id":19,"response_letter_date":19},90,[173,174,175,72,176,13,13,13],"\u003Ctime datetime=\"2026-06-16T04:00:00Z\">06\u002F16\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-30T04:00:00Z\">04\u002F30\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzoll-medical-corporation-711320-04302026\">ZOLL Medical Corporation\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>ZOLL Medical Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>269 Mill Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chelmsford\u003C\u002Fspan>, \u003Cspan>ME\u003C\u002Fspan> \u003Cspan>01824\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jrennert@zoll.com\"> jrennert@zoll.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 711320\u003C\u002Fp>\u003Cp>April 30, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Rennert:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Chelmsford, MA from February 27, 2025 through April 15, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures X Series\u002FAdvanced automated external defibrillators (AEDs) (Class 3), Zoll MRI Compatible 731 Ventilators (Class 2), OneStep electrodes (Class 3), and Accuvent Sensors (Class 3). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. We received responses from Paul Dias, Vice President of Service, Quality and Regulatory Affairs, dated May 6, 2025, from Brian Abbott, Principal Quality Assurance Compliance Engineer, dated June 8, 2025 and July 8, 2025, September 8, 2025, October 8, 2025, November 7, 2025, December 8, 2025, January 10, 2026, February 6, 2026, March 6, 2026, April 6, 2026 and from Jill McFadden, Principal Quality Assurance Compliance Engineer, dated August 8, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm on April 15, 2025. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1) Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm did not adequately establish your “Corrective and Preventive Action Procedure,” 5004-0002-RP, Revision W.&nbsp;\u003C\u002Fp>\u003Cp>For example:\u003C\u002Fp>\u003Cp>A. Your firm failed to identify the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems, as required by 21 CFR 820.100(a)(3). Specifically, your firm did not follow your Corrective and Preventive Action (CAPA) Procedure, 5004-0002-RP, section 7.3 which states “Quality Assurance and CAPA Committee Review Team will review the CAPA request and determine if a corrective action, preventive action, or no action is required. […] It will determine the potential impact of the problem and the risk to the company and\u002For customer will be determined. […] If the request is determined to be a CAPA, Quality Assurance will enter the information into the CAPA System and a CAPA number will be assigned.”\u003C\u002Fp>\u003Cp>For example, DMR 12426 was initiated on February 11, 2025, for the Onestep Pediatric GC Electrode (P\u002FN 8900-000252-05), documenting that the tin under the gel on the electrode was burnt and there were air pockets surrounding the burn location. As a result of the nonconformity, a CAPA request under CAR # 131 was made on March 5, 2025. The request form collected during the inspection was not completely filled out, and the CAPA request was rejected on March 5, 2025. The stated justification for the rejection was that this was the first-time instance of such an event, even though CAR # 131 identified that the nonconformance, which could cause “arcing and burning a patient carries an end severity of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which requires a CAPA request per SOP-682.”\u003C\u002Fp>\u003Cp>B. Your firm failed to analyze complaints and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a)(1). For example:\u003C\u002Fp>\u003Cp>i. The failure trend analysis specified under Procedure, Field Data Analysis, 5004-0003-RP, Revision YE, is ineffective to detect and mitigate recurring quality problems related to “No Fault Found,” “No Product Returned,” and “User Attempted Repair.” Specifically, CAPA CA 90 was initiated on April 9, 2024, for 731 Series Ventilators with MRI compatibility nonconformances, resulting in a Class I recall that was not initiated until April 30, 2024. The CAPA CA 90 was escalated during the internal labeling review of the device as a result of recent MRI testing. Your firm was unable to detect the issue through the CAPA process as six of these complaints were coded as “User Errors,” nine as “No Fault Found,” seven as “No Product Returned” and two as “User Attempted Repairs.” These ventilator failures caused malfunctions and shutdowns that led to the stoppage of ventilatory support and the need for alternative means of ventilation. CAPA CA 90 was closed as effective September 20, 2024. You have received 6 complaints relating to the MRI compatibility issues from November 15, 2024, through January 16, 2025, after closure of the CAPA and no additional CAPAs have been initiated by your firm.\u003C\u002Fp>\u003Cp>ii. Complaints were not further escalated to a CAPA if they failed to meet a specified threshold per Procedure, Field Data Analysis, Document Number 5004-0003-RP, Revision YE and as per Procedure, Health Risk Assessment, Document Number 5005-000149-RP, Revision P, Effective Date October 7, 2024. Your firm received complaints related to inaccurate and inconsistent end tidal CO2 readings for the X Series System Defibrillator; the decision, however, was not to open a CAPA for such complaints based on a determination that the complaint trends are reviewed monthly. The risk file of the X Series identified inaccurate CO2 monitoring measurement with a hazard of misdiagnosis with a severity level of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, level \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as per the risk management plan for X Series. Examples include Complaints 1065028, 956175, 970112, 971261, 970108, and 1064552.\u003C\u002Fp>\u003Cp>iii. Your firm analyzes complaint trends for potential corrective\u002Fpreventive actions and risk assessment based on the root cause code and does not consider the incident type. Your firm received at least 28 complaints from January 1, 2022, to February 27, 2025, where the BVM feature of the Accuvent Sensor was not working, with an incident code 038100, where 15 of 28 complaints were that the device was either not reading or not accurately reading tidal volume and\u002For ventilation rate. However, no CAPA was initiated as the complaints trend did not meet the escalation criteria where 16 out of 28 complaints were coded with “No fault found” and “No product was returned.” Therefore, only the remaining 10 complaints, where the issues were confirmed, were used in the trending analysis, resulting in the escalation criteria not being met.\u003C\u002Fp>\u003Cp>The responses dated May 6, 2025, and June 8, 2025, are not adequate. Your May 6, 2025 response promises a revised complaint handling procedure that involves your firm reviewing complaint trends from a complaint mode perspective, continuing to review trends from a failure mode perspective, escalating complaint and failure modes that do not present a risk to a CAPA based on historical trends, escalating complaint and failure modes that present risk to a CAPA if their occurrence falls outside of the expectations of the product’s risk management files, and updating product risk management files when new hazards are identified from field data. Attachment 19 of your June 8, 2025, response addresses the review of the six additional complaints associated with MRI distance after your CAPA was closed on September 20, 2024, as promised on page 9 of your May 6, 2025, response, but your responses do not address completing a retrospective review of complaints. In addition, your firm’s responses did not provide enough information to determine whether your responses are adequate. Specifically, attachment 24 included with your June 8, 2025, response states “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. Your firm found that \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of the 51 reports were attributed to a device component failure, and the remaining reports were attributed to something other than a component failure. Please provide additional information on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> reports attributed to component failures and additional information on why this did not trigger a CAPA request.\u003C\u002Fp>\u003Cp>We cannot determine the adequacy of your firm’s August 8, 2025, response since your next step will consist of performing further analysis of the complaint data collected over a \u003Cstrong>(b)(4)\u003C\u002Fstrong> period that has an indication of a potential statistically significant upward trend. Your firm promises to provide the results of this analysis as part of a monthly response update.\u003C\u002Fp>\u003Cp>2) Failure to establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). Specifically, your firm failed to verify and validate the labeling change of your 731 MRI compatible ventilators adequately as per your procedure, Design Verification and Validation Requirements, 5002-0005-SOP, Revision T, as per the following:\u003C\u002Fp>\u003Cp>A. The Z Vent Ventilator is an MRI-compatible device intended to be used with 1.5T and 3T clinical scanners. Per MRI Compatibility of Zoll Medical Corporation’s Z Vent Ventilator Final Report, dated June 21, 2023, the Z Vent Ventilator was evaluated to test for MRI compatibility only by using the 3T MRI scanner. No rationale or justification for lack of testing with the 1.5T MRI scanner was documented. Based on the testing, it was determined that the ventilator should be placed behind the 130 Gauss field line (approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the bore opening of a 3T MRI magnet); however, the labeling fails to specify how far the ventilator should be placed when using 1.5T MRI. You received complaint 1102291 on July 18, 2024, for the use of the Z Vent Ventilator when using 1.5T MRI equipment where the customer experienced discrepancies in the imaging quality. The facility confirmed that the vent was used \u003Cstrong>(b)(4)\u003C\u002Fstrong> away from the MRI. The vent specification is for \u003Cstrong>(b)(4)\u003C\u002Fstrong> with a 3T MRI, no specifications were evaluated by your firm for a 1.5T MRI.\u003C\u002Fp>\u003Cp>B. MRI Compatibility of Zoll Medical Corporation’s Z Vent Ventilator Final Report, dated June 21, 2023, shows that one Z Vent Ventilator was used for the evaluation of MRI compatibility of Zoll 731 Series Ventilators (which includes the Z Vent, Eagle 2, and EMV Plus ventilators) with MRI Compatibility. The justification provided states that the devices are identical mechanically and differ in cosmetic features only. However, 731 Series Ventilator Platform Validation Plan – Zoll Z Vent, Document Number 1731-000001-VP01, Revision 01, Page 5, identifies \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These factors were not assessed when performing the MRI compatibility testing.\u003C\u002Fp>\u003Cp>The responses dated May 6, 2025, and July 8, 2025, are not adequate. Your May 6, 2025, response states “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, the 731 Series Ventilator Platform Validation Plan – Zoll Z Vent, Document Number 1731- 000001-VP01, Revision 01, Page 5, identifies \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These factors were not assessed when your firm performed the MRI compatibility testing. The 731 Series platform models include EMV, EMV+, AEV, and Eagle II included under part number 703-0731-04. This part number was not listed in table 1-731 Ventilator Configurations Overview provided in your response. The IFUs for EMV Plus indicate that when marked with an “MRI conditional” label, the ZOLL Ventilators are suitable for use in an MRI environment with appropriate precautions.\u003C\u002Fp>\u003Cp>We cannot determine the adequacy of your May 6, 2025, or July 8, 2025, responses regarding not testing the MRI compatibility when used with 1.5T scanners. You state in your July 8, 2025, response that MRI compatibility testing of the Z Vent Ventilator in a 1.5 \u003Cstrong>(b)(4)\u003C\u002Fstrong> environment in accordance with FDA-recognized ASTM standards has been completed; and “[t]he testing demonstrated that the device meets all applicable criteria for magnetic field interactions. Based on the results, the Z Vent Ventilator has been determined to be MR Conditional, with specific use conditions defined for both 1.5 T and 3 T MRI environments. The labeling is the same for 1.5T or 3T and there are no changes needed.” Please provide additional information on whether or not you conducted any additional reviews of complaint 1102291 which occurred on July 18, 2024 where a customer confirmed that the 731 Impact Z vent was used \u003Cstrong>(b)(4)\u003C\u002Fstrong> away from the 1.5T MRI equipment and the Z vent affected the imaging quality of the 1.5T MRI equipment and if you have received any additional complaints regarding 1.5T MRI equipment compatibility.\u003C\u002Fp>\u003Cp>3) Failure to establish and maintain procedures for validating the device design which includes a risk analysis as required by 21 CFR 820.30(g). Specifically, Procedure, Health Risk Assessment, Document Number 5005-000149-RP, Revision P, Effective Date October 7, 2024, fails to require a complete assessment of potential \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> when calculating the adverse health risk assessment. Section 7.5.3 of this procedure requires a risk of harm investigation that includes calculating the occurrence of harm of the event by using product field data from a complaint history search to be included on a HRA form. However, your firm has failed to perform a complete complaint history search while performing a health risk assessment. In addition, your firm has failed to follow your Risk Management procedure, Document Number 5008-000011-SOP, Revision T for the risk analysis for the X Series defibrillators. For example:\u003C\u002Fp>\u003Cp>A. For the 731 Ventilators MRI compatibility issue, the risk was calculated only by using the adverse events (24 malfunction reports) and complaints (27 complaints) that may be related to the device defect. Your Health Hazard Evaluation stated, “Although the risk is life-threatening, the likelihood of a potentially hazardous occurrence related to the omission of information, is considered remote”. However, during the inspection, the investigator reviewed the complaint analysis for CA 90 with \u003Cstrong>(b)(4)\u003C\u002Fstrong> employees from your firm and found there were 50 complaints, not 27, received from 2016 to 2024.\u003C\u002Fp>\u003Cp>B. The risk analysis performed for X Series defibrillators is ineffective. You failed to follow your Risk Management procedure, Document Number 5008-000011-SOP, Revision T. Page 11 of the procedure requires your firm to follow the risk estimation criteria listed in the procedure for the products that were introduced after the initial release of the procedure in December 2011. The X series defibrillator was introduced after December 2011. It was originally cleared on March 21, 2012, as a Class III 510(k) product under K112432 and was later approved on December 27, 2017, through P160022. Your firm should therefore follow the risk estimation criteria listed in your Risk Management procedure for the X series defibrillator.\u003C\u002Fp>\u003Cp>However, unlike the risk estimation criteria listed in your Risk Management procedure, the risk ranking for the X Series and Propaq products and accessories has an additional acceptable level of risk associated with the term Negligible (Occurrence Rank of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Legacy, \u003Cstrong>(b)(4)\u003C\u002Fstrong> for X series) occurrence classification as per Risk Management Plan, X Series\u002FPropaq, Document Number 1127-0001-RMP, Revision 5. Where the occurrence has an estimated likelihood of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and a probability of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the level of risk will always be considered \u003Cstrong>(b)(4)\u003C\u002Fstrong> despite the level of severity.\u003C\u002Fp>\u003Cp>C. You have failed to assess the risk of visible corrosion spots larger than \u003Cstrong>(b)(4)\u003C\u002Fstrong> in diameter for the One Step electrode. Your design verification, VPN 1334R, dated 3\u002F15\u002F19, of OneStep Adult Electrodes for use for defibrillation, cardioversion, and ECG Monitoring, identified that corrosion spots as large as \u003Cstrong>(b)(4)\u003C\u002Fstrong> diameter can function as intended; however, your firm failed to assess the risk for corrosion larger than \u003Cstrong>(b)(4)\u003C\u002Fstrong> diameter when within the shelf life of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm received complaint 895198, aware date 3\u002F4\u002F22, where it was reported that after a cardioversion, they were removing the pads from the patient and found corrosion at the center of the metal element of the posterior portion of the pad. This problem was reported on January 25, 2022, which was the day of the expiration for the pads. Your investigation determined that “Discoloration and air bubbles shown in these pictures are signs that will lead to a malfunction with the pads.”\u003C\u002Fp>\u003Cp>The adequacy of your May 6, 2025, June 8, 2025, July 8, 2025, August 8, 2025, and September 8, 2025, responses cannot be determined at this time. Your firm’s May 6, 2025, response states that you did not share \u003Cstrong>(b)(4)\u003C\u002Fstrong> with the investigator during the inspection and have completed the testing and provided the testing in your response.\u003C\u002Fp>\u003Cp>Your firm reviewed the initial Hazard Analysis documents for Pedi-Padz II Electrodes, ProPadz Radiolucent Solid Gel\u002FProPadz Radiolucent\u002FHWD Electrodes, Pedi-Padz Radiolucent Electrodes, Pro-Padz Adult MFE LG Electrodes, Pedi-Padz LG Electrodes, Aspirator and G3\u002FG3 Elite were finalized following Quality Assurance Management Review on July 3, 2025. Your August 8, 2025, September 8, 2025, October 8, 2025, November 7, 2025, responses, in alignment with the approach outlined in the Project Quality Plan, provided new \u003Cstrong>(b)(4)\u003C\u002Fstrong> documents in lieu of updating the existing \u003Cstrong>(b)(4)\u003C\u002Fstrong> documents. What is your rationale for risk acceptability (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) determined since your risk categorization appears to be mostly \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> for all of your new Hazard Analysis documents received to date? For example, attachment 44 included with your August 8, 2025 response has a hazardous situation column with a delay in defibrillation causing a harm of clinically relevant delay contributed to irreversible harm or death receiving a risk categorization of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for two out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> with the same hazard of algorithm analysis incorrect but the \u003Cstrong>(b)(4)\u003C\u002Fstrong> hazardous situation (delay in defibrillation) has a different harm stating clinically relevant delay in patient receiving appropriate treatment receiving a risk categorization of \u003Cstrong>(b)(4)\u003C\u002Fstrong> not \u003Cstrong>(b)(4)\u003C\u002Fstrong> since the clinically relevant delay does not contribute to irreversible harm or death.\u003C\u002Fp>\u003Cp>4) Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements as required by 21 CFR 820.50. Specifically, your firm failed to establish and maintain the requirements, including quality requirements, that must be met by suppliers, contractors, and consultants, as required by 21 CFR 820.50(a). For example:\u003C\u002Fp>\u003Cp>A. Your firm failed to categorize two suppliers according to your Supplier Assessment and Qualification Procedure, Document Number 5004-2162-SOP, Revision YD. Per the procedure, suppliers that deliver materials, components or other services that shall influence the safety and effectiveness of the product are required to be classified as Level \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The supplier of the AccuVent Sensor, a feature of your X series ventilator used to provide ventilation feedback on volume, breath rate and quality of ventilation of \u003Cstrong>(b)(4)\u003C\u002Fstrong> delivered breaths via Real BVM Help, was categorized as Level \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Level \u003Cstrong>(b)(4)\u003C\u002Fstrong> suppliers are considered critical to business needs but not to the safety and effectiveness of the product. Similarly, your firm categorized the supplier that provides RescueNet software, including the RescueNet CaseReview that is used to review the performance of the device during a complaint investigation, as a Level \u003Cstrong>(b)(4)\u003C\u002Fstrong> supplier, which is defined as not directly impacting the production or quality of a device.\u003C\u002Fp>\u003Cp>B. Your firm failed to establish a Supplier Change Control Agreement with the supplier that provides RescueNet software to your firm as required by your Supplier Assessment and Qualification Procedure, Document Number 5004-2162-SOP, Revision YD. RescueNet is the software that you describe on your website and in other marketing materials as allowing clinicians to remotely view real-time data from the monitor\u002Fdefibrillators, optimizing care and driving efficiency from EMS to the hospital, and capturing clinical event information from AEDs to use in quality review, analysis and post-event debriefing.\u003C\u002Fp>\u003Cp>Your responses dated May 6, 2025, June 8, 2025, July 8, 2025, and August 8, 2025, are not adequate, because your firm continues to not take into account the effect the suppliers that deliver materials, components or other services may have on the safety or effectiveness of your finished devices. This includes all suppliers that are Level \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Level \u003Cstrong>(b)(4)\u003C\u002Fstrong> for components used in finished devices.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit a report to FDA no later than 30 calendar days after the day that your firm receives or otherwise becomes aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fp>\u003Cp>For example, the information included for Incident No. 1095284 reasonably suggests that your firm’s ventilator malfunctioned (i.e. insufficient user instructions that led to an unexpected shutdown) while operating near an MRI. According to the preamble to the MDR final rule published on December 11, 1995 (60 FR 63578), a malfunction is reportable if the malfunction involves a device that is considered to be life‐supporting or life-sustaining and thus is essential to maintaining human life. Your firm’s ventilator is a life-supporting\u002Flife-sustaining device. The information included in the complaint reasonably suggests that the malfunction would be likely to cause or contribute to a death or serious injury, if it were to recur. Therefore, the referenced complaint represents an MDR reportable event as defined in 21 CFR 803.3(o). Your firm became aware of the event on June 20, 2024, and FDA received the MDR, 1220908‐2025‐00947, for the corresponding incident on March 10, 2025, which is beyond the 30‐calendar day timeframe.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses dated May 6, 2025, June 8, 2025, July 8, 2025, and August 8, 2025, cannot be determined at this time. Although an MDR for the corresponding incident was received by FDA on March 10, 2025, your firm states in its May 6, 2025, response that it plans to revise its reporting process and conduct a retrospective review based on further communication with the FDA clarifying the reportability determination. However, there has been no evidence provided documenting the completion of these activities. We acknowledge from your August 8, 2025, response that you have completed your updates to your risk management files and are continuing to work on your retrospective review based on your revised risk analysis.\u003C\u002Fp>\u003Cp>Our understanding is that your firm’s RescueNet Live software analyzes data from a monitoring device and generates a secondary alarm and is not merely receiving and displaying alarms generated by the monitoring device. If that is the case, your software is a medical device and is adulterated under 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.&nbsp;\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a \u003Cu>final rule\u003C\u002Fu> amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on February 27, 2025, through April 15, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Establishment Assessment Team 1 Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 711320” when replying. If you have any questions about the contents of this letter, please contact: Robert Maffei, Compliance Officer at robert.maffei@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden\u003Cbr>Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nZOLL Medical Corporation\n\n269 Mill Road\n\nChelmsford, ME 01824\n\nUnited States\n\njrennert@zoll.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 711320\nApril 30, 2026\nDear Mr. Rennert:\nDuring an inspection of your firm located in Chelmsford, MA from February 27, 2025 through April 15, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures X Series\u002FAdvanced automated external defibrillators (AEDs) (Class 3), Zoll MRI Compatible 731 Ventilators (Class 2), OneStep electrodes (Class 3), and Accuvent Sensors (Class 3). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from Paul Dias, Vice President of Service, Quality and Regulatory Affairs, dated May 6, 2025, from Brian Abbott, Principal Quality Assurance Compliance Engineer, dated June 8, 2025 and July 8, 2025, September 8, 2025, October 8, 2025, November 7, 2025, December 8, 2025, January 10, 2026, February 6, 2026, March 6, 2026, April 6, 2026 and from Jill McFadden, Principal Quality Assurance Compliance Engineer, dated August 8, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm on April 15, 2025. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1) Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm did not adequately establish your “Corrective and Preventive Action Procedure,” 5004-0002-RP, Revision W.\nFor example:\nA. Your firm failed to identify the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems, as required by 21 CFR 820.100(a)(3). Specifically, your firm did not follow your Corrective and Preventive Action (CAPA) Procedure, 5004-0002-RP, section 7.3 which states “Quality Assurance and CAPA Committee Review Team will review the CAPA request and determine if a corrective action, preventive action, or no action is required. […] It will determine the potential impact of the problem and the risk to the company and\u002For customer will be determined. […] If the request is determined to be a CAPA, Quality Assurance will enter the information into the CAPA System and a CAPA number will be assigned.”\nFor example, DMR 12426 was initiated on February 11, 2025, for the Onestep Pediatric GC Electrode (P\u002FN 8900-000252-05), documenting that the tin under the gel on the electrode was burnt and there were air pockets surrounding the burn location. As a result of the nonconformity, a CAPA request under CAR # 131 was made on March 5, 2025. The request form collected during the inspection was not completely filled out, and the CAPA request was rejected on March 5, 2025. The stated justification for the rejection was that this was the first-time instance of such an event, even though CAR # 131 identified that the nonconformance, which could cause “arcing and burning a patient carries an end severity of (b)(4), which requires a CAPA request per SOP-682.”\nB. Your firm failed to analyze complaints and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a)(1). For example:\ni. The failure trend analysis specified under Procedure, Field Data Analysis, 5004-0003-RP, Revision YE, is ineffective to detect and mitigate recurring quality problems related to “No Fault Found,” “No Product Returned,” and “User Attempted Repair.” Specifically, CAPA CA 90 was initiated on April 9, 2024, for 731 Series Ventilators with MRI compatibility nonconformances, resulting in a Class I recall that was not initiated until April 30, 2024. The CAPA CA 90 was escalated during the internal labeling review of the device as a result of recent MRI testing. Your firm was unable to detect the issue through the CAPA process as six of these complaints were coded as “User Errors,” nine as “No Fault Found,” seven as “No Product Returned” and two as “User Attempted Repairs.” These ventilator failures caused malfunctions and shutdowns that led to the stoppage of ventilatory support and the need for alternative means of ventilation. CAPA CA 90 was closed as effective September 20, 2024. You have received 6 complaints relating to the MRI compatibility issues from November 15, 2024, through January 16, 2025, after closure of the CAPA and no additional CAPAs have been initiated by your firm.\nii. Complaints were not further escalated to a CAPA if they failed to meet a specified threshold per Procedure, Field Data Analysis, Document Number 5004-0003-RP, Revision YE and as per Procedure, Health Risk Assessment, Document Number 5005-000149-RP, Revision P, Effective Date October 7, 2024. Your firm received complaints related to inaccurate and inconsistent end tidal CO2 readings for the X Series System Defibrillator; the decision, however, was not to open a CAPA for such complaints based on a determination that the complaint trends are reviewed monthly. The risk file of the X Series identified inaccurate CO2 monitoring measurement with a hazard of misdiagnosis with a severity level of (b)(4), level (b)(4), as per the risk management plan for X Series. Examples include Complaints 1065028, 956175, 970112, 971261, 970108, and 1064552.\niii. Your firm analyzes complaint trends for potential corrective\u002Fpreventive actions and risk assessment based on the root cause code and does not consider the incident type. Your firm received at least 28 complaints from January 1, 2022, to February 27, 2025, where the BVM feature of the Accuvent Sensor was not working, with an incident code 038100, where 15 of 28 complaints were that the device was either not reading or not accurately reading tidal volume and\u002For ventilation rate. However, no CAPA was initiated as the complaints trend did not meet the escalation criteria where 16 out of 28 complaints were coded with “No fault found” and “No product was returned.” Therefore, only the remaining 10 complaints, where the issues were confirmed, were used in the trending analysis, resulting in the escalation criteria not being met.\nThe responses dated May 6, 2025, and June 8, 2025, are not adequate. Your May 6, 2025 response promises a revised complaint handling procedure that involves your firm reviewing complaint trends from a complaint mode perspective, continuing to review trends from a failure mode perspective, escalating complaint and failure modes that do not present a risk to a CAPA based on historical trends, escalating complaint and failure modes that present risk to a CAPA if their occurrence falls outside of the expectations of the product’s risk management files, and updating product risk management files when new hazards are identified from field data. Attachment 19 of your June 8, 2025, response addresses the review of the six additional complaints associated with MRI distance after your CAPA was closed on September 20, 2024, as promised on page 9 of your May 6, 2025, response, but your responses do not address completing a retrospective review of complaints. In addition, your firm’s responses did not provide enough information to determine whether your responses are adequate. Specifically, attachment 24 included with your June 8, 2025, response states “(b)(4)”. Your firm found that (b)(4) out of the 51 reports were attributed to a device component failure, and the remaining reports were attributed to something other than a component failure. Please provide additional information on the (b)(4) reports attributed to component failures and additional information on why this did not trigger a CAPA request.\nWe cannot determine the adequacy of your firm’s August 8, 2025, response since your next step will consist of performing further analysis of the complaint data collected over a (b)(4) period that has an indication of a potential statistically significant upward trend. Your firm promises to provide the results of this analysis as part of a monthly response update.\n2) Failure to establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). Specifically, your firm failed to verify and validate the labeling change of your 731 MRI compatible ventilators adequately as per your procedure, Design Verification and Validation Requirements, 5002-0005-SOP, Revision T, as per the following:\nA. The Z Vent Ventilator is an MRI-compatible device intended to be used with 1.5T and 3T clinical scanners. Per MRI Compatibility of Zoll Medical Corporation’s Z Vent Ventilator Final Report, dated June 21, 2023, the Z Vent Ventilator was evaluated to test for MRI compatibility only by using the 3T MRI scanner. No rationale or justification for lack of testing with the 1.5T MRI scanner was documented. Based on the testing, it was determined that the ventilator should be placed behind the 130 Gauss field line (approximately (b)(4) to the bore opening of a 3T MRI magnet); however, the labeling fails to specify how far the ventilator should be placed when using 1.5T MRI. You received complaint 1102291 on July 18, 2024, for the use of the Z Vent Ventilator when using 1.5T MRI equipment where the customer experienced discrepancies in the imaging quality. The facility confirmed that the vent was used (b)(4) away from the MRI. The vent specification is for (b)(4) with a 3T MRI, no specifications were evaluated by your firm for a 1.5T MRI.\nB. MRI Compatibility of Zoll Medical Corporation’s Z Vent Ventilator Final Report, dated June 21, 2023, shows that one Z Vent Ventilator was used for the evaluation of MRI compatibility of Zoll 731 Series Ventilators (which includes the Z Vent, Eagle 2, and EMV Plus ventilators) with MRI Compatibility. The justification provided states that the devices are identical mechanically and differ in cosmetic features only. However, 731 Series Ventilator Platform Validation Plan – Zoll Z Vent, Document Number 1731-000001-VP01, Revision 01, Page 5, identifies (b)(4). These factors were not assessed when performing the MRI compatibility testing.\nThe responses dated May 6, 2025, and July 8, 2025, are not adequate. Your May 6, 2025, response states “(b)(4).” However, the 731 Series Ventilator Platform Validation Plan – Zoll Z Vent, Document Number 1731- 000001-VP01, Revision 01, Page 5, identifies (b)(4). These factors were not assessed when your firm performed the MRI compatibility testing. The 731 Series platform models include EMV, EMV+, AEV, and Eagle II included under part number 703-0731-04. This part number was not listed in table 1-731 Ventilator Configurations Overview provided in your response. The IFUs for EMV Plus indicate that when marked with an “MRI conditional” label, the ZOLL Ventilators are suitable for use in an MRI environment with appropriate precautions.\nWe cannot determine the adequacy of your May 6, 2025, or July 8, 2025, responses regarding not testing the MRI compatibility when used with 1.5T scanners. You state in your July 8, 2025, response that MRI compatibility testing of the Z Vent Ventilator in a 1.5 (b)(4) environment in accordance with FDA-recognized ASTM standards has been completed; and “[t]he testing demonstrated that the device meets all applicable criteria for magnetic field interactions. Based on the results, the Z Vent Ventilator has been determined to be MR Conditional, with specific use conditions defined for both 1.5 T and 3 T MRI environments. The labeling is the same for 1.5T or 3T and there are no changes needed.” Please provide additional information on whether or not you conducted any additional reviews of complaint 1102291 which occurred on July 18, 2024 where a customer confirmed that the 731 Impact Z vent was used (b)(4) away from the 1.5T MRI equipment and the Z vent affected the imaging quality of the 1.5T MRI equipment and if you have received any additional complaints regarding 1.5T MRI equipment compatibility.\n3) Failure to establish and maintain procedures for validating the device design which includes a risk analysis as required by 21 CFR 820.30(g). Specifically, Procedure, Health Risk Assessment, Document Number 5005-000149-RP, Revision P, Effective Date October 7, 2024, fails to require a complete assessment of potential (b)(4) and (b)(4) when calculating the adverse health risk assessment. Section 7.5.3 of this procedure requires a risk of harm investigation that includes calculating the occurrence of harm of the event by using product field data from a complaint history search to be included on a HRA form. However, your firm has failed to perform a complete complaint history search while performing a health risk assessment. In addition, your firm has failed to follow your Risk Management procedure, Document Number 5008-000011-SOP, Revision T for the risk analysis for the X Series defibrillators. For example:\nA. For the 731 Ventilators MRI compatibility issue, the risk was calculated only by using the adverse events (24 malfunction reports) and complaints (27 complaints) that may be related to the device defect. Your Health Hazard Evaluation stated, “Although the risk is life-threatening, the likelihood of a potentially hazardous occurrence related to the omission of information, is considered remote”. However, during the inspection, the investigator reviewed the complaint analysis for CA 90 with (b)(4) employees from your firm and found there were 50 complaints, not 27, received from 2016 to 2024.\nB. The risk analysis performed for X Series defibrillators is ineffective. You failed to follow your Risk Management procedure, Document Number 5008-000011-SOP, Revision T. Page 11 of the procedure requires your firm to follow the risk estimation criteria listed in the procedure for the products that were introduced after the initial release of the procedure in December 2011. The X series defibrillator was introduced after December 2011. It was originally cleared on March 21, 2012, as a Class III 510(k) product under K112432 and was later approved on December 27, 2017, through P160022. Your firm should therefore follow the risk estimation criteria listed in your Risk Management procedure for the X series defibrillator.\nHowever, unlike the risk estimation criteria listed in your Risk Management procedure, the risk ranking for the X Series and Propaq products and accessories has an additional acceptable level of risk associated with the term Negligible (Occurrence Rank of (b)(4) for Legacy, (b)(4) for X series) occurrence classification as per Risk Management Plan, X Series\u002FPropaq, Document Number 1127-0001-RMP, Revision 5. Where the occurrence has an estimated likelihood of (b)(4) and a probability of (b)(4), the level of risk will always be considered (b)(4) despite the level of severity.\nC. You have failed to assess the risk of visible corrosion spots larger than (b)(4) in diameter for the One Step electrode. Your design verification, VPN 1334R, dated 3\u002F15\u002F19, of OneStep Adult Electrodes for use for defibrillation, cardioversion, and ECG Monitoring, identified that corrosion spots as large as (b)(4) diameter can function as intended; however, your firm failed to assess the risk for corrosion larger than (b)(4) diameter when within the shelf life of (b)(4). Your firm received complaint 895198, aware date 3\u002F4\u002F22, where it was reported that after a cardioversion, they were removing the pads from the patient and found corrosion at the center of the metal element of the posterior portion of the pad. This problem was reported on January 25, 2022, which was the day of the expiration for the pads. Your investigation determined that “Discoloration and air bubbles shown in these pictures are signs that will lead to a malfunction with the pads.”\nThe adequacy of your May 6, 2025, June 8, 2025, July 8, 2025, August 8, 2025, and September 8, 2025, responses cannot be determined at this time. Your firm’s May 6, 2025, response states that you did not share (b)(4) with the investigator during the inspection and have completed the testing and provided the testing in your response.\nYour firm reviewed the initial Hazard Analysis documents for Pedi-Padz II Electrodes, ProPadz Radiolucent Solid Gel\u002FProPadz Radiolucent\u002FHWD Electrodes, Pedi-Padz Radiolucent Electrodes, Pro-Padz Adult MFE LG Electrodes, Pedi-Padz LG Electrodes, Aspirator and G3\u002FG3 Elite were finalized following Quality Assurance Management Review on July 3, 2025. Your August 8, 2025, September 8, 2025, October 8, 2025, November 7, 2025, responses, in alignment with the approach outlined in the Project Quality Plan, provided new (b)(4) documents in lieu of updating the existing (b)(4) documents. What is your rationale for risk acceptability ((b)(4)) determined since your risk categorization appears to be mostly (b)(4) and (b)(4) for all of your new Hazard Analysis documents received to date? For example, attachment 44 included with your August 8, 2025 response has a hazardous situation column with a delay in defibrillation causing a harm of clinically relevant delay contributed to irreversible harm or death receiving a risk categorization of (b)(4) for two out of (b)(4) with the same hazard of algorithm analysis incorrect but the (b)(4) hazardous situation (delay in defibrillation) has a different harm stating clinically relevant delay in patient receiving appropriate treatment receiving a risk categorization of (b)(4) not (b)(4) since the clinically relevant delay does not contribute to irreversible harm or death.\n4) Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements as required by 21 CFR 820.50. Specifically, your firm failed to establish and maintain the requirements, including quality requirements, that must be met by suppliers, contractors, and consultants, as required by 21 CFR 820.50(a). For example:\nA. Your firm failed to categorize two suppliers according to your Supplier Assessment and Qualification Procedure, Document Number 5004-2162-SOP, Revision YD. Per the procedure, suppliers that deliver materials, components or other services that shall influence the safety and effectiveness of the product are required to be classified as Level (b)(4). The supplier of the AccuVent Sensor, a feature of your X series ventilator used to provide ventilation feedback on volume, breath rate and quality of ventilation of (b)(4) delivered breaths via Real BVM Help, was categorized as Level (b)(4). Level (b)(4) suppliers are considered critical to business needs but not to the safety and effectiveness of the product. Similarly, your firm categorized the supplier that provides RescueNet software, including the RescueNet CaseReview that is used to review the performance of the device during a complaint investigation, as a Level (b)(4) supplier, which is defined as not directly impacting the production or quality of a device.\nB. Your firm failed to establish a Supplier Change Control Agreement with the supplier that provides RescueNet software to your firm as required by your Supplier Assessment and Qualification Procedure, Document Number 5004-2162-SOP, Revision YD. RescueNet is the software that you describe on your website and in other marketing materials as allowing clinicians to remotely view real-time data from the monitor\u002Fdefibrillators, optimizing care and driving efficiency from EMS to the hospital, and capturing clinical event information from AEDs to use in quality review, analysis and post-event debriefing.\nYour responses dated May 6, 2025, June 8, 2025, July 8, 2025, and August 8, 2025, are not adequate, because your firm continues to not take into account the effect the suppliers that deliver materials, components or other services may have on the safety or effectiveness of your finished devices. This includes all suppliers that are Level (b)(4) and Level (b)(4) for components used in finished devices.\nMedical Device Reporting (MDR) Violation(s)\nOur inspection also revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\nFailure to submit a report to FDA no later than 30 calendar days after the day that your firm receives or otherwise becomes aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\nFor example, the information included for Incident No. 1095284 reasonably suggests that your firm’s ventilator malfunctioned (i.e. insufficient user instructions that led to an unexpected shutdown) while operating near an MRI. According to the preamble to the MDR final rule published on December 11, 1995 (60 FR 63578), a malfunction is reportable if the malfunction involves a device that is considered to be life‐supporting or life-sustaining and thus is essential to maintaining human life. Your firm’s ventilator is a life-supporting\u002Flife-sustaining device. The information included in the complaint reasonably suggests that the malfunction would be likely to cause or contribute to a death or serious injury, if it were to recur. Therefore, the referenced complaint represents an MDR reportable event as defined in 21 CFR 803.3(o). Your firm became aware of the event on June 20, 2024, and FDA received the MDR, 1220908‐2025‐00947, for the corresponding incident on March 10, 2025, which is beyond the 30‐calendar day timeframe.\nThe adequacy of your firm’s responses dated May 6, 2025, June 8, 2025, July 8, 2025, and August 8, 2025, cannot be determined at this time. Although an MDR for the corresponding incident was received by FDA on March 10, 2025, your firm states in its May 6, 2025, response that it plans to revise its reporting process and conduct a retrospective review based on further communication with the FDA clarifying the reportability determination. However, there has been no evidence provided documenting the completion of these activities. We acknowledge from your August 8, 2025, response that you have completed your updates to your risk management files and are continuing to work on your retrospective review based on your revised risk analysis.\nOur understanding is that your firm’s RescueNet Live software analyzes data from a monitoring device and generates a secondary alarm and is not merely receiving and displaying alarms generated by the monitoring device. If that is the case, your software is a medical device and is adulterated under 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on February 27, 2025, through April 15, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Establishment Assessment Team 1 Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 711320” when replying. If you have any questions about the contents of this letter, please contact: Robert Maffei, Compliance Officer at robert.maffei@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nDirector\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","ZOLL Medical Corporation","zoll-medical-corporation-711320-04302026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzoll-medical-corporation-711320-04302026","2026-10-26T08:10:39.74889+00:00","2026-06-16","711320","2026-08-19T04:37:12.557+00:00","2026-04-30",{"id":188,"raw":189,"subject":192,"body_html":193,"body_text":194,"firm_name":195,"letter_id":196,"created_at":18,"fei_number":19,"letter_url":197,"updated_at":198,"action_type":22,"case_status":23,"posted_date":119,"marcs_cms_no":199,"product_type":83,"closeout_date":19,"issuing_office":72,"recipient_name":200,"body_fetched_at":201,"delivery_method":105,"recipient_title":19,"reference_number":19,"action_taken_date":202,"medical_device_id":19,"response_letter_date":19},952,[110,190,191,72,192,13,13,13],"\u003Ctime datetime=\"2025-04-09T04:00:00Z\">04\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnoah-medical-corporation-702414-04092025\">Noah Medical Corporation\u003C\u002Fa>","CGMP\u002FQSR\u002FManufacture\u002FPacking\u002FStorage\u002FInstallation\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jian Zhang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Noah Medical Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2075 Zanker Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Jose\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>95131\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jianzhang@noahmed.com\"> jianzhang@noahmed.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS #702414\u003C\u002Fp>\u003Cp>April 09, 2025\u003Cbr>\u003Cbr>Dear Ms. Zhang:\u003C\u002Fp>\u003Cp>During an inspection of your firm located at 2075 Zanker Road, San Jose, CA 95131 on October 28, 2024, through November 26, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures bronchoscopes and accessories (branded as the Galaxy System). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received responses from Richard W. Reeves, Vice President Quality Assurance and Regulatory Affairs, dated December 18, 2024, and January 21, 2025, concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fp>\u003Cp>Specifically, your firm failed to adequately establish your “Corrective and Preventive Action (CAPA)” procedure (SOP-019 Rev. B, Effective Date: 10\u002F30\u002F2024), as your firm did not adequately conduct and document CAPA investigations. For example, according to your procedure, a Corrective Action\u002FPreventive Action (CAPA) process shall be established to ensure “investigations are conducted to a degree sufficient to determine the root cause.” However, 2 out of 17 CAPA records selected for review by our investigators did not identify the root causes and necessary corrective and preventive actions as required by your CAPA procedure. The following describes the two CAPA records:\u003C\u002Fp>\u003Cp>a. CAPA 24-007 dated 9\u002F11\u002F2024: Your firm failed to conduct adequate investigations as required by your CAPA procedure. For example, your firm failed to explore sufficiently to determine the root cause for “biopsy tools couldn’t pass through bronchoscope’s working channels.” You did not investigate, sufficiently to determine the root cause, the lot-to-lot variation of the distal end measurements of the working channels and how it may impact your root cause analysis.\u003C\u002Fp>\u003Cp>b. CAPA 23-005 dated 4\u002F14\u002F2023: This CAPA record reported two scope pouches leaking due to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> poking holes in the pouches during shelf-life\u002Fpackaging transportation study Protocol “Design Verification Protocol for Bronchoscope Packaging,” (DOC: TP-099 Rev. B), and test report #WP-12154A. During execution of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> aging testing of the sterile bronchoscope, a test failure was noted during a gross leak testing of the scope pouches. Your firm did not evaluate how many scope pouches were leaking to identify other potential causes of the failed leak test, such as quality issues with your suppliers. Subsequently, your scope pouches failed leak test during a \u003Cstrong>(b)(4)\u003C\u002Fstrong> aging study (test report number #WP-16128A), but your firm did not document the cause of the leak nor reference this failed leak test in CAPA 23-005.\u003C\u002Fp>\u003Cp>We reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-028. You indicate that your firm made immediate corrections to CAPA 24-007; plans to contract with a third-party to retrospectively review all open and closed CAPAs, including the CAPAs cited during the last inspection; revised the CAPA process; and completed relevant training on the revised CAPA procedure including revised work instructions. However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA 24-028 record.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003C\u002Fp>\u003Cp>Specifically, your complaint procedure, “Complaint Management,” (SOP-025, Rev. G, Effective Date: 10\u002F28\u002F2024) has not been adequately established as your firm did not adequately conduct and\u002For document complaint investigations. For example,\u003C\u002Fp>\u003Cp>a. Your procedure indicates complaint investigations are conducted to “determine the cause of any product defects and\u002For malfunctions, whether product met specifications, or whether product specifications were met, but were inadequate.” Your firm did not follow your procedure as exemplified below:\u003C\u002Fp>\u003Cp>i. Complaint #00003531 described a failure to acquire live video feed upon attaching the scope to the instrument driving mechanism (IDM). Your firm did not adequately investigate the cause(s) of camera image loss.\u003C\u002Fp>\u003Cp>ii. Complaint #00002229 involved a user experiencing scope buckling errors due to severe kink in the distal area and the user had to replace with another scope. However, your firm did not investigate cause(s) for the kinks.\u003C\u002Fp>\u003Cp>iii. Complaint #00003614 described a patient experiencing excessive bleeding during Galaxy-assisted procedure. Complaint record states “scope buckling malfunction was observed.” However, your firm did not identify cause(s) for scope buckling.\u003C\u002Fp>\u003Cp>b. Your procedure states complaint “investigation examples may include, but is not limited to … batch record review to determine if there were nonconformances, material used, or process steps that could have contributed to the complaint.” For complaint #00003610 involving a patient who had pneumothorax while undergoing a Galaxy-assisted biopsy procedure for a 14mm lesion in the left upper lobe, the patient got a chest tube insert and was admitted to the hospital for 3 days. Your firm did not review batch records and other quality data sources for the bronchoscope used in this procedure to investigate and determine whether your device could have contributed to the patient’s injury.\u003C\u002Fp>\u003Cp>c. Your procedure states that “additional information from the complainant may be required to process a complaint” and that “various methods of communication … should be attempted in order to make a good faith effort to contact the complainant.” However, your firm failed to conduct and\u002For document a good faith effort to obtain additional information to support the complaint investigations. For example:\u003C\u002Fp>\u003Cp>i. Complaint #00003544 has a death reported due to excess bleeding when a patient was undergoing a Galaxy-assisted bronchoscopy procedure. According to your firm’s representative and associated complaint record, the physician stated that “the patient had possibly forgotten to stop taking blood thinners” and patient possibly was “puncture[d] by biopsy forceps.” Your firm’s Clinical Engineer reviewed the video of the procedure and said she could not see the forceps puncturing the blood vessel because there was too much blood blocking the camera view. Your firm did not make any attempt(s) to verify the causes further.\u003C\u002Fp>\u003Cp>ii. Complaint #00003337 involves a procedure that was aborted due to broken joysticks on two different controllers resulting in the scope drifting significantly into the patient’s right upper lobe of the lung. There was no documented information on when the patient was rescheduled for another procedure nor if the patient experienced any adverse event(s) after aborted procedures.\u003C\u002Fp>\u003Cp>We reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-025, CAPA 24-026, and CAPA 24-015. Your responses indicate that your firm has made some progress including completion of the root cause investigation for CAPA 24-015. However, the CAPA activities are still ongoing for all three CAPA records, and your responses do not clearly specify the target completion dates for each overall CAPA record.\u003C\u002Fp>\u003Cp>3. Failure to establish and maintain procedures for design control, as required by 21 CFR 820.30.\u003C\u002Fp>\u003Cp>Specifically, your design control procedure, “Design Controls” (SOP-002, Rev. G, Effective Date: 10\u002F21\u002F2024), has not been adequately established.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> For example, your design control procedure states that “Design verification and validation shall be conducted in accordance with SOP-033…to ensure design outputs meet the design input requirements and the product meets its intended use.” However, your firm failed to establish the procedure as follows:\u003C\u002Fp>\u003Cp>a. Your firm failed to adequately conduct design validation for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> biopsy tools, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, listed on page 23 of IFU Rev J, Effective Date: 09\u002F25\u002F2024. During design validation, your firm only performed design validation for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and used the \u003Cstrong>(b)(4)\u003C\u002Fstrong> as the worst-case tool for biopsy tool passage. Furthermore, your firm only tested biopsy tool passage in a \u003Cstrong>(b)(4)\u003C\u002Fstrong> configuration of the bronchoscope instead of \u003Cstrong>(b)(4)\u003C\u002Fstrong> configuration to account for bending of the bronchoscope. Your firm initiated CAPA 24-007 after the complaint trend associated with biopsy tools not passing through working channel “exceeded the required action threshold.”\u003C\u002Fp>\u003Cp>b. Your procedure failed to define the requirements to test sterility as part of the shelf-life validations. Your bronchoscopes are sold as sterile with an expiration date of two years, but your firm did not test product sterility as part of the shelf-life validations in the following protocols:\u003C\u002Fp>\u003Cp>i. Protocol #TP-008, Revision E, describing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> aging study, titled: “Galaxy Bronchoscope Verification Test Plan” and Summary Report #TR-087, Revision C.\u003C\u002Fp>\u003Cp>ii. Protocol #TP-008, Revision E, describing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> aging study, titled: “Galaxy Bronchoscope Verification Test Plan,” and Summary Report WP-16128A, Date Reviewed 05\u002F08\u002F2024.\u003C\u002Fp>\u003Cp>iii. Protocol #TP-099, Revision B, relating to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> aging study, titled: “Design Verification Protocol for Bronchoscope Packaging (includes \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> configurations)” and Summary Report #TR-378, Revision A.\u003C\u002Fp>\u003Cp>We reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-016 and CAPA 24-018. You indicate “as part of the Corrective Action, all instances of Design Verification and Validation of Requirements are being reviewed and where assumptions were made, these are being tested against documented evidence” (your firm’s response dated January 21, 2025). The CAPA activities are still ongoing for all three CAPA records, and your responses do not clearly specify the target completion dates for each overall CAPA record.\u003C\u002Fp>\u003Cp>4. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a).\u003C\u002Fp>\u003Cp>Specifically, your procedure, “Nonconforming Material,” (SOP-018 Rev. G, Effective Date: 09\u002F24\u002F2024,), has not been adequately implemented. Your firm failed to conduct investigations to identify the root cause(s) as required by your nonconforming material procedure. For example:\u003C\u002Fp>\u003Cp>a. NCR 0367 (Dated 04\u002F11\u002F2024) involves \u003Cstrong>(b)(4)\u003C\u002Fstrong> bronchoscopes failing leak test due to \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the working channels (part \u003Cstrong>(b)(4)\u003C\u002Fstrong>). However, your firm did not conduct investigation to identify the root cause(s) of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> nor implement a SCAR with your supplier.\u003C\u002Fp>\u003Cp>b. NCR 0605 (Dated 09\u002F20\u002F2024) involves \u003Cstrong>(b)(4)\u003C\u002Fstrong> bronchoscopes failing leak tests. One failure was due to the working channel not adequately bonded to the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the other \u003Cstrong>(b)(4)\u003C\u002Fstrong> failures were due to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your firm did not conduct investigation to identify the root cause(s) for the inadequate bonding nor the exposed \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>c. NCR 0071 (Dated 07\u002F27\u002F2023) involves \u003Cstrong>(b)(4)\u003C\u002Fstrong> working channels found to have kinks. However, your firm failed to investigate to identify the root cause(s) for the kinks nor implement a SCAR with your supplier.\u003C\u002Fp>\u003Cp>We reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-021. Your responses indicate that your firm plans to update your procedures, conduct training once the revised procedures are complete, and address immediate issues including review of all NCRs to date (starting from May 2023, approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> NCRs) and identify those which require investigation or revisions. Also, you indicate that there was immediate containment for the NCRs cited during the recent inspection and your firm issued SCAR number 24-010 to your supplier to determine the root cause of working channel defects. However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA record.\u003C\u002Fp>\u003Cp>5. Failure to establish and maintain procedures for rework, to include retesting and reevaluation of the nonconforming product after rework, to ensure that the product meets its current approved specifications, as required by 21 CFR 820.90(b)(2). Rework and reevaluation activities, including a determination of any adverse effect from the rework upon the product, shall be documented in the device history record (DHR), as required by 21 CFR 820.90(b)(2).\u003C\u002Fp>\u003Cp>Specifically, your procedure, “Rework and Deviation,” (SOP-020 Rev. B, Effective Date: 11\u002F28\u002F2022), has not been adequately established. For example, your Rework and Deviation procedure failed to include the requirement for determining whether there has been any adverse effect from rework upon the product when documenting rework and reevaluation activities. For example, the DHR for “Galaxy, Cart, \u003Cstrong>(b)(4)\u003C\u002Fstrong>” CRB-1516 (part number \u003Cstrong>(b)(4)\u003C\u002Fstrong>), relates to nonconformance #108, which described a nonconformance with an instrument driving mechanism (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) on the Galaxy System robot. This nonconformance resulted in frozen bronchoscope camera images. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> were replaced. However, your firm did not document a determination of whether there has been any adverse effect from reworking the \u003Cstrong>(b)(4)\u003C\u002Fstrong> upon the “Galaxy, Cart, \u003Cstrong>(b)(4)\u003C\u002Fstrong>” CRB-1516.\u003C\u002Fp>\u003Cp>We reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-022. Your responses indicate that you have revised your Rework and Deviation procedure and plan to conduct “a retrospective review of NCRs, rework, complaints and field repairs for all shipped systems to date as well as those in inventory to determine if any adverse effects are evident, and plan to implement corrections” (your response dated January 21, 2025). However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA record.\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s Galaxy Systems are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the devices that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\u003C\u002Fp>\u003Cp>For example, the information included for Complaint #00003935 and #00003614 reasonably suggests that during a procedure where your firm’s Galaxy System was used, the patients sustained injuries resulting in bleeding that were treated with irrigation and suction (Complaint #00003935) and Levophed administration (Complaint #00003614). We determined that these interventions were necessitated to prevent permanent impairment of a body function or permanent damage to a body structure (21 CFR 803.3(w)(3)). Your firm became aware of Complaint #00003935 on August 21, 2024, and FDA has not yet received an MDR for the corresponding MDR reportable event.\u003C\u002Fp>\u003Cp>Your firm became aware of Complaint #00003614 on July 24, 2024. Although the corresponding MDR #3021325287-2024-00024 was received by FDA on January 13, 2025, it was received beyond the 30-calendar-day timeframe.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. The responses indicate that your firm initiated a root cause investigation, plans to streamline its MDR reporting process, and is conducting a retrospective review of complaints for reportability. However, in the responses, your firm did not include documentation or evidence to demonstrate that the systemic corrective actions have been fully implemented, as these efforts are still ongoing.\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, the document titled “Medical Device Reporting,” Doc# SOP-026, Rev. C, dated 10\u002F28\u002F2024, was presented as your firm’s written MDR procedure. After reviewing the MDR procedure, the following deficiencies were noted:\u003C\u002Fp>\u003Cp>The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure omits the definitions of the terms “caused or contributed” from 21 CFR 803.3 and “reasonably suggests” found in 803.20(c)(1). The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\u003Cp>Your firm’s responses did not address the noted procedural deficiencies, as these were not included in the FDA Form 483.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent to: cdrhenforcement@fda.hhs.gov. Please include in the subject line, CMS case #702414 when replying. If you have any questions about the contents of this letter, please contact: Linda Linh Adams, Compliance Officer, at lindalinh.adams@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>Cc: Sam Mostafavi, Regulatory Advisor\u002F Management Representative, at sammostafavi@noahmed.com\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> FDA also received a response dated February 18, 2025. This letter does not address that response given timing considerations. That response will be considered along with any response to this letter.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Under 21 CFR 820.3(k), “establish” means define, document (in writing or electronically), and implement.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJian Zhang\n\nRecipient Title\n\nChief Executive Officer\n\nNoah Medical Corporation\n\n2075 Zanker Road\n\nSan Jose, CA 95131\n\nUnited States\n\njianzhang@noahmed.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS #702414\nApril 09, 2025\n\nDear Ms. Zhang:\nDuring an inspection of your firm located at 2075 Zanker Road, San Jose, CA 95131 on October 28, 2024, through November 26, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures bronchoscopes and accessories (branded as the Galaxy System). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received responses from Richard W. Reeves, Vice President Quality Assurance and Regulatory Affairs, dated December 18, 2024, and January 21, 2025, concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm1. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\nSpecifically, your firm failed to adequately establish your “Corrective and Preventive Action (CAPA)” procedure (SOP-019 Rev. B, Effective Date: 10\u002F30\u002F2024), as your firm did not adequately conduct and document CAPA investigations. For example, according to your procedure, a Corrective Action\u002FPreventive Action (CAPA) process shall be established to ensure “investigations are conducted to a degree sufficient to determine the root cause.” However, 2 out of 17 CAPA records selected for review by our investigators did not identify the root causes and necessary corrective and preventive actions as required by your CAPA procedure. The following describes the two CAPA records:\na. CAPA 24-007 dated 9\u002F11\u002F2024: Your firm failed to conduct adequate investigations as required by your CAPA procedure. For example, your firm failed to explore sufficiently to determine the root cause for “biopsy tools couldn’t pass through bronchoscope’s working channels.” You did not investigate, sufficiently to determine the root cause, the lot-to-lot variation of the distal end measurements of the working channels and how it may impact your root cause analysis.\nb. CAPA 23-005 dated 4\u002F14\u002F2023: This CAPA record reported two scope pouches leaking due to the (b)(4) poking holes in the pouches during shelf-life\u002Fpackaging transportation study Protocol “Design Verification Protocol for Bronchoscope Packaging,” (DOC: TP-099 Rev. B), and test report #WP-12154A. During execution of the (b)(4) aging testing of the sterile bronchoscope, a test failure was noted during a gross leak testing of the scope pouches. Your firm did not evaluate how many scope pouches were leaking to identify other potential causes of the failed leak test, such as quality issues with your suppliers. Subsequently, your scope pouches failed leak test during a (b)(4) aging study (test report number #WP-16128A), but your firm did not document the cause of the leak nor reference this failed leak test in CAPA 23-005.\nWe reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-028. You indicate that your firm made immediate corrections to CAPA 24-007; plans to contract with a third-party to retrospectively review all open and closed CAPAs, including the CAPAs cited during the last inspection; revised the CAPA process; and completed relevant training on the revised CAPA procedure including revised work instructions. However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA 24-028 record.\n2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\nSpecifically, your complaint procedure, “Complaint Management,” (SOP-025, Rev. G, Effective Date: 10\u002F28\u002F2024) has not been adequately established as your firm did not adequately conduct and\u002For document complaint investigations. For example,\na. Your procedure indicates complaint investigations are conducted to “determine the cause of any product defects and\u002For malfunctions, whether product met specifications, or whether product specifications were met, but were inadequate.” Your firm did not follow your procedure as exemplified below:\ni. Complaint #00003531 described a failure to acquire live video feed upon attaching the scope to the instrument driving mechanism (IDM). Your firm did not adequately investigate the cause(s) of camera image loss.\nii. Complaint #00002229 involved a user experiencing scope buckling errors due to severe kink in the distal area and the user had to replace with another scope. However, your firm did not investigate cause(s) for the kinks.\niii. Complaint #00003614 described a patient experiencing excessive bleeding during Galaxy-assisted procedure. Complaint record states “scope buckling malfunction was observed.” However, your firm did not identify cause(s) for scope buckling.\nb. Your procedure states complaint “investigation examples may include, but is not limited to … batch record review to determine if there were nonconformances, material used, or process steps that could have contributed to the complaint.” For complaint #00003610 involving a patient who had pneumothorax while undergoing a Galaxy-assisted biopsy procedure for a 14mm lesion in the left upper lobe, the patient got a chest tube insert and was admitted to the hospital for 3 days. Your firm did not review batch records and other quality data sources for the bronchoscope used in this procedure to investigate and determine whether your device could have contributed to the patient’s injury.\nc. Your procedure states that “additional information from the complainant may be required to process a complaint” and that “various methods of communication … should be attempted in order to make a good faith effort to contact the complainant.” However, your firm failed to conduct and\u002For document a good faith effort to obtain additional information to support the complaint investigations. For example:\ni. Complaint #00003544 has a death reported due to excess bleeding when a patient was undergoing a Galaxy-assisted bronchoscopy procedure. According to your firm’s representative and associated complaint record, the physician stated that “the patient had possibly forgotten to stop taking blood thinners” and patient possibly was “puncture[d] by biopsy forceps.” Your firm’s Clinical Engineer reviewed the video of the procedure and said she could not see the forceps puncturing the blood vessel because there was too much blood blocking the camera view. Your firm did not make any attempt(s) to verify the causes further.\nii. Complaint #00003337 involves a procedure that was aborted due to broken joysticks on two different controllers resulting in the scope drifting significantly into the patient’s right upper lobe of the lung. There was no documented information on when the patient was rescheduled for another procedure nor if the patient experienced any adverse event(s) after aborted procedures.\nWe reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-025, CAPA 24-026, and CAPA 24-015. Your responses indicate that your firm has made some progress including completion of the root cause investigation for CAPA 24-015. However, the CAPA activities are still ongoing for all three CAPA records, and your responses do not clearly specify the target completion dates for each overall CAPA record.\n3. Failure to establish and maintain procedures for design control, as required by 21 CFR 820.30.\nSpecifically, your design control procedure, “Design Controls” (SOP-002, Rev. G, Effective Date: 10\u002F21\u002F2024), has not been adequately established.2 For example, your design control procedure states that “Design verification and validation shall be conducted in accordance with SOP-033…to ensure design outputs meet the design input requirements and the product meets its intended use.” However, your firm failed to establish the procedure as follows:\na. Your firm failed to adequately conduct design validation for the (b)(4) biopsy tools, such as (b)(4), listed on page 23 of IFU Rev J, Effective Date: 09\u002F25\u002F2024. During design validation, your firm only performed design validation for the (b)(4) and used the (b)(4) as the worst-case tool for biopsy tool passage. Furthermore, your firm only tested biopsy tool passage in a (b)(4) configuration of the bronchoscope instead of (b)(4) configuration to account for bending of the bronchoscope. Your firm initiated CAPA 24-007 after the complaint trend associated with biopsy tools not passing through working channel “exceeded the required action threshold.”\nb. Your procedure failed to define the requirements to test sterility as part of the shelf-life validations. Your bronchoscopes are sold as sterile with an expiration date of two years, but your firm did not test product sterility as part of the shelf-life validations in the following protocols:\ni. Protocol #TP-008, Revision E, describing the (b)(4) aging study, titled: “Galaxy Bronchoscope Verification Test Plan” and Summary Report #TR-087, Revision C.\nii. Protocol #TP-008, Revision E, describing the (b)(4) aging study, titled: “Galaxy Bronchoscope Verification Test Plan,” and Summary Report WP-16128A, Date Reviewed 05\u002F08\u002F2024.\niii. Protocol #TP-099, Revision B, relating to the (b)(4) aging study, titled: “Design Verification Protocol for Bronchoscope Packaging (includes (b)(4) and (b)(4) configurations)” and Summary Report #TR-378, Revision A.\nWe reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-016 and CAPA 24-018. You indicate “as part of the Corrective Action, all instances of Design Verification and Validation of Requirements are being reviewed and where assumptions were made, these are being tested against documented evidence” (your firm’s response dated January 21, 2025). The CAPA activities are still ongoing for all three CAPA records, and your responses do not clearly specify the target completion dates for each overall CAPA record.\n4. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a).\nSpecifically, your procedure, “Nonconforming Material,” (SOP-018 Rev. G, Effective Date: 09\u002F24\u002F2024,), has not been adequately implemented. Your firm failed to conduct investigations to identify the root cause(s) as required by your nonconforming material procedure. For example:\na. NCR 0367 (Dated 04\u002F11\u002F2024) involves (b)(4) bronchoscopes failing leak test due to (b)(4) in the working channels (part (b)(4)). However, your firm did not conduct investigation to identify the root cause(s) of the (b)(4) nor implement a SCAR with your supplier.\nb. NCR 0605 (Dated 09\u002F20\u002F2024) involves (b)(4) bronchoscopes failing leak tests. One failure was due to the working channel not adequately bonded to the (b)(4), and the other (b)(4) failures were due to (b)(4). However, your firm did not conduct investigation to identify the root cause(s) for the inadequate bonding nor the exposed (b)(4).\nc. NCR 0071 (Dated 07\u002F27\u002F2023) involves (b)(4) working channels found to have kinks. However, your firm failed to investigate to identify the root cause(s) for the kinks nor implement a SCAR with your supplier.\nWe reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-021. Your responses indicate that your firm plans to update your procedures, conduct training once the revised procedures are complete, and address immediate issues including review of all NCRs to date (starting from May 2023, approximately (b)(4) NCRs) and identify those which require investigation or revisions. Also, you indicate that there was immediate containment for the NCRs cited during the recent inspection and your firm issued SCAR number 24-010 to your supplier to determine the root cause of working channel defects. However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA record.\n5. Failure to establish and maintain procedures for rework, to include retesting and reevaluation of the nonconforming product after rework, to ensure that the product meets its current approved specifications, as required by 21 CFR 820.90(b)(2). Rework and reevaluation activities, including a determination of any adverse effect from the rework upon the product, shall be documented in the device history record (DHR), as required by 21 CFR 820.90(b)(2).\nSpecifically, your procedure, “Rework and Deviation,” (SOP-020 Rev. B, Effective Date: 11\u002F28\u002F2022), has not been adequately established. For example, your Rework and Deviation procedure failed to include the requirement for determining whether there has been any adverse effect from rework upon the product when documenting rework and reevaluation activities. For example, the DHR for “Galaxy, Cart, (b)(4)” CRB-1516 (part number (b)(4)), relates to nonconformance #108, which described a nonconformance with an instrument driving mechanism ((b)(4)) on the Galaxy System robot. This nonconformance resulted in frozen bronchoscope camera images. The (b)(4) were replaced. However, your firm did not document a determination of whether there has been any adverse effect from reworking the (b)(4) upon the “Galaxy, Cart, (b)(4)” CRB-1516.\nWe reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-022. Your responses indicate that you have revised your Rework and Deviation procedure and plan to conduct “a retrospective review of NCRs, rework, complaints and field repairs for all shipped systems to date as well as those in inventory to determine if any adverse effects are evident, and plan to implement corrections” (your response dated January 21, 2025). However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA record.\nOur inspection also revealed that your firm’s Galaxy Systems are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the devices that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\nFailure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\nFor example, the information included for Complaint #00003935 and #00003614 reasonably suggests that during a procedure where your firm’s Galaxy System was used, the patients sustained injuries resulting in bleeding that were treated with irrigation and suction (Complaint #00003935) and Levophed administration (Complaint #00003614). We determined that these interventions were necessitated to prevent permanent impairment of a body function or permanent damage to a body structure (21 CFR 803.3(w)(3)). Your firm became aware of Complaint #00003935 on August 21, 2024, and FDA has not yet received an MDR for the corresponding MDR reportable event.\nYour firm became aware of Complaint #00003614 on July 24, 2024. Although the corresponding MDR #3021325287-2024-00024 was received by FDA on January 13, 2025, it was received beyond the 30-calendar-day timeframe.\nThe adequacy of your firm’s responses cannot be determined at this time. The responses indicate that your firm initiated a root cause investigation, plans to streamline its MDR reporting process, and is conducting a retrospective review of complaints for reportability. However, in the responses, your firm did not include documentation or evidence to demonstrate that the systemic corrective actions have been fully implemented, as these efforts are still ongoing.\nOur inspection also revealed that your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, the document titled “Medical Device Reporting,” Doc# SOP-026, Rev. C, dated 10\u002F28\u002F2024, was presented as your firm’s written MDR procedure. After reviewing the MDR procedure, the following deficiencies were noted:\nThe procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure omits the definitions of the terms “caused or contributed” from 21 CFR 803.3 and “reasonably suggests” found in 803.20(c)(1). The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\nYour firm’s responses did not address the noted procedural deficiencies, as these were not included in the FDA Form 483.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent to: cdrhenforcement@fda.hhs.gov. Please include in the subject line, CMS case #702414 when replying. If you have any questions about the contents of this letter, please contact: Linda Linh Adams, Compliance Officer, at lindalinh.adams@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCc: Sam Mostafavi, Regulatory Advisor\u002F Management Representative, at sammostafavi@noahmed.com\n_______________________\n1 FDA also received a response dated February 18, 2025. This letter does not address that response given timing considerations. That response will be considered along with any response to this letter.\n2 Under 21 CFR 820.3(k), “establish” means define, document (in writing or electronically), and implement.","Noah Medical Corporation","noah-medical-corporation-702414-04092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnoah-medical-corporation-702414-04092025","2026-10-26T08:09:34.20429+00:00","702414","Jian Zhang","2026-08-19T16:52:23.305+00:00","2025-04-09",{"id":204,"raw":205,"subject":210,"body_html":211,"body_text":212,"firm_name":213,"letter_id":214,"created_at":137,"fei_number":19,"letter_url":215,"updated_at":216,"action_type":22,"case_status":23,"posted_date":217,"marcs_cms_no":218,"product_type":63,"closeout_date":19,"issuing_office":209,"recipient_name":219,"body_fetched_at":220,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":221,"medical_device_id":19,"response_letter_date":19},2257,[206,207,208,209,210,13,13,13],"\u003Ctime datetime=\"2023-01-11T15:00:00Z\">01\u002F11\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-10T05:00:00Z\">01\u002F10\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mikes-inc-647603-01102023\">Medical Mikes, Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mike Vanacoro\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Medical Mikes, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3393 Nutly Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Yorktown Heights\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10598\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:hello@medicalmikes.com\"> hello@medicalmikes.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Federal Trade Commission\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 647603\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: January 10, 2023\u003C\u002Fp>\n\n\u003Cp>RE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fmedicalmikes.com\u002F on December 7, 2022, and January 6, 2023, respectively. The FDA has observed that your website offers cannabidiol (CBD) products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d)\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>Some examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Health Benefits of CBD Oil\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The science behind CBD and health continues to grow every day, and emerging studies have linked CBD to a number of medicinal and health benefits. The application of CBD is broad and can help alleviate symptoms of many common ailments. . . .\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Boosts Immune System: This 2020 review of existing research concluded that CBD could control immune responses to cytokines, chemokines, and regulatory cell induction, creating a potential use case for Covid treatment by preventing Cytokine Storms–the condition that transforms standard cases into life-threatening scenarios.” [From your September 2021 blog post titled “CBD FOR SENIORS: BEST PRODUCTS, BENEFITS, SAFETY, AND USES” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcbd-for-seniors-best-products-benefits-safety-and-uses]\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Researchers Recommend CBD-Based Clinical Trials for Covid-19 Prevention\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Marsha Rosner of the University of Chicago and her team, who recently published a study in Science Advances, want to see CBD at the forefront of Covid-19 prevention studies. Why? Their widely circulated research indicated that highly potent oral CBD inhibits Covid infection in human lung cells and mice. According to their findings, CBD may work by inhibiting viral gene expression while boosting the body’s stress and immune responses.” [From your February 2022 blog post titled “COVID-19 AND CBD RESEARCH: THE LATEST FINDINGS AND TAKEAWAYS” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcovid-19-and-cbd-research-the-latest-findings-and-takeaways]\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Lab Research Says CBDa and CBGa Can Stop Covid-19\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We’ve talked a lot about the potential of concentrated, oral CBD formulas for Covid-19. But what about other hemp compounds? . . .\u003C\u002Fp>\n\n\u003Cp>Study investigators found that, of hemp’s hundreds of cannabinoids, CBDa and CBGa exhibited the most powerful ability to inhibit the Covid protein from seizing human cells. Even more profound, these minor cannabinoids reduced viral infection loads (still, in a petri dish) by an astounding 50%.” [From your February 2022 blog post titled “COVID-19 AND CBD RESEARCH: THE LATEST FINDINGS AND TAKEAWAYS” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcovid-19-and-cbd-research-the-latest-findings-and-takeaways]\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address this matter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act.\u003Cstrong> Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act. This list can be found at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\">http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>FTC Cease and Desist Demand:\u003C\u002Fstrong> In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease and desist making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $50,120 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Serena Viswanathan, Associate Director of the FTC’s Division of Advertising Practices, at sviswanathan@ftc.gov certifying that you have ceased making unsubstantiated claims for the product identified above. If you have any questions regarding compliance with the FTC Act, please contact Ms. Viswanathan at 202-326-3244.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Tina Smith\u003Cbr>\nActing Director\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,&nbsp;\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Serena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMike Vanacoro\n\nMedical Mikes, Inc.\n\n3393 Nutly Circle\n\nYorktown Heights, NY 10598\n\nUnited States\n\nhello@medicalmikes.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nFederal Trade Commission\n\nWARNING LETTER\n\nRE: 647603\n\nDate: January 10, 2023\n\nRE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fmedicalmikes.com\u002F on December 7, 2022, and January 6, 2023, respectively. The FDA has observed that your website offers cannabidiol (CBD) products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nSome examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\n\n“Health Benefits of CBD Oil\n\nThe science behind CBD and health continues to grow every day, and emerging studies have linked CBD to a number of medicinal and health benefits. The application of CBD is broad and can help alleviate symptoms of many common ailments. . . .\n\no Boosts Immune System: This 2020 review of existing research concluded that CBD could control immune responses to cytokines, chemokines, and regulatory cell induction, creating a potential use case for Covid treatment by preventing Cytokine Storms–the condition that transforms standard cases into life-threatening scenarios.” [From your September 2021 blog post titled “CBD FOR SENIORS: BEST PRODUCTS, BENEFITS, SAFETY, AND USES” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcbd-for-seniors-best-products-benefits-safety-and-uses]\n\n“Researchers Recommend CBD-Based Clinical Trials for Covid-19 Prevention\n\nMarsha Rosner of the University of Chicago and her team, who recently published a study in Science Advances, want to see CBD at the forefront of Covid-19 prevention studies. Why? Their widely circulated research indicated that highly potent oral CBD inhibits Covid infection in human lung cells and mice. According to their findings, CBD may work by inhibiting viral gene expression while boosting the body’s stress and immune responses.” [From your February 2022 blog post titled “COVID-19 AND CBD RESEARCH: THE LATEST FINDINGS AND TAKEAWAYS” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcovid-19-and-cbd-research-the-latest-findings-and-takeaways]\n\n“Lab Research Says CBDa and CBGa Can Stop Covid-19\n\nWe’ve talked a lot about the potential of concentrated, oral CBD formulas for Covid-19. But what about other hemp compounds? . . .\n\nStudy investigators found that, of hemp’s hundreds of cannabinoids, CBDa and CBGa exhibited the most powerful ability to inhibit the Covid protein from seizing human cells. Even more profound, these minor cannabinoids reduced viral infection loads (still, in a petri dish) by an astounding 50%.” [From your February 2022 blog post titled “COVID-19 AND CBD RESEARCH: THE LATEST FINDINGS AND TAKEAWAYS” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcovid-19-and-cbd-research-the-latest-findings-and-takeaways]\n\nYou should take immediate action to address this matter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\n\nFTC Cease and Desist Demand: In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease and desist making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $50,120 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Serena Viswanathan, Associate Director of the FTC’s Division of Advertising Practices, at sviswanathan@ftc.gov certifying that you have ceased making unsubstantiated claims for the product identified above. If you have any questions regarding compliance with the FTC Act, please contact Ms. Viswanathan at 202-326-3244.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Tina Smith\n\nActing Director\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission\n\n______________________\n\n1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","Medical Mikes, Inc.","medical-mikes-inc-647603-01102023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mikes-inc-647603-01102023","2026-10-26T08:09:23.002096+00:00","2023-01-11","647603","Mike Vanacoro","2026-08-20T01:19:26.495+00:00","2023-01-10",{"id":223,"raw":224,"subject":176,"body_html":230,"body_text":231,"firm_name":232,"letter_id":233,"created_at":234,"fei_number":19,"letter_url":235,"updated_at":236,"action_type":22,"case_status":140,"posted_date":237,"marcs_cms_no":238,"product_type":83,"closeout_date":239,"issuing_office":228,"recipient_name":240,"body_fetched_at":241,"delivery_method":242,"recipient_title":19,"reference_number":19,"action_taken_date":243,"medical_device_id":19,"response_letter_date":19},2524,[225,226,227,228,176,13,229,13],"\u003Ctime datetime=\"2022-08-09T13:20:00Z\">08\u002F09\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-07-12T04:00:00Z\">07\u002F12\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzyno-medical-llc-629844-07122022\">Zyno Medical LLC\u003C\u002Fa>","Office of Medical Devices and Radiological Health Operations Div. 1 East","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintuvie-holdings-llc-629844-07162026\">\u003Ctime datetime=\"2026-07-21T04:00:00Z\">07\u002F21\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Chaoyoung Lee, PhD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO &amp; Founder\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Zyno Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>177 Pine Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Natick\u003C\u002Fspan>, \u003Cspan>MA\u003C\u002Fspan> \u003Cspan>01760\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Medical Devices and Radiological Health Operations Div. 1 East\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS# 629844\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 12, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Lee:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located at 177 Pine Street, Natick, MA 01760 on January 29, 2022 through February 15, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer of infusion pumps and associated administration sets, including, but not limited to, the Z-800 series infusion systems and&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Administration sets. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cstrong>Code of Federal Regulations\u003C\u002Fstrong> (CFR), Part 820. We received a response(s) from Lorraine Hanley, VP Global Quality and Regulatory Affairs dated March 8, 2022, along with three updated responses dated April 11, 2022, May 11, 2022, and June 13, 2022, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically,\u003C\u002Fp>\n\n\u003Cp>Your firm’s procedure, 006-SOP Corrective Action and Preventive Action (CAPA) Rev K, effective 1\u002F15\u002F19, includes a section (7.1.2) which states: “appropriate statistical methodology shall be employed when necessary to detect recurring quality problems.” The Director of Regulatory Affairs and Design Assurance stated the procedure should have included a statement that any product-related complaint which is reported \u003Cstrong>(b)(4)\u003C\u002Fstrong> over a 12-month rolling period will automatically trigger a CAPA Request and that your firm uses this threshold for initiating a CAPA request. He stated there was no statistical rationale for the threshold of 10 complaints but explained that this threshold was selected after a review of your baseline complaint numbers. Your firm did not follow this procedure of CAPA initiation for the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Approximately 64 complaints reporting flow rate issues in a twelve-month period (September 1, 2020 through August 31, 2021)\u003C\u002Fli>\n\t\u003Cli>Approximately 13 complaints reporting the air-in-line sensor does not alarm in a twelve-month period (November 1, 2020 through October 31, 2021)\u003C\u002Fli>\n\t\u003Cli>Approximately 22 complaints related to battery-related issues, including 10 complaints reporting the Z-800 series Infusion Pumps do not hold their charge in a seven-month period (May 1, 2021 through November 31, 2021)\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. We acknowledge your commitments to perform several action items in your March 8, 2022 response related to remediation of this violation including revisions to CAPA related procedures &amp; forms, issuance of new CAPAs for battery-related, power-related, and flow rate issues, performing a retrospective review of CAPAs, and complaint trending to determine the need for additional CAPAs revisions. We also acknowledge that you supplied additional responses dated April 11, 2022, May 11, 2022, and June 13, 2022. However, none of your promised actions have been completed and anticipated timeframes for the conduction and completion of your promised actions were not provided. In your response, explain how the firm’s current criteria for receiving ten or more product-related complaints within a twelve-month period is an appropriate statistical methodology. Additionally, provide a timeframe for the activities promised as well as the results of activities as they become available.\u003C\u002Fp>\n\n\u003Cp>2. Failure to adequately establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i). Specifically:\u003C\u002Fp>\n\n\u003Cp>Your firm’s design control procedure (Document # 001-SOP; Rev. K; effective 1\u002F18\u002F19) includes a section (7) which states that for design changes, “verification and validation activities shall be carried out to determine whether a change could significantly affect safety and effectiveness of the device.” Your firm did not perform adequate verification and validation activities for the following changes made to three of your firm’s Administration Sets&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>: change in sterilization method&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm waived verification testing for these design changes to the administration sets tubing stating that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Administration sets were identical to a previous series (B2) of administration sets which had proven durable (\u003Cstrong>(b)(4)\u003C\u002Fstrong>; dated 6\u002F21\u002F19). These sets were not identical as noted in your firm’s engineering change order for this tubing change, as documented in Engineering Change Request Form (ECR# 2019-ECR-004; dated 3\u002F27\u002F19) where you list several material changes for compatibility with gamma irradiation.\u003C\u002Fli>\n\t\u003Cli>Your firm changed and approved the sterilization method from ethylene oxide to gamma radiation through Engineering Change Request 2019-ECR-004; dated 03\u002F27\u002F19. Your firm also changed several components and materials on your infusion sets without appropriate review of devices using the new sterilization method prior to approval of the change.\u003C\u002Fli>\n\t\u003Cli>Your firm did not perform adequate validation of user needs for \u003Cstrong>(b)(4)\u003C\u002Fstrong> administration sets in accordance with your Usability Engineering SOP (#035-SOP; Rev. C; dated 3\u002F9\u002F18) in which section 6.5.3 lists a required sample size of 15 users for human factors simulation testing. The SOP in Appendix A also notes that usability studies should include test participant feedback regarding “device use, critical tasks, use errors, and problems.” However, both your Usability Validation Plan for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Administration Set Series (Document# \u003Cstrong>(b)(4)\u003C\u002Fstrong>; dated 8\u002F9\u002F19) and Usability Assessment for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Administration Set Series (Document# \u003Cstrong>(b)(4)\u003C\u002Fstrong>; dated 8\u002F26\u002F19) only lists 10 users, and not 15 as required in your SOP. Further, your Usability Assessment in Appendix B of Section 10 and Section 11 only includes minimal feedback on usability of the subject device.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. We acknowledge your commitments to perform several action items in your March 8, 2022 response related to remediation of this violation including revisions to your design control system and conducting durability testing, shelf-life studies, and packaging validation. We also acknowledge that you supplied additional responses dated April 11, 2022, May 11, 2022, and June 13, 2022. However, none of your promised actions have been completed and anticipated timeframes for the conduction and completion of your promised actions were not provided. In your response, provide a timeframe for the activities promised as well as the results of activities as they become available.\u003C\u002Fp>\n\n\u003Cp>3. Failure to adequately review, evaluate, and investigate any complaint involving the possible failure of a device to meet any of its specifications, unless such investigation has already been performed and another investigation is not necessary, as required by 21 CFR § 820.198(c).\u003Cbr>\nSpecifically,\u003C\u002Fp>\n\n\u003Cp>Three (3) of the 30 complaint records reviewed involved the possible failure of the device to meet specifications and no failure investigation was performed.\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Complaint #2021v-004, dated 01\u002F18\u002F21, alleging white markings on the outside of the pigtail of administration set model BG-70071-D-TP, lot number: 200077111. The complaint record stated that samples will be sent from this lot by complainant. However in the investigation\u002Fconclusion section of the complaint record it states: “The affected device was not returned. Therefore, no investigation could be performed and no cause could be established”. No additional investigation was conducted and no other information is provided in the record that references another investigation performed for a similar complaint.\u003C\u002Fli>\n\t\u003Cli>Complaint #2021v-007, dated 2\u002F22\u002F21, alleging that administration set model B2-70071-DF, lot number 20085018 “was leaking at the filter closest to the patient” on two separate occasions. The record then states that the “the sets that had the leaks were discarded and will not be returned” and that the complainant “had ten sets left in the box” which were going to be sent for testing. However in the investigation\u002Fconclusion section of the complaint record it states: “The affected device was not returned. Therefore, no investigation could be performed and no cause could be established”. No additional investigation was conducted and no other information is provided in the record that references another investigation performed for a similar complaint.\u003C\u002Fli>\n\t\u003Cli>Complaint #2021v-015, dated 04\u002F13\u002F21, alleging “an administration set model BG-70071-DF-TP 20086809 tube was leaking near the drip chamber.” A MDR was sent for this complaint (MDR No.: 3006575795-2021-00023). However, the investigation section of the complaint record states: “Set will not be returned because of the drug in the tubing.” No additional investigation was conducted and no other information is provided in the record that references another investigation performed for a similar complaint.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In each of these complaint records, it is noted that the device will be returned for evaluation but your reason for not performing an investigation states that the device was not returned. No further details regarding similar investigations, additional attempts to have the device returned, or further communication with the complainant are included in the complaint record.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. We acknowledge your commitments to perform several action items in your March 8, 2022 response related to remediation of this violation including revisions to your complaint system to include procedures, work instructions, tools and templates, remediation of complaint files having incomplete or no investigations, and a retrospective review of complaints. We also acknowledge that you supplied additional responses dated April 11, 2022, May 11, 2022, and June 13, 2022. However, none of your promised actions have been completed and anticipated timeframes for the conduction and completion of your promised actions were not provided. In your response, provide a timeframe for the activities promised as well as the results of activities as they become available.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s administration sets are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include the following:\u003C\u002Fp>\n\n\u003Cp>Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2). For example, the information included for Complaint 2021v-005 references a malfunction (i.e., leakage) of each of three of your firm’s Administration Sets while in use. Your firm became aware of three separate events on January 18, 2021. Although your firm submitted an MDR #3006575795-2021-00002 on January 29, 2021, it included information about three separate device malfunction events. Your firm failed to submit a malfunction MDR to FDA for each of the three individual MDR Reportable events referenced in the above complaint.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response dated March 8, 2022, cannot be determined at this time. Your firm noted in its response that it will submit two additional MDRs to account for each of the three reportable events referenced in Complaint 2021v-005. Your firm also noted that it will take systemic corrective actions, including a retrospective review of adverse events received from May 2019 to January 2022. However, it failed to indicate whether it is submitting a supplemental report to MDR #3006575795-2021-00002 to clarify that it is submitting two additional individual malfunction MDRs to account for each event referenced in the subject MDR. When submitting a supplemental report your firm should cross reference the MDR numbers of each of the two additional individual reports it submits for the events referenced in the initial MDR #3006575795-2021-00002. Also, your firm did not provide documentation or evidence of the systemic corrective actions as they are still presently ongoing.\u003C\u002Fp>\n\n\u003Cp>Your firm’s responses dated April 11, 2022, May 11, 2022, and June 13, 2022 do not address this issue.\u003C\u002Fp>\n\n\u003Cp>Additionally, our inspection revealed that your administration sets are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. §360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The administration sets are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\n\n\u003Cp>For example, your firm made the following modifications to your administration sets that require the submission of a new 510(k):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Change in sterilization method from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. While the change in sterilization method was cleared under K132841, your firm changed several components and materials on your infusion sets. Changes in sterilization methods may affect material biocompatibility and performance, which may also impact product shelf life.\u003C\u002Fli>\n\t\u003Cli>Replacement of the spike with \u003Cstrong>(b)(4)\u003C\u002Fstrong> and changes to several materials, including the drip chamber, back-check valve, slide clamp, filter and a portion of the tubing between the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and drip chamber. According to your records, these changes were implemented to address new market needs.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b) The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at&nbsp;\u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\">http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\u003C\u002Fa>. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the circumstances above. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS #629844 when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan at 410-779-5134 or sean.moynihan@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney H. Lias, Ph. D.\u003Cbr>\nDirector\u003Cbr>\nOHT 3: Office of GastroRenal, ObGyn,\u003Cbr>\n&nbsp; General Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Joseph Matrisciano, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 1 - East\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nChaoyoung Lee, PhD\n\nRecipient Title\n\nCEO & Founder\n\nZyno Medical LLC\n\n177 Pine Street\n\nNatick, MA 01760\n\nUnited States\n\nIssuing Office:\n\nOffice of Medical Devices and Radiological Health Operations Div. 1 East\n\nUnited States\n\nWARNING LETTER\n\nCMS# 629844\n\nJuly 12, 2022\n\nDear Dr. Lee:\n\nDuring an inspection of your firm located at 177 Pine Street, Natick, MA 01760 on January 29, 2022 through February 15, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer of infusion pumps and associated administration sets, including, but not limited to, the Z-800 series infusion systems and (b)(4) Administration sets. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response(s) from Lorraine Hanley, VP Global Quality and Regulatory Affairs dated March 8, 2022, along with three updated responses dated April 11, 2022, May 11, 2022, and June 13, 2022, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically,\n\nYour firm’s procedure, 006-SOP Corrective Action and Preventive Action (CAPA) Rev K, effective 1\u002F15\u002F19, includes a section (7.1.2) which states: “appropriate statistical methodology shall be employed when necessary to detect recurring quality problems.” The Director of Regulatory Affairs and Design Assurance stated the procedure should have included a statement that any product-related complaint which is reported (b)(4) over a 12-month rolling period will automatically trigger a CAPA Request and that your firm uses this threshold for initiating a CAPA request. He stated there was no statistical rationale for the threshold of 10 complaints but explained that this threshold was selected after a review of your baseline complaint numbers. Your firm did not follow this procedure of CAPA initiation for the following:\n\nApproximately 64 complaints reporting flow rate issues in a twelve-month period (September 1, 2020 through August 31, 2021)\n\nApproximately 13 complaints reporting the air-in-line sensor does not alarm in a twelve-month period (November 1, 2020 through October 31, 2021)\n\nApproximately 22 complaints related to battery-related issues, including 10 complaints reporting the Z-800 series Infusion Pumps do not hold their charge in a seven-month period (May 1, 2021 through November 31, 2021)\n\nThe adequacy of your firm’s response cannot be determined at this time. We acknowledge your commitments to perform several action items in your March 8, 2022 response related to remediation of this violation including revisions to CAPA related procedures & forms, issuance of new CAPAs for battery-related, power-related, and flow rate issues, performing a retrospective review of CAPAs, and complaint trending to determine the need for additional CAPAs revisions. We also acknowledge that you supplied additional responses dated April 11, 2022, May 11, 2022, and June 13, 2022. However, none of your promised actions have been completed and anticipated timeframes for the conduction and completion of your promised actions were not provided. In your response, explain how the firm’s current criteria for receiving ten or more product-related complaints within a twelve-month period is an appropriate statistical methodology. Additionally, provide a timeframe for the activities promised as well as the results of activities as they become available.\n\n2. Failure to adequately establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i). Specifically:\n\nYour firm’s design control procedure (Document # 001-SOP; Rev. K; effective 1\u002F18\u002F19) includes a section (7) which states that for design changes, “verification and validation activities shall be carried out to determine whether a change could significantly affect safety and effectiveness of the device.” Your firm did not perform adequate verification and validation activities for the following changes made to three of your firm’s Administration Sets (b)(4): change in sterilization method (b)(4). For example:\n\nYour firm waived verification testing for these design changes to the administration sets tubing stating that the (b)(4) Administration sets were identical to a previous series (B2) of administration sets which had proven durable ((b)(4); dated 6\u002F21\u002F19). These sets were not identical as noted in your firm’s engineering change order for this tubing change, as documented in Engineering Change Request Form (ECR# 2019-ECR-004; dated 3\u002F27\u002F19) where you list several material changes for compatibility with gamma irradiation.\n\nYour firm changed and approved the sterilization method from ethylene oxide to gamma radiation through Engineering Change Request 2019-ECR-004; dated 03\u002F27\u002F19. Your firm also changed several components and materials on your infusion sets without appropriate review of devices using the new sterilization method prior to approval of the change.\n\nYour firm did not perform adequate validation of user needs for (b)(4) administration sets in accordance with your Usability Engineering SOP (#035-SOP; Rev. C; dated 3\u002F9\u002F18) in which section 6.5.3 lists a required sample size of 15 users for human factors simulation testing. The SOP in Appendix A also notes that usability studies should include test participant feedback regarding “device use, critical tasks, use errors, and problems.” However, both your Usability Validation Plan for (b)(4) Administration Set Series (Document# (b)(4); dated 8\u002F9\u002F19) and Usability Assessment for (b)(4) Administration Set Series (Document# (b)(4); dated 8\u002F26\u002F19) only lists 10 users, and not 15 as required in your SOP. Further, your Usability Assessment in Appendix B of Section 10 and Section 11 only includes minimal feedback on usability of the subject device.\n\nThe adequacy of your firm’s response cannot be determined at this time. We acknowledge your commitments to perform several action items in your March 8, 2022 response related to remediation of this violation including revisions to your design control system and conducting durability testing, shelf-life studies, and packaging validation. We also acknowledge that you supplied additional responses dated April 11, 2022, May 11, 2022, and June 13, 2022. However, none of your promised actions have been completed and anticipated timeframes for the conduction and completion of your promised actions were not provided. In your response, provide a timeframe for the activities promised as well as the results of activities as they become available.\n\n3. Failure to adequately review, evaluate, and investigate any complaint involving the possible failure of a device to meet any of its specifications, unless such investigation has already been performed and another investigation is not necessary, as required by 21 CFR § 820.198(c).\n\nSpecifically,\n\nThree (3) of the 30 complaint records reviewed involved the possible failure of the device to meet specifications and no failure investigation was performed.\n\nFor example:\n\nComplaint #2021v-004, dated 01\u002F18\u002F21, alleging white markings on the outside of the pigtail of administration set model BG-70071-D-TP, lot number: 200077111. The complaint record stated that samples will be sent from this lot by complainant. However in the investigation\u002Fconclusion section of the complaint record it states: “The affected device was not returned. Therefore, no investigation could be performed and no cause could be established”. No additional investigation was conducted and no other information is provided in the record that references another investigation performed for a similar complaint.\n\nComplaint #2021v-007, dated 2\u002F22\u002F21, alleging that administration set model B2-70071-DF, lot number 20085018 “was leaking at the filter closest to the patient” on two separate occasions. The record then states that the “the sets that had the leaks were discarded and will not be returned” and that the complainant “had ten sets left in the box” which were going to be sent for testing. However in the investigation\u002Fconclusion section of the complaint record it states: “The affected device was not returned. Therefore, no investigation could be performed and no cause could be established”. No additional investigation was conducted and no other information is provided in the record that references another investigation performed for a similar complaint.\n\nComplaint #2021v-015, dated 04\u002F13\u002F21, alleging “an administration set model BG-70071-DF-TP 20086809 tube was leaking near the drip chamber.” A MDR was sent for this complaint (MDR No.: 3006575795-2021-00023). However, the investigation section of the complaint record states: “Set will not be returned because of the drug in the tubing.” No additional investigation was conducted and no other information is provided in the record that references another investigation performed for a similar complaint.\n\nIn each of these complaint records, it is noted that the device will be returned for evaluation but your reason for not performing an investigation states that the device was not returned. No further details regarding similar investigations, additional attempts to have the device returned, or further communication with the complainant are included in the complaint record.\n\nThe adequacy of your firm’s response cannot be determined at this time. We acknowledge your commitments to perform several action items in your March 8, 2022 response related to remediation of this violation including revisions to your complaint system to include procedures, work instructions, tools and templates, remediation of complaint files having incomplete or no investigations, and a retrospective review of complaints. We also acknowledge that you supplied additional responses dated April 11, 2022, May 11, 2022, and June 13, 2022. However, none of your promised actions have been completed and anticipated timeframes for the conduction and completion of your promised actions were not provided. In your response, provide a timeframe for the activities promised as well as the results of activities as they become available.\n\nOur inspection also revealed that your firm’s administration sets are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include the following:\n\nFailure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2). For example, the information included for Complaint 2021v-005 references a malfunction (i.e., leakage) of each of three of your firm’s Administration Sets while in use. Your firm became aware of three separate events on January 18, 2021. Although your firm submitted an MDR #3006575795-2021-00002 on January 29, 2021, it included information about three separate device malfunction events. Your firm failed to submit a malfunction MDR to FDA for each of the three individual MDR Reportable events referenced in the above complaint.\n\nThe adequacy of your firm’s response dated March 8, 2022, cannot be determined at this time. Your firm noted in its response that it will submit two additional MDRs to account for each of the three reportable events referenced in Complaint 2021v-005. Your firm also noted that it will take systemic corrective actions, including a retrospective review of adverse events received from May 2019 to January 2022. However, it failed to indicate whether it is submitting a supplemental report to MDR #3006575795-2021-00002 to clarify that it is submitting two additional individual malfunction MDRs to account for each event referenced in the subject MDR. When submitting a supplemental report your firm should cross reference the MDR numbers of each of the two additional individual reports it submits for the events referenced in the initial MDR #3006575795-2021-00002. Also, your firm did not provide documentation or evidence of the systemic corrective actions as they are still presently ongoing.\n\nYour firm’s responses dated April 11, 2022, May 11, 2022, and June 13, 2022 do not address this issue.\n\nAdditionally, our inspection revealed that your administration sets are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. §360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The administration sets are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\n\nFor example, your firm made the following modifications to your administration sets that require the submission of a new 510(k):\n\nChange in sterilization method from (b)(4). While the change in sterilization method was cleared under K132841, your firm changed several components and materials on your infusion sets. Changes in sterilization methods may affect material biocompatibility and performance, which may also impact product shelf life.\n\nReplacement of the spike with (b)(4) and changes to several materials, including the drip chamber, back-check valve, slide clamp, filter and a portion of the tubing between the (b)(4) and drip chamber. According to your records, these changes were implemented to address new market needs.\n\nFor a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b) The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nThis letter notifies you of our findings and provides you an opportunity to address the circumstances above. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS #629844 when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan at 410-779-5134 or sean.moynihan@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph. D.\n\nDirector\n\nOHT 3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nJoseph Matrisciano, Jr.\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 1 - East","Zyno Medical LLC","zyno-medical-llc-629844-07122022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzyno-medical-llc-629844-07122022","2026-10-26T08:10:40.242986+00:00","2022-08-09","629844","2026-07-21","Chaoyoung Lee, PhD","2026-08-20T01:41:20.299+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","2022-07-12",{"id":245,"raw":246,"subject":250,"body_html":251,"body_text":252,"firm_name":253,"letter_id":254,"created_at":255,"fei_number":19,"letter_url":256,"updated_at":257,"action_type":22,"case_status":23,"posted_date":258,"marcs_cms_no":259,"product_type":164,"closeout_date":19,"issuing_office":153,"recipient_name":260,"body_fetched_at":261,"delivery_method":262,"recipient_title":19,"reference_number":263,"action_taken_date":264,"medical_device_id":19,"response_letter_date":19},21927,[247,248,249,153,250,13,13,13],"\u003Ctime datetime=\"2026-10-20T04:00:00Z\">10\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-06T04:00:00Z\">10\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftides-medical-llc-727246-10062026\">Tides Medical LLC\u003C\u002Fa>","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 26-727246\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Joe Spell\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Tides Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>605 Kaliste Saloom Road, Suite 1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lafayette\u003C\u002Fspan>, \u003Cspan>LA\u003C\u002Fspan> \u003Cspan>70508\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jspell@tidesmedical.com\"> jspell@tidesmedical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>October 6, 2026\u003C\u002Fp>\u003Cp>CBER 26-727246\u003C\u002Fp>\u003Cp>Dear Mr. Spell:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) has learned that your firm is distributing APLICOR 3D in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act). Under section 201(h) of the Act, 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>FDA has reviewed information and records, including your website at https:\u002F\u002Fwww.tidesmedical.com\u002Faplicor-3d\u002F (last visited October 2026), and determined that APLICOR 3D is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) for these devices in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). APLICOR 3D is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of these devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\u003Cp>Your firm has stated that the APLICOR 3D device is a Class I device exempt from the requirement of premarket notification. You have indicated that the APLICOR 3D device is a liquid medication dispenser under product code KYX and 21 CFR 880.6430. Devices classified under 21 CFR 880.6430, liquid medication dispenser, are exempt from premarket notification unless they exceed the limitations of exemptions at 21 CFR 880.9. However, there is evidence that APLICOR 3D is intended for uses that are different from those of legally marketed devices classified under 21 CFR 880.6430, liquid medication dispenser. 21 CFR 880.6430(a) states that a liquid medication dispenser is a device intended for medical purposes that is used to issue a measured amount of liquid medication. However, your firm is distributing APLICOR 3D for the following intended uses:\u003C\u002Fp>\u003Cul>\u003Cli>“APLICOR 3D is a hyper-personalized 3D bioprinting platform that uses a patient’s own adipose tissue to create customized grafts for acute and chronic wounds. With a single application, this system simplifies workflows and accelerates wound progression.”\u003C\u002Fli>\u003Cli>“APLICOR 3D is a single-use 3D bioprinting system that transforms autologous adipose tissue into a personalized graft, precisely matching the size and depth of a patient’s wound.”\u003C\u002Fli>\u003Cli>“APLICOR 3D is designed for use in treating acute and chronic wounds such as diabetic foot ulcers, venous stasis ulcers, pressure injuries, burns, and trauma.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Because there is evidence that APLICOR 3D is intended for uses that are different from those of legally marketed devices classified under 21 CFR 880.6430, it exceeds the limitations described in 21 CFR 880.9 and is not exempt from premarket notification.\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before FDA. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our office requests that Tides Medical LLC cease any activities that result in the misbranding or adulteration of APLICOR 3D, including the commercial distribution of these devices for the uses discussed above.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to promptly and adequately address this matter may result in regulatory action being initiated by FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Please notify our office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions your firm has taken, which should address any systemic problems. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen (15) business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that APLICOR 3D is not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov. Refer to the CBER number at the top of this letter when replying.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm. It is your firm’s responsibility to ensure compliance with the applicable laws and regulations administered by FDA.\u003C\u002Fp>\u003Cp>Sincerely,\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Vincent Amatrudo\u003Cbr>Acting Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>___________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> FDA acknowledges receipt of your February 26, 2026, correspondence responding to the February 25, 2026, letter sent to your firm from FDA’s Center for Devices and Radiological Health.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER 26-727246\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJoe Spell\n\nRecipient Title\n\nChief Executive Officer\n\nTides Medical LLC\n\n605 Kaliste Saloom Road, Suite 1\n\nLafayette, LA 70508\n\nUnited States\n\njspell@tidesmedical.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nOctober 6, 2026\nCBER 26-727246\nDear Mr. Spell:\nThe United States Food and Drug Administration (FDA) has learned that your firm is distributing APLICOR 3D in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act). Under section 201(h) of the Act, 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.1\nFDA has reviewed information and records, including your website at https:\u002F\u002Fwww.tidesmedical.com\u002Faplicor-3d\u002F (last visited October 2026), and determined that APLICOR 3D is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) for these devices in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). APLICOR 3D is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of these devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\nYour firm has stated that the APLICOR 3D device is a Class I device exempt from the requirement of premarket notification. You have indicated that the APLICOR 3D device is a liquid medication dispenser under product code KYX and 21 CFR 880.6430. Devices classified under 21 CFR 880.6430, liquid medication dispenser, are exempt from premarket notification unless they exceed the limitations of exemptions at 21 CFR 880.9. However, there is evidence that APLICOR 3D is intended for uses that are different from those of legally marketed devices classified under 21 CFR 880.6430, liquid medication dispenser. 21 CFR 880.6430(a) states that a liquid medication dispenser is a device intended for medical purposes that is used to issue a measured amount of liquid medication. However, your firm is distributing APLICOR 3D for the following intended uses:\n“APLICOR 3D is a hyper-personalized 3D bioprinting platform that uses a patient’s own adipose tissue to create customized grafts for acute and chronic wounds. With a single application, this system simplifies workflows and accelerates wound progression.”\n“APLICOR 3D is a single-use 3D bioprinting system that transforms autologous adipose tissue into a personalized graft, precisely matching the size and depth of a patient’s wound.”\n“APLICOR 3D is designed for use in treating acute and chronic wounds such as diabetic foot ulcers, venous stasis ulcers, pressure injuries, burns, and trauma.”\nBecause there is evidence that APLICOR 3D is intended for uses that are different from those of legally marketed devices classified under 21 CFR 880.6430, it exceeds the limitations described in 21 CFR 880.9 and is not exempt from premarket notification.\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before FDA. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\nConclusion\nOur office requests that Tides Medical LLC cease any activities that result in the misbranding or adulteration of APLICOR 3D, including the commercial distribution of these devices for the uses discussed above.\nYour firm should take prompt action to address any violations identified in this letter. Failure to promptly and adequately address this matter may result in regulatory action being initiated by FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nPlease notify our office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions your firm has taken, which should address any systemic problems. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen (15) business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that APLICOR 3D is not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\nSend your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov. Refer to the CBER number at the top of this letter when replying.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm. It is your firm’s responsibility to ensure compliance with the applicable laws and regulations administered by FDA.\nSincerely,\n\u002FS\u002F\nVincent Amatrudo\nActing Director\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n___________________\n1 FDA acknowledges receipt of your February 26, 2026, correspondence responding to the February 25, 2026, letter sent to your firm from FDA’s Center for Devices and Radiological Health.","Tides Medical LLC","tides-medical-llc-727246-10062026","2026-10-27T01:18:54.544251+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftides-medical-llc-727246-10062026","2026-11-17T01:02:03.701861+00:00","2026-10-20","727246","Joe Spell","2026-10-27T01:19:42.766+00:00","VIA UPS and Electronic Mail","CBER 26-727246","2026-10-06",{"id":266,"raw":267,"subject":176,"body_html":271,"body_text":272,"firm_name":273,"letter_id":274,"created_at":58,"fei_number":19,"letter_url":275,"updated_at":276,"action_type":22,"case_status":23,"posted_date":277,"marcs_cms_no":278,"product_type":83,"closeout_date":19,"issuing_office":72,"recipient_name":279,"body_fetched_at":280,"delivery_method":105,"recipient_title":19,"reference_number":19,"action_taken_date":281,"medical_device_id":19,"response_letter_date":19},434,[268,269,270,72,176,13,13,13],"\u003Ctime datetime=\"2025-12-09T05:00:00Z\">12\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-11T05:00:00Z\">11\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fenvoy-medical-inc-718762-11112025\">Envoy Medical Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Brent T. Lucas\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO &amp; Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Envoy Medical Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4875 White Bear Parkway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint Paul\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55110-3325\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:blucas@envoymedical.com\"> blucas@envoymedical.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 718762\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 11, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Lucas:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Saint Paul, MN from June 24, 2025, through July 2, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufacturers the Esteem II Implantable Hearing System. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that this device is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, its manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received your response dated July 22, 2025, from Maksim Trofimovich, Quality Manager, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to you. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003C\u002Fp>\u003Cp>Specifically, your firm has not adequately implemented your Complaint Handling, Medical Device Reporting and Vigilance Reporting, Document Number 000978, Revision 26, Dated 20-May-2024, to ensure complaints are processed in a uniform and timely manner. For example:\u003C\u002Fp>\u003Cp>a) On November 25, 2024, your firm received Complaint CR-03201 documenting explantation of an Esteem II System due to patient infection. The physical device was received on December 5, 2024, and the incident was reported as a serious injury Medical Device Report (MDR) on December 18, 2024. As of the inspection's conclusion on July 2, 2025, approximately seven months after initial complaint receipt, the investigation remained incomplete. Your firm's complaint procedure (Document 000978) does not include specific requirements for uniform and timely complaint processing. In addition, your firm maintains a procedure for returned product analysis (Document 001005, Revision 12, dated May 20, 2024) that outlines specific failure mode analysis requirements and analytical methods. However, your firm did not conduct and document an investigation for Complaint CR-03201 in accordance with these established protocols as of the conclusion of the July 2025 inspection.\u003C\u002Fp>\u003Cp>b) Your firm received Complaint CR-03042 on September 28, 2023, involving sudden battery depletion of the Esteem II System. Your firm determined this complaint to be a significant high-risk event and reported it as a serious injury on April 12, 2024, or approximately seven months after the initial complaint receipt. The device was received for investigation on June 26, 2024. Documentation for Complaint CR-03042 shows that Complaint File Review (CFR) meetings in September 2024 and October 2024 did not determine which engineering team member would be assigned to conduct the required engineering investigation, with the decision deferred further to the November 2024 CFR meeting. At the time of the inspection ending July 2, 2025, this complaint remained pending an engineering review as required by your firm's complaint procedures. No progress updates beyond October 2024 are documented in the complaint record.\u003C\u002Fp>\u003Cp>c) Your firm received Complaint CR-03165 on August 22, 2024, involving an Esteem II Transducer that was causing feedback and difficulty programming the Esteem II System, which led to revision surgery to replace the sensor. The device was received for investigation on February 4, 2025, and the incident was reported as a serious injury Medical Device Report (MDR) on February 14, 2025. Your Quality Engineer indicated the device investigation is incomplete pending calibration of inspection equipment required for returned product analysis, however, similar calibrated equipment used in production could potentially be utilized for the returned product analysis but was not employed. At the time of the inspection ending July 2, 2025, this complaint remained open and pending testing as required by the firm's complaint procedures. No progress updates beyond January 2025 are documented in the complaint record.\u003C\u002Fp>\u003Cp>The response dated July 22, 2025, is not adequate. Your firm’s response includes a revised SOP 000978 \"Complaint Handling, Medical Device Reporting and Vigilance Reporting\" (Attachment D - redlined version) which represents a proposed changes rather than an approved, implemented procedure. Concerning timeliness requirements outlined in the procedure, that complaint investigations be completed within 6 months of the first aware date, this may be considered lengthy for addressing regulatory compliance issues. Your firm’s response also includes documentation to demonstrate closure of CR-03201 and CR-03165, but only a progress report for CR-03042 was provided rather than the complete updated complaint record. This suggests CR-03042 remains open pending completion of the ongoing engineering investigation. Your firm’s response indicates your firm’s intent to complete all open complaints by September 2025. However, we have received no updated response(s) from your firm for September\u002FOctober 2025 to demonstrate the investigation completion of CR-03042 and its closure. In addition, your response acknowledges resource diversion to other work priorities but doesn't provide specific safeguards to ensure adequate resources for complaint investigations going forward.\u003C\u002Fp>\u003Cp>2. Failure to adequately establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fp>\u003Cp>Specifically, your firm's CAPA procedures, Corrective and Preventive Actions, Document Number 000422, Revision 17, Dated September 20, 2024; Quality Event Risk Assessment &amp; CAPA Escalation, Document Number 006411, Revision 03, Dated May 15, 2024; and CAPA Work Instruction, Document Number 006342, Revision 08, Dated September 20, 2024, have not been adequately implemented concerning two critical CAPAs involving high particulate counts in your firm’s ISO Class 8 Cleanrooms. For example:\u003C\u002Fp>\u003Cp>a) Your firm opened CAPA-00684 on March 2, 2022, following the discovery of high \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate counts during \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanroom monitoring conducted on February 16, 2022. The monitoring, performed by a third-party service identified particulate counts of \u003Cstrong>(b)(4)\u003C\u002Fstrong> at location \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your large cleanroom, which exceeded the ISO Class 8 requirement of below 3,520,000 particulates\u002Fm³. No Health Hazard Evaluation (HHE), Document 006330, was conducted to assess the potential adverse impact to user safety, including assessment of any impact to products manufactured between February 16, 2022, and May 19, 2022, for the extended period of non-conforming cleanroom conditions.\u003C\u002Fp>\u003Cp>b) Your firm opened CAPA-00708 on July 10, 2024, for high \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate counts discovered during \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanroom monitoring conducted on May 8, 2024. The third-party monitoring service found particulate counts of \u003Cstrong>(b)(4)\u003C\u002Fstrong> at location \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> at location \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your large cleanroom, both exceeding ISO Class 8 specifications. No HHE was conducted and no further assessment of any impact to products manufactured between February 27, 2024, and October 14, 2024, for the extended period of non-conforming manufacturing conditions.\u003C\u002Fp>\u003Cp>The response dated July 22, 2025, is not adequate. Your response includes CAPA CA-00712 that addresses the immediate product impact issues both CA-00684 and CA-00708 failed to evaluate. However, CAPA CA-00712 does not provide for an investigation to correct the underlying CAPA system deficiencies that allowed a fundamental failure in risk assessment to occur. Specifically, why qualified personnel conducting CA-00684, and the subsequent CAPA CA-00708, failed to recognize nonconforming conditions, assess the competency or decision-making factors that led to inadequate risk assessment, or updates to underlying CAPA procedures (Documents 000422, 006411, 006342) that allowed the inadequate evaluation to occur. Our concern remains that there appears to be ongoing systemic issues in your CAPA process that CA-00712 does not specifically address.\u003C\u002Fp>\u003Cp>3. Failure to adequately establish and maintain design validation procedures to ensure proper risk analysis is completed, as required by 21 CFR 820.30(g).\u003C\u002Fp>\u003Cp>Specifically, your firm's implementation of your primary risk assessment procedure \"Risk Management Process\", Document Number 001000, Revision 11, dated April 17, 2025, did not ensure routine updating of hazard evaluation documentation and the consistent assessment of infection-related risks. For example:\u003C\u002Fp>\u003Cp>a) CAPA CA-00701 identified that \u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in assembly processes may have incomplete \u003Cstrong>(b)(4)\u003C\u002Fstrong> due to \u003Cstrong>(b)(4)\u003C\u002Fstrong> excursions in your firm’s large ISO Class 8 cleanroom. However, the risk documentation for the Esteem II Sound Processors which includes Esteem II System HA, Document Number 003682, Revision 12, dated April 20, 2017, and Esteem II FMECA, Document Number 006411, Revision 12, dated April 20, 2017, do not include the hazard identified from CA-00701, to evaluate the risk and its potential effects on the Esteem II System.\u003C\u002Fp>\u003Cp>b) Your firm's risk assessment does not consistently evaluate infection risks for the Esteem II System. Your risk analysis document establishes three contamination events that lead to the same outcome of patient infection but are assigned different severity ratings. \"Insufficient flow of filtered air\" and \"Contaminated \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system\" resulting in \"Excessive contamination or bioburden on parts\" are rated as severity \u003Cstrong>(b)(4)\u003C\u002Fstrong>, while the \"Contamination not removed from assembly\" with \"Infection or reaction\" is rated as severity \u003Cstrong>(b)(4)\u003C\u002Fstrong>. According to your firm’s Risk Management Process procedure, severity \u003Cstrong>(b)(4)\u003C\u002Fstrong> indicates temporary health problems requiring routine medical care, while severity \u003Cstrong>(b)(4)\u003C\u002Fstrong> indicates life-threatening consequences. It is unclear why these three contamination sources that could all lead to patient infection were given different severity ratings when the potential patient harm would be the same.\u003C\u002Fp>\u003Cp>c) Your firm's Risk Management Process procedure does not specifically identify endotoxins as a hazard to be considered in the risk management process, and you only perform in-process endotoxin testing of your \u003Cstrong>(b)(4) \u003C\u002Fstrong>water system while omitting testing of the finished device, Esteem II System. Your firm maintains no documentation demonstrating that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system testing is representative of endotoxin risk for the finished device or provides for consideration of other possible sources of endotoxin contamination in your manufacturing process for the device.\u003C\u002Fp>\u003Cp>The response dated July 22, 2025, is not adequate. Your response includes CAPA CA-00716 and identified training deficiencies and procedural gaps as root causes. However, your response does not adequately address why your risk analysis system failed to identify and incorporate critical hazards such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> effects on \u003Cstrong>(b)(4)\u003C\u002Fstrong> for nearly a \u003Cstrong>(b)(4)\u003C\u002Fstrong>, or why your risk assessment methodology allowed inconsistent severity ratings for infection-related failure modes that could result in similar patient harm. Your immediate corrections including updating FMECA 003799, to add \u003Cstrong>(b)(4)\u003C\u002Fstrong> risks and align infection severity ratings, along with hazard analysis training completed in July 2025. This may address the immediate technical issues but does not demonstrate a comprehensive evaluation of your risk analysis process to ensure all relevant hazards have been identified and properly assessed for your sterile implantable device. Your response also includes CAPA CA-00714 indicating a commitment to implement endotoxin testing for finished devices by September 2025 and update procedure 000500 by August 2025. However, your response does not include any retrospective risk assessment of previously released products that were distributed without endotoxin testing. While your corrective actions focus on procedural documentation improvements including updating procedure 000500 to include endotoxin testing requirements, you do not address updates to procedures including your Risk Management Process (Document 001000), Hazard Analysis (Document 003682), and FMECA (Document 003799), to include endotoxin contamination as an identified critical hazard requiring control for your sterile implantable device.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent to: Melissa Michurski, Assistant Director, at CDRHEnforcement@fda.hhs.gov. Refer to CMS # 718762 when replying. If you have any questions about the contents of this letter, please contact Salvatore Randazzo, Compliance Officer, at 407-475-4712 or salvatore.randazzo@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden\u003Cbr>Acting Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nBrent T. Lucas\n\nRecipient Title\n\nCEO & Director\n\nEnvoy Medical Inc.\n\n4875 White Bear Parkway\n\nSaint Paul, MN 55110-3325\n\nUnited States\n\nblucas@envoymedical.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 718762\nNovember 11, 2025\nDear Mr. Lucas:\nDuring an inspection of your firm located in Saint Paul, MN from June 24, 2025, through July 2, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufacturers the Esteem II Implantable Hearing System. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violation(s)\nThis inspection revealed that this device is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, its manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received your response dated July 22, 2025, from Maksim Trofimovich, Quality Manager, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to you. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\nSpecifically, your firm has not adequately implemented your Complaint Handling, Medical Device Reporting and Vigilance Reporting, Document Number 000978, Revision 26, Dated 20-May-2024, to ensure complaints are processed in a uniform and timely manner. For example:\na) On November 25, 2024, your firm received Complaint CR-03201 documenting explantation of an Esteem II System due to patient infection. The physical device was received on December 5, 2024, and the incident was reported as a serious injury Medical Device Report (MDR) on December 18, 2024. As of the inspection's conclusion on July 2, 2025, approximately seven months after initial complaint receipt, the investigation remained incomplete. Your firm's complaint procedure (Document 000978) does not include specific requirements for uniform and timely complaint processing. In addition, your firm maintains a procedure for returned product analysis (Document 001005, Revision 12, dated May 20, 2024) that outlines specific failure mode analysis requirements and analytical methods. However, your firm did not conduct and document an investigation for Complaint CR-03201 in accordance with these established protocols as of the conclusion of the July 2025 inspection.\nb) Your firm received Complaint CR-03042 on September 28, 2023, involving sudden battery depletion of the Esteem II System. Your firm determined this complaint to be a significant high-risk event and reported it as a serious injury on April 12, 2024, or approximately seven months after the initial complaint receipt. The device was received for investigation on June 26, 2024. Documentation for Complaint CR-03042 shows that Complaint File Review (CFR) meetings in September 2024 and October 2024 did not determine which engineering team member would be assigned to conduct the required engineering investigation, with the decision deferred further to the November 2024 CFR meeting. At the time of the inspection ending July 2, 2025, this complaint remained pending an engineering review as required by your firm's complaint procedures. No progress updates beyond October 2024 are documented in the complaint record.\nc) Your firm received Complaint CR-03165 on August 22, 2024, involving an Esteem II Transducer that was causing feedback and difficulty programming the Esteem II System, which led to revision surgery to replace the sensor. The device was received for investigation on February 4, 2025, and the incident was reported as a serious injury Medical Device Report (MDR) on February 14, 2025. Your Quality Engineer indicated the device investigation is incomplete pending calibration of inspection equipment required for returned product analysis, however, similar calibrated equipment used in production could potentially be utilized for the returned product analysis but was not employed. At the time of the inspection ending July 2, 2025, this complaint remained open and pending testing as required by the firm's complaint procedures. No progress updates beyond January 2025 are documented in the complaint record.\nThe response dated July 22, 2025, is not adequate. Your firm’s response includes a revised SOP 000978 \"Complaint Handling, Medical Device Reporting and Vigilance Reporting\" (Attachment D - redlined version) which represents a proposed changes rather than an approved, implemented procedure. Concerning timeliness requirements outlined in the procedure, that complaint investigations be completed within 6 months of the first aware date, this may be considered lengthy for addressing regulatory compliance issues. Your firm’s response also includes documentation to demonstrate closure of CR-03201 and CR-03165, but only a progress report for CR-03042 was provided rather than the complete updated complaint record. This suggests CR-03042 remains open pending completion of the ongoing engineering investigation. Your firm’s response indicates your firm’s intent to complete all open complaints by September 2025. However, we have received no updated response(s) from your firm for September\u002FOctober 2025 to demonstrate the investigation completion of CR-03042 and its closure. In addition, your response acknowledges resource diversion to other work priorities but doesn't provide specific safeguards to ensure adequate resources for complaint investigations going forward.\n2. Failure to adequately establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\nSpecifically, your firm's CAPA procedures, Corrective and Preventive Actions, Document Number 000422, Revision 17, Dated September 20, 2024; Quality Event Risk Assessment & CAPA Escalation, Document Number 006411, Revision 03, Dated May 15, 2024; and CAPA Work Instruction, Document Number 006342, Revision 08, Dated September 20, 2024, have not been adequately implemented concerning two critical CAPAs involving high particulate counts in your firm’s ISO Class 8 Cleanrooms. For example:\na) Your firm opened CAPA-00684 on March 2, 2022, following the discovery of high (b)(4) particulate counts during (b)(4) cleanroom monitoring conducted on February 16, 2022. The monitoring, performed by a third-party service identified particulate counts of (b)(4) at location (b)(4) in your large cleanroom, which exceeded the ISO Class 8 requirement of below 3,520,000 particulates\u002Fm³. No Health Hazard Evaluation (HHE), Document 006330, was conducted to assess the potential adverse impact to user safety, including assessment of any impact to products manufactured between February 16, 2022, and May 19, 2022, for the extended period of non-conforming cleanroom conditions.\nb) Your firm opened CAPA-00708 on July 10, 2024, for high (b)(4) particulate counts discovered during (b)(4) cleanroom monitoring conducted on May 8, 2024. The third-party monitoring service found particulate counts of (b)(4) at location (b)(4) and (b)(4) at location (b)(4) in your large cleanroom, both exceeding ISO Class 8 specifications. No HHE was conducted and no further assessment of any impact to products manufactured between February 27, 2024, and October 14, 2024, for the extended period of non-conforming manufacturing conditions.\nThe response dated July 22, 2025, is not adequate. Your response includes CAPA CA-00712 that addresses the immediate product impact issues both CA-00684 and CA-00708 failed to evaluate. However, CAPA CA-00712 does not provide for an investigation to correct the underlying CAPA system deficiencies that allowed a fundamental failure in risk assessment to occur. Specifically, why qualified personnel conducting CA-00684, and the subsequent CAPA CA-00708, failed to recognize nonconforming conditions, assess the competency or decision-making factors that led to inadequate risk assessment, or updates to underlying CAPA procedures (Documents 000422, 006411, 006342) that allowed the inadequate evaluation to occur. Our concern remains that there appears to be ongoing systemic issues in your CAPA process that CA-00712 does not specifically address.\n3. Failure to adequately establish and maintain design validation procedures to ensure proper risk analysis is completed, as required by 21 CFR 820.30(g).\nSpecifically, your firm's implementation of your primary risk assessment procedure \"Risk Management Process\", Document Number 001000, Revision 11, dated April 17, 2025, did not ensure routine updating of hazard evaluation documentation and the consistent assessment of infection-related risks. For example:\na) CAPA CA-00701 identified that (b)(4) of (b)(4) used in assembly processes may have incomplete (b)(4) due to (b)(4) excursions in your firm’s large ISO Class 8 cleanroom. However, the risk documentation for the Esteem II Sound Processors which includes Esteem II System HA, Document Number 003682, Revision 12, dated April 20, 2017, and Esteem II FMECA, Document Number 006411, Revision 12, dated April 20, 2017, do not include the hazard identified from CA-00701, to evaluate the risk and its potential effects on the Esteem II System.\nb) Your firm's risk assessment does not consistently evaluate infection risks for the Esteem II System. Your risk analysis document establishes three contamination events that lead to the same outcome of patient infection but are assigned different severity ratings. \"Insufficient flow of filtered air\" and \"Contaminated (b)(4) water system\" resulting in \"Excessive contamination or bioburden on parts\" are rated as severity (b)(4), while the \"Contamination not removed from assembly\" with \"Infection or reaction\" is rated as severity (b)(4). According to your firm’s Risk Management Process procedure, severity (b)(4) indicates temporary health problems requiring routine medical care, while severity (b)(4) indicates life-threatening consequences. It is unclear why these three contamination sources that could all lead to patient infection were given different severity ratings when the potential patient harm would be the same.\nc) Your firm's Risk Management Process procedure does not specifically identify endotoxins as a hazard to be considered in the risk management process, and you only perform in-process endotoxin testing of your (b)(4) water system while omitting testing of the finished device, Esteem II System. Your firm maintains no documentation demonstrating that the (b)(4) water system testing is representative of endotoxin risk for the finished device or provides for consideration of other possible sources of endotoxin contamination in your manufacturing process for the device.\nThe response dated July 22, 2025, is not adequate. Your response includes CAPA CA-00716 and identified training deficiencies and procedural gaps as root causes. However, your response does not adequately address why your risk analysis system failed to identify and incorporate critical hazards such as (b)(4) effects on (b)(4) for nearly a (b)(4), or why your risk assessment methodology allowed inconsistent severity ratings for infection-related failure modes that could result in similar patient harm. Your immediate corrections including updating FMECA 003799, to add (b)(4) risks and align infection severity ratings, along with hazard analysis training completed in July 2025. This may address the immediate technical issues but does not demonstrate a comprehensive evaluation of your risk analysis process to ensure all relevant hazards have been identified and properly assessed for your sterile implantable device. Your response also includes CAPA CA-00714 indicating a commitment to implement endotoxin testing for finished devices by September 2025 and update procedure 000500 by August 2025. However, your response does not include any retrospective risk assessment of previously released products that were distributed without endotoxin testing. While your corrective actions focus on procedural documentation improvements including updating procedure 000500 to include endotoxin testing requirements, you do not address updates to procedures including your Risk Management Process (Document 001000), Hazard Analysis (Document 003682), and FMECA (Document 003799), to include endotoxin contamination as an identified critical hazard requiring control for your sterile implantable device.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent to: Melissa Michurski, Assistant Director, at CDRHEnforcement@fda.hhs.gov. Refer to CMS # 718762 when replying. If you have any questions about the contents of this letter, please contact Salvatore Randazzo, Compliance Officer, at 407-475-4712 or salvatore.randazzo@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nActing Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Envoy Medical Inc.","envoy-medical-inc-718762-11112025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fenvoy-medical-inc-718762-11112025","2026-10-26T08:08:35.801946+00:00","2025-12-09","718762","Brent T. Lucas","2026-08-19T11:14:00.787+00:00","2025-11-11",{"id":283,"raw":284,"subject":287,"body_html":288,"body_text":289,"firm_name":290,"letter_id":291,"created_at":18,"fei_number":19,"letter_url":292,"updated_at":293,"action_type":22,"case_status":23,"posted_date":294,"marcs_cms_no":295,"product_type":63,"closeout_date":19,"issuing_office":11,"recipient_name":296,"body_fetched_at":297,"delivery_method":29,"recipient_title":19,"reference_number":298,"action_taken_date":24,"medical_device_id":19,"response_letter_date":19},735,[285,8,286,11,287,13,13,13],"\u003Ctime datetime=\"2025-08-05T04:00:00Z\">08\u002F05\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Foasis-medical-inc-707198-07152025\">Oasis Medical, Inc.\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-93\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Norman Craig Delgado\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Oasis Medical, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>514 S. Vermont Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Glendora\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91741\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-93\u003C\u002Fp>\u003Cp>July 15, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Delgado:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facilities, Oasis Medical, Inc., FEI 2083373, at 514 S. Vermont Avenue, Glendora, from January 15 to 27, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your February 17, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to ensure the use of reproducible manufacturing processes for the production of sterile ophthalmic drug products. You also lacked an ongoing program to establish stable manufacturing operations, monitor ongoing process control, and provide for consistent drug quality. For example,\u003C\u002Fp>\u003Cul>\u003Cli>Your process lacked adequate control and is prone to producing an excessive number of defective units. A substantial portion of batches have been rejected, including total reject levels \u003Cstrong>(b)(4)\u003C\u002Fstrong> in a number of cases. Of special concern are the excessive number of defective products due to visible particulate contamination (e.g., recurring instances of levels greater than \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Batches with very high defect levels were nonetheless distributed.\u003C\u002Fli>\u003Cli>You failed to establish and follow an adequate visual inspection program for the ophthalmic drugs manufactured by your firm.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>There was no classification as to the severity of the defects (i.e., critical, major, minor) or limit for the number of defects allowed, if any.\u003C\u002Fp>\u003Cul>\u003Cli>The most recently completed requalification study for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle was conducted in 2023 and inadequately considered potential changes from previous qualifications and the original validation. The 2023 requalification did not include an assessment of \u003Cstrong>(b)(4)\u003C\u002Fstrong> maintenance or changes to the drug product components.\u003C\u002Fli>\u003Cli>The maximum duration of the hold steps in your manufacturing process (e.g., extensive hold times prior to \u003Cstrong>(b)(4)\u003C\u002Fstrong>) has not been validated.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your response fails to address your lack of process capability, and the overreliance on visual inspection in an attempt to remove excessive defective units from batches.\u003C\u002Fp>\u003Cp>You do not commit to thoroughly investigate the root causes of the visible particulates and excessive occurrence of these critical defects. You also lack appropriate interim steps to prevent production of further batches from a low capability process while you make efforts to remediate it. In addition, the response lacks a commitment to address potentially contaminated products in distribution.\u003C\u002Fp>\u003Cp>Regarding the visual inspection program, your response lacks a commitment to perform a comprehensive reassessment of this program.\u003C\u002Fp>\u003Cp>Regarding production hold times, your response acknowledges that you have not performed validation of your hold steps. But you do not commit to validating all in-process hold times and include a date by which these studies will be completed.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process through its lifecycle. Each significant stage of a manufacturing process must be designed appropriately to ensure the quality of raw material inputs, materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality are necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed retrospective review and assessment of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> program. The retrospective review and assessment should include all changes to the drug product, container closure system, and packaging (e.g., canula sheath); and an evaluation of changes to, and maintenance of, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment. If changes are identified, provide your plan to evaluate the safety and quality of distributed finished products that remain within expiry and a plan to ensure the safety and quality of your drug products until the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process is successfully validated.\u003C\u002Fli>\u003Cli>Thorough investigation(s), including corrective actions and preventive actions (CAPA), regarding finished product batches manufactured and released for distribution despite high numbers of rejected units.\u003C\u002Fli>\u003Cli>Complete results of your examination of retains\u002Freserve samples for all batches from January 2023 to present for defects, and any related investigation(s) and corrective actions.\u003C\u002Fli>\u003Cli>A list of all batches since January 1, 2023, to present, with the following information:\u003Cbr>o Product name\u003Cbr>o Batch number\u003Cbr>o Date of manufacture\u003Cbr>o Date of expiration\u003Cbr>o Batch size (original quantity of theoretical syringes)\u003Cbr>o Actual batch yield (number of pouched syringe units)\u003Cbr>o Number of rejects due to particulates\u003Cbr>o Number of rejects due to other defects (include the top 3 other defect types for each batch, beyond particulate defects)\u003Cbr>o Percent yield\u003C\u002Fli>\u003Cli>A remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability, and assures that manufacturing (including both production and packaging) operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment and remediation plan for systems used in the visual inspection of sterile drugs for defects (including but not limited to particulate matter). The assessment should include adequacy of inspection methods, acceptance and rejection criteria, personnel training, supervision, equipment and personnel qualification, equipment maintenance, and the procedures governing them. Provide your detailed remediation action plan that includes dates by which each remediation activity will be completed, and provisions for periodic independent reassessment of the plan’s effectiveness.\u003C\u002Fli>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. Also, summarize the program for qualification of your equipment and facility.\u003C\u002Fli>\u003Cli>Timelines for completing further PPQ studies on remediated processes for marketed drug products for which a state of control has not been adequately established.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm lacked meaningful investigations of failed sterility and bioburden test results. For example:\u003C\u002Fp>\u003Cp>\u003Cem>Sterility Failure\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not adequately investigate a failed sterility test result for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product, VISCO SHIELD Topical Drops, lot V0724N. Your external testing laboratory performs two sterility tests: one for the contents within the syringe and the other for the sterility of the syringe and cap primary packaging components. Your external testing laboratory reported a sterility failure for the syringe and cap portion of the testing. You concluded in NCR 24014 that, because the contaminant was found only on the syringe and cap and not the contents of the syringe, the likely root cause of the sterility failure was laboratory contamination due to excessive handling during the test. However, your contract testing laboratory’s investigation concluded that there was no laboratory error. You failed to resolve the conflicting root cause conclusions and did not extend your investigation to other potential sources of contamination or ensure it was of appropriate scope. Although the batch remained under your control, your QU had dispositioned this batch “USE AS IS” on September 30, 2024, to be distributed to the U.S. market.\u003C\u002Fp>\u003Cp>In your response to the sterility failure, we acknowledge your intention to create a specific procedure to address external laboratory out-of-specification (OOS) investigations. However, your investigation failed to consider conditions that led to the sterility failure or determine potential root causes to ensure effective CAPAs were promptly initiated. Additionally, you do not adequately address the potential non-integrity failure mode of the packaged finished drug product (e.g., breach in packaging integrity following \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\u003Cp>\u003Cem>Bioburden OOS\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm did not adequately investigate your firm’s pre-sterilization bioburden results that exceeded their specifications (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) for VISCO SHIELD Topical Drops, lot V0724G. One sample exceeded the specification for the aerobic plate count test with a result of 570 CFU\u002Fsample and another sample exceeded the specification for the yeast and mold count test with a result of 334 CFU\u002Fsample.\u003C\u002Fp>\u003Cp>In your response to the bioburden OOS, your investigation fails to consider the conditions that led to the OOS. You do not identify the microbes recovered or determine resistance of any spore-forming microbes that may have been present. You also do not address potential root causes during the production process that could contribute to excess bioburden. Assessment of the number of types of microbes in pre-sterilization bioburden helps to determine whether the validated \u003Cstrong>(b)(4)\u003C\u002Fstrong> process continues to be capable of rendering the finished product sterile.\u003C\u002Fp>\u003Cp>Whenever an investigation lacks conclusive evidence of laboratory error, a thorough investigation of potential manufacturing causes must be performed.\u003C\u002Fp>\u003Cp>For more information about handling failing, OOS, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document \u003Cem>Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F158416\u002Fdownload. While this guidance generally applies to chemistry-based laboratory testing, many of the principles are relevant to microbiological testing.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>The disposition status of the referenced batch, VISCO SHIELD Topical Drops, lot V0724N. If the lot was released for distribution, provide the dates of release and distribution.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final QU decisions, and is fully supported by executive management.\u003C\u002Fli>\u003Cli>A retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for US products within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\u003Cbr>o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>o For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fli>\u003Cli>A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include, but not be limited to, addressing the following:\u003Cbr>o QU oversight of laboratory investigations.\u003Cbr>o Identification of adverse laboratory control trends.\u003Cbr>o Resolution of causes of laboratory variation.\u003Cbr>o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified.\u003Cbr>o Adequately scoping of each investigation and its CAPA.\u003Cbr>o Revised OOS investigation procedures with these and other remediations.\u003C\u002Fli>\u003Cli>A detailed retrospective review and assessment of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> program. The retrospective review and assessment should include:\u003Cbr>o All changes to the drug product, container closure system, and packaging (e.g., canula sheath).\u003Cbr>o An evaluation of changes to, and maintenance of, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment.\u003Cbr>o A plan to evaluate the safety and quality of distributed finished products that remain within expiry if significant changes occurred that may pose a risk to quality or safety.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity. You also failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.160(b)) and (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Finished Product Testing\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your finished product testing for release of ophthalmic drug product batches did not include adequate analytical testing to determine the identification or assay of the active ingredient, hydroxypropyl methylcellulose (Hypromellose).\u003C\u002Fp>\u003Cp>Your response and subsequent updates are inadequate. You commit to updating your finished product specifications. However, you reference an internally-developed, non-specific method for assay (strength) without providing adequate documentation and scientific justification to support its use. In contrast, a method is available in the USP that employs a reference standard and spectrophotometric measurements to determine Hypromellose assay.\u003C\u002Fp>\u003Cp>\u003Cem>Stability Program\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm lacked an adequate stability program to support the \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiration date. For example:\u003C\u002Fp>\u003Cul>\u003Cli>Your firm did not establish appropriate tests and specifications for your ophthalmic drug products to monitor the active ingredient identity or assay at release and throughout expiry. Your stability program did not include an adequate test for assay of the active ingredient, hydroxypropyl methylcellulose (Hypromellose). In place of the USP assay, your firm used an in-house method based on loss-on-drying without scientific justification.\u003C\u002Fli>\u003Cli>Your firm did not follow your Operational Procedure,\u003Cem> Control, Testing, and Release of Drug Products\u003C\u002Fem>, which requires placement of samples from one commercial batch of each product on the stability program each year, and testing at \u003Cstrong>(b)(4)\u003C\u002Fstrong> intervals. Your 2023 batch was delayed in its entry to your stability program and your 2024 testing was not initiated. A similar pattern of non-compliance was noted during your 2018 inspection.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your response is inadequate. You reference stability studies from batches made in 2013 and 2016 to justify reduced stability testing intervals. You fail to provide a root cause or an adequate CAPA to address the failure to follow your own stability procedure.\u003C\u002Fp>\u003Cp>Drug product batches must be tested for identity, strength, quality, and purity prior to release. Without sufficient release and ongoing stability testing, defective drug products that may pose a risk to consumers are unlikely to be detected.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>The method validation protocol, report, and supporting data for your current Hypromellose assay method, and any revised methods. Include the scientific rationale for its use as release and stability indicating tests.\u003C\u002Fli>\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods.\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003Cbr>o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\u003C\u002Fli>\u003Cli>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and (d)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s QU failed to adequately execute its responsibilities.\u003C\u002Fp>\u003Cp>This includes oversight of both internal and external manufacturing activities, including laboratory services.\u003C\u002Fp>\u003Cp>Regarding functions that occurred at your facility, the records and information you provided demonstrate that your QU did not effectively exercise its responsibilities to oversee the quality of your ophthalmic drug manufacturing operations. Your firm failed to follow established procedures. For example, you had not conducted annual product reviews since 2018, which was cited as an observation in a previous inspection. In addition, your firm did not conduct annual examinations of reserve samples for the past 2 years.\u003C\u002Fp>\u003Cp>Regarding external functions performed on your behalf, your ongoing oversight of critical contract services was insufficient.\u003C\u002Fp>\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities. Our inspectional findings indicate that your QU is not conducting appropriate oversight of drug CGMP operations.\u003C\u002Fp>\u003Cp>Your response is inadequate. Although you commit to addressing the observations we identified, your response lacks detail on systemic remediations needed for your QU and your quality system.\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint).\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices. o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003Cli>Also describe how top management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm and because you failed to correct repeat violations, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2083373 and ATTN: Carrie A. Hughes.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-25-93\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Norman Craig Delgado\n\nRecipient Title\n\nPresident and CEO\n\nOasis Medical, Inc.\n\n514 S. Vermont Avenue\n\nGlendora, CA 91741\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-93\nJuly 15, 2025\nDear Mr. Delgado:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facilities, Oasis Medical, Inc., FEI 2083373, at 514 S. Vermont Avenue, Glendora, from January 15 to 27, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your February 17, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYour firm failed to ensure the use of reproducible manufacturing processes for the production of sterile ophthalmic drug products. You also lacked an ongoing program to establish stable manufacturing operations, monitor ongoing process control, and provide for consistent drug quality. For example,\nYour process lacked adequate control and is prone to producing an excessive number of defective units. A substantial portion of batches have been rejected, including total reject levels (b)(4) in a number of cases. Of special concern are the excessive number of defective products due to visible particulate contamination (e.g., recurring instances of levels greater than (b)(4)). Batches with very high defect levels were nonetheless distributed.\nYou failed to establish and follow an adequate visual inspection program for the ophthalmic drugs manufactured by your firm.\nThere was no classification as to the severity of the defects (i.e., critical, major, minor) or limit for the number of defects allowed, if any.\nThe most recently completed requalification study for your (b)(4) cycle was conducted in 2023 and inadequately considered potential changes from previous qualifications and the original validation. The 2023 requalification did not include an assessment of (b)(4) maintenance or changes to the drug product components.\nThe maximum duration of the hold steps in your manufacturing process (e.g., extensive hold times prior to (b)(4)) has not been validated.\nYour response fails to address your lack of process capability, and the overreliance on visual inspection in an attempt to remove excessive defective units from batches.\nYou do not commit to thoroughly investigate the root causes of the visible particulates and excessive occurrence of these critical defects. You also lack appropriate interim steps to prevent production of further batches from a low capability process while you make efforts to remediate it. In addition, the response lacks a commitment to address potentially contaminated products in distribution.\nRegarding the visual inspection program, your response lacks a commitment to perform a comprehensive reassessment of this program.\nRegarding production hold times, your response acknowledges that you have not performed validation of your hold steps. But you do not commit to validating all in-process hold times and include a date by which these studies will be completed.\nProcess validation evaluates the soundness of design and state of control of a process through its lifecycle. Each significant stage of a manufacturing process must be designed appropriately to ensure the quality of raw material inputs, materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality are necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nIn response to this letter, provide:\nA detailed retrospective review and assessment of your (b)(4) program. The retrospective review and assessment should include all changes to the drug product, container closure system, and packaging (e.g., canula sheath); and an evaluation of changes to, and maintenance of, the (b)(4) equipment. If changes are identified, provide your plan to evaluate the safety and quality of distributed finished products that remain within expiry and a plan to ensure the safety and quality of your drug products until the (b)(4) process is successfully validated.\nThorough investigation(s), including corrective actions and preventive actions (CAPA), regarding finished product batches manufactured and released for distribution despite high numbers of rejected units.\nComplete results of your examination of retains\u002Freserve samples for all batches from January 2023 to present for defects, and any related investigation(s) and corrective actions.\nA list of all batches since January 1, 2023, to present, with the following information:\no Product name\no Batch number\no Date of manufacture\no Date of expiration\no Batch size (original quantity of theoretical syringes)\no Actual batch yield (number of pouched syringe units)\no Number of rejects due to particulates\no Number of rejects due to other defects (include the top 3 other defect types for each batch, beyond particulate defects)\no Percent yield\nA remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability, and assures that manufacturing (including both production and packaging) operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\nA comprehensive, independent assessment and remediation plan for systems used in the visual inspection of sterile drugs for defects (including but not limited to particulate matter). The assessment should include adequacy of inspection methods, acceptance and rejection criteria, personnel training, supervision, equipment and personnel qualification, equipment maintenance, and the procedures governing them. Provide your detailed remediation action plan that includes dates by which each remediation activity will be completed, and provisions for periodic independent reassessment of the plan’s effectiveness.\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. Also, summarize the program for qualification of your equipment and facility.\nTimelines for completing further PPQ studies on remediated processes for marketed drug products for which a state of control has not been adequately established.\n2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYour firm lacked meaningful investigations of failed sterility and bioburden test results. For example:\nSterility Failure\nYour quality unit (QU) did not adequately investigate a failed sterility test result for your (b)(4) drug product, VISCO SHIELD Topical Drops, lot V0724N. Your external testing laboratory performs two sterility tests: one for the contents within the syringe and the other for the sterility of the syringe and cap primary packaging components. Your external testing laboratory reported a sterility failure for the syringe and cap portion of the testing. You concluded in NCR 24014 that, because the contaminant was found only on the syringe and cap and not the contents of the syringe, the likely root cause of the sterility failure was laboratory contamination due to excessive handling during the test. However, your contract testing laboratory’s investigation concluded that there was no laboratory error. You failed to resolve the conflicting root cause conclusions and did not extend your investigation to other potential sources of contamination or ensure it was of appropriate scope. Although the batch remained under your control, your QU had dispositioned this batch “USE AS IS” on September 30, 2024, to be distributed to the U.S. market.\nIn your response to the sterility failure, we acknowledge your intention to create a specific procedure to address external laboratory out-of-specification (OOS) investigations. However, your investigation failed to consider conditions that led to the sterility failure or determine potential root causes to ensure effective CAPAs were promptly initiated. Additionally, you do not adequately address the potential non-integrity failure mode of the packaged finished drug product (e.g., breach in packaging integrity following (b)(4)).\nBioburden OOS\nYour firm did not adequately investigate your firm’s pre-sterilization bioburden results that exceeded their specifications ((b)(4)) for VISCO SHIELD Topical Drops, lot V0724G. One sample exceeded the specification for the aerobic plate count test with a result of 570 CFU\u002Fsample and another sample exceeded the specification for the yeast and mold count test with a result of 334 CFU\u002Fsample.\nIn your response to the bioburden OOS, your investigation fails to consider the conditions that led to the OOS. You do not identify the microbes recovered or determine resistance of any spore-forming microbes that may have been present. You also do not address potential root causes during the production process that could contribute to excess bioburden. Assessment of the number of types of microbes in pre-sterilization bioburden helps to determine whether the validated (b)(4) process continues to be capable of rendering the finished product sterile.\nWhenever an investigation lacks conclusive evidence of laboratory error, a thorough investigation of potential manufacturing causes must be performed.\nFor more information about handling failing, OOS, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F158416\u002Fdownload. While this guidance generally applies to chemistry-based laboratory testing, many of the principles are relevant to microbiological testing.\nIn response to this letter, provide:\nThe disposition status of the referenced batch, VISCO SHIELD Topical Drops, lot V0724N. If the lot was released for distribution, provide the dates of release and distribution.\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nAn independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final QU decisions, and is fully supported by executive management.\nA retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for US products within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\no Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\nA comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include, but not be limited to, addressing the following:\no QU oversight of laboratory investigations.\no Identification of adverse laboratory control trends.\no Resolution of causes of laboratory variation.\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified.\no Adequately scoping of each investigation and its CAPA.\no Revised OOS investigation procedures with these and other remediations.\nA detailed retrospective review and assessment of your (b)(4) program. The retrospective review and assessment should include:\no All changes to the drug product, container closure system, and packaging (e.g., canula sheath).\no An evaluation of changes to, and maintenance of, the (b)(4) equipment.\no A plan to evaluate the safety and quality of distributed finished products that remain within expiry if significant changes occurred that may pose a risk to quality or safety.\n3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity. You also failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.160(b)) and (21 CFR 211.166(a)).\nFinished Product Testing\nYour finished product testing for release of ophthalmic drug product batches did not include adequate analytical testing to determine the identification or assay of the active ingredient, hydroxypropyl methylcellulose (Hypromellose).\nYour response and subsequent updates are inadequate. You commit to updating your finished product specifications. However, you reference an internally-developed, non-specific method for assay (strength) without providing adequate documentation and scientific justification to support its use. In contrast, a method is available in the USP that employs a reference standard and spectrophotometric measurements to determine Hypromellose assay.\nStability Program\nYour firm lacked an adequate stability program to support the (b)(4) expiration date. For example:\nYour firm did not establish appropriate tests and specifications for your ophthalmic drug products to monitor the active ingredient identity or assay at release and throughout expiry. Your stability program did not include an adequate test for assay of the active ingredient, hydroxypropyl methylcellulose (Hypromellose). In place of the USP assay, your firm used an in-house method based on loss-on-drying without scientific justification.\nYour firm did not follow your Operational Procedure, Control, Testing, and Release of Drug Products, which requires placement of samples from one commercial batch of each product on the stability program each year, and testing at (b)(4) intervals. Your 2023 batch was delayed in its entry to your stability program and your 2024 testing was not initiated. A similar pattern of non-compliance was noted during your 2018 inspection.\nYour response is inadequate. You reference stability studies from batches made in 2013 and 2016 to justify reduced stability testing intervals. You fail to provide a root cause or an adequate CAPA to address the failure to follow your own stability procedure.\nDrug product batches must be tested for identity, strength, quality, and purity prior to release. Without sufficient release and ongoing stability testing, defective drug products that may pose a risk to consumers are unlikely to be detected.\nIn response to this letter, provide:\nThe method validation protocol, report, and supporting data for your current Hypromellose assay method, and any revised methods. Include the scientific rationale for its use as release and stability indicating tests.\nA comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods.\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\nAll procedures that describe these and other elements of your remediated stability program.\n4. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and (d)).\nYour firm’s QU failed to adequately execute its responsibilities.\nThis includes oversight of both internal and external manufacturing activities, including laboratory services.\nRegarding functions that occurred at your facility, the records and information you provided demonstrate that your QU did not effectively exercise its responsibilities to oversee the quality of your ophthalmic drug manufacturing operations. Your firm failed to follow established procedures. For example, you had not conducted annual product reviews since 2018, which was cited as an observation in a previous inspection. In addition, your firm did not conduct annual examinations of reserve samples for the past 2 years.\nRegarding external functions performed on your behalf, your ongoing oversight of critical contract services was insufficient.\nYour QU is responsible for fully exercising its authority and responsibilities. Our inspectional findings indicate that your QU is not conducting appropriate oversight of drug CGMP operations.\nYour response is inadequate. Although you commit to addressing the observations we identified, your response lacks detail on systemic remediations needed for your QU and your quality system.\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Detailed definition of the specific attributes to be tested at each station (timepoint).\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices. o A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nAlso describe how top management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm and because you failed to correct repeat violations, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2083373 and ATTN: Carrie A. Hughes.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Oasis Medical, Inc.","oasis-medical-inc-707198-07152025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Foasis-medical-inc-707198-07152025","2026-10-26T08:09:36.575698+00:00","2025-08-05","707198","Mr. Norman Craig Delgado","2026-08-19T16:31:41.001+00:00","320-25-93",{"id":300,"raw":301,"subject":306,"body_html":307,"body_text":308,"firm_name":309,"letter_id":310,"created_at":311,"fei_number":19,"letter_url":312,"updated_at":313,"action_type":22,"case_status":23,"posted_date":314,"marcs_cms_no":315,"product_type":83,"closeout_date":19,"issuing_office":72,"recipient_name":316,"body_fetched_at":317,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":318,"medical_device_id":19,"response_letter_date":19},1152,[302,303,304,72,305,13,13,13],"\u003Ctime datetime=\"2024-11-26T14:20:00Z\">11\u002F26\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-10-11T04:00:00Z\">10\u002F11\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadept-medical-ltd-692226-10112024\">Adept Medical Ltd. \u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Murray Fenton\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder, CEO and Guiding Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Adept Medical Ltd. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2-6 Mc Donald Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Morningside\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Auckland\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>New Zealand\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>October 11, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Fenton:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Auckland, New Zealand on May 13, 2024, through May 16, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Tympanostomy Tubes \"NeoZoline Ventilation Tubes\". Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. §351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Ms. Yi Huang, Quality and Regulatory Manager dated June 13, 2024, concerning our investigator's observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures for acceptance activities, which include inspections, tests, or other verification activities, as required by 21 CFR 820.80(a).\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cp>1) Your firm's current incoming inspection and acceptance procedure for Biological Indicator \u003Cstrong>(b)(4)\u003C\u002Fstrong> (BI) is not adequately established. This inadequacy could compromise the sterilization process, potentially affecting the safety and effectiveness of the NeoZoline V ntilation Tubes. Your firm discards the Certificate of Conformance provided by&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> with each BI batch, which was requested by the FDA investigator during the inspection. It appears that your firm failed to retain critical documents such as the reconciliation sheet, production batch record, or \u003Cstrong>(b)(4)\u003C\u002Fstrong> Certification of Conformance, which are required under your own WI22 \"Production QC and Release Product Register,\" specifically section 2.3, to demonstrate that the product was successfully sterilized. The inspection revealed that your firm does not perform BI Population verification tests on the received BI batches to ensure that the population has not changed during shipping or storage. This is a critical step is necessary to provide a high degree of assurance that the BIs are viable to support verification that finished product is successfully sterilized through the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Sterilization process. Additionally, the inspection revealed that critical information such as the batch number and expiration date of the BI used in the sterile load is not documented on the post-sterilization B1 Test Reports, which are used as part of the finished device acceptance and release process.\u003C\u002Fp>\n\n\u003Cp>2) Your firm's incoming inspection and acceptance procedure for Sterile Potties (M1421, M1422) used for storing ultrasound cleaned NeoZoline Ventilation Tubes is not adequately established. The inspection revealed that your firm accepts incoming sterile pottle lots without a Certificate of Sterilization from the supplier. \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm stated that no additional testing or verification is performed to ensure the sterility of the incoming potties.&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on June 1, 2024. Your firm concluded that a risk analysis of the specific observation indicates no risk to end users for products currently in distribution and manufacturing. That conclusion is based on the following factors:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Biological Indicator is an off the shelf product from supplier where \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;has claimed compliance with ISO 11138-1:2017 and ISO 11138-2:2017.\u003C\u002Fli>\n\t\u003Cli>The BI is packaged in a foil pouch designed to protect the product from humidity excursions.\u003C\u002Fli>\n\t\u003Cli>The potties are used to store non-sterile Ventilation Tubes hence the sterility of the pottle is not a requirement.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Additionally, your firm has outlined a plan with the following actions to be completed by December 1, 2024, which includes the following actions:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on your firm's response there is an ambiguity in the definition of the term `pottle' and whether it is required to be sterile or not. \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>your firm's response states that there is no risk for the stenle products manufactured at your facility because the BIs that they use conform to ISO 11138-1:2017 and ISO 11138-2:2017, and that they are in their sterile packaging until they are needed. However, the inspection demonstrated that your firm does not do any testing to verify that the BIs purchased for the purpose of demonstrating that terminal sterilization is achieved, are actually viable when they are used. Additionally, the inspection revealed that they do not capture key data such as BI batch number and expiration date, and thus if a BI falsely indicated that a sterilization was successful, there is no mechanism by which your firm can trace the lots of sterile products back to a failed BI.\u003C\u002Fp>\n\n\u003Cp>Additionally, your firm did not include documentation or evidence of the corrections or corrective actions because they are in progress and have not been completed. Additionally, given the observations described above, your firm has not provided a commitment to conduct a retrospective assessment of all finished devices whose sterilization was verified using Biological Indicator \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>to determine whether sterility was compromised.\u003C\u002Fp>\n\n\u003Cp>2. Failure to ensure that where the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a). For example:\u003C\u002Fp>\n\n\u003Cp>1) Your firm's ultrasonic cleaning process using the&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Cleaner&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>is not adequately validated according to your firm's Manufacturing Process&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cstrong>&nbsp;\u003C\u002Fstrong>During the inspection, FDA's investigator revealed that the ultrasonic cleaning process was not adequately validated because critical details—such as the description of the NeoZoline Ventilation Tube (including part number, size, and shape), the number of validation batches (runs), validation batch size, and sample size used—were not documented.\u003C\u002Fp>\n\n\u003Cp>2) During the inspection, your firm stated that it had not validated the \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>process for the NeoZoline Ventilation Tube&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm&nbsp;stated that the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>.&nbsp; Adept Medical also confirmed during the inspection that&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;had not validated the NeoZoline Ventilation Tube&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;and that prior to Spring 2023,&nbsp;\u003Cstrong>(b)(4) \u003C\u002Fstrong>the\u003Cstrong>&nbsp;\u003C\u002Fstrong>NeoZoline Ventilation Tube \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>who also did not have a&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> NeoZoline Ventilation Tube.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates its Initial Action was completed on June 1, 2024. Your firm concluded that there is no risk to end users for products currently in supply and with distributors, based on the following factors:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>There is an existing validated sterilization process indicating a sterility assurance level of \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Annual bioburden results of pre-cleaned devices have bioburden levels below&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU.\u003C\u002Fli>\n\t\u003Cli>Current validation data, although not well documented in its sample selection and setting, still indicated the current setting provided adequate bioburden results, well within the capability of the sterilization process.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Additionally, your firm has outlined a plan to be completed by June 1, 2025, which includes the following actions:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>However, your firm has not provided any evidence to substantiate your claims that the&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>sterility assurance level or the bioburden limits below \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU were consistently achievable. The inspection raised concerns about your firm sterilization process, as discussed in the above section regarding compliance with 21 CFR 820.80(a). It is noteworthy that FDA requested validation documents for the \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Cleaner during the May 2024 inspection and did not receive any documentation to indicate that this process was validated.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100. For example:\u003C\u002Fp>\n\n\u003Cp>Your firm's Corrective and Preventive Action (CAPA) procedure (M05-03) fails to ensure that:\u003C\u002Fp>\n\n\u003Cp>1) The quality data is adequately analyzed to identify potential and existing causes of nonconformances or other quality issues. Your firm stated to the FDA investigator that, although data is analyzed, they do not evaluate the results to determine whether any corrective or preventive actions are necessary, as required by 21 CFR 820.100(a)(3).\u003C\u002Fp>\n\n\u003Cp>2) Your firm failed to adequately verify the effectiveness of corrective actions for several CAPAs before closing them. Specifically, CAPAs CA-459, CA-438, and CA-437 were closed after implementing corrective actions, but your firm did not verify the effectiveness of these actions, as required by 21 CFR 820.100(a)(4).\u003C\u002Fp>\n\n\u003Cp>3) CA-429 was closed on February 16, 2023; at the time of the inspection, your firm stated that they had not started any of the corrective actions identified in the CAPA. As a result of the discussion during the inspection, your firm volunteered to mark the CAPA as 'open,' so that the corrective actions could be implemented.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that although procedure&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>the procedure did not instruct how to this data should be analyzed, and what subsequent actions should be taken once the data analysis is complete. However, your firm's procedure&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm has outlined the following plan to be completed by April 1, 2025, which includes the following actions:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>However, your firm's response does not identify conducting a retrospective analysis for all past CAPAs, to determine the impact of the lack of data analysis, and whether the appropriate corrective and\u002For preventive action was taken to address each CAPA's root cause. Additionally, your firm did not identify what actions it would take to address the lack of implementation of identified corrective actions and whether that issue is a systemic problem.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish and maintain procedures to control product that does not conform to specified requirements, including the identification, documentation, evaluation, segregation, and disposition of nonconforming product; and failure to ensure that the evaluation includes a determination of the need for an investigation, as required by 21 CFR 820.90(a). For example:\u003C\u002Fp>\n\n\u003Cp>The FDA investigator reviewed six NC records related to your firm's NeoZoline Ventilation Tubes. All six NC records were closed (NC-2516, NC-2767, NC-2641, NC-2640, NC-2738, NC-2523), but showed the following deficiencies in documentation:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The NC records did not adequately document the evaluation of the identified nonconformities.\u003C\u002Fli>\n\t\u003Cli>The rationale for not conducting related investigations was inadequately documented in all six NC records.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm explained that incoming NeoZoline Ventilation Tubes \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>are not inspected upon arrival.&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cstrong>&nbsp;\u003C\u002Fstrong>Your firm further stated that they \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cstrong>&nbsp;\u003C\u002Fstrong>This target achievement was cited as the reason for not taking further action.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that there is no risk to end users for products currently in supply and with distributors. That conclusion is based on postmarket surveillance data, which shows no product safety or performance complaints since the product's launch. However, a lack of documented safety signals does not ensure that nonconforming product was controlled and not introduced into commerce.\u003C\u002Fp>\n\n\u003Cp>Additionally, your firm has outlined a plan to be completed by April 1, 2025, which includes the following actions:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>However, your firm did not include documentation to demonstrate that it has evaluated or will evaluate all past non-conformances against your new procedure to determine whether additional corrective action was required to address the non-conformances identified in your NC Records.\u003C\u002Fp>\n\n\u003Cp>5. Failure to define the type and extent of control to be exercised over the product, services, suppliers, contractors, and consultants, based on the evaluation results, as required by 21 CFR 820.50(a)(2). For example:\u003C\u002Fp>\n\n\u003Cp>During the inspection, your firm was asked whether the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the NeoZoline ventilation tubes was validated&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm stated you have no knowledge or documentation regarding&nbsp;whether the&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>for the NeoZoline Ventilation Tubes had been properly&nbsp;validated.&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Adept Medical learned the&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Adept Medical received \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;units of NeoZoline Ventilation Tubes in various types from&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;between June 2023 and November 2023. They released \u003Cstrong>(b)(4) \u003C\u002Fstrong>units\u003Cstrong>&nbsp;\u003C\u002Fstrong>(\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>boxes) of the NeoZoline Ventilation Tubes to the United States. Prior to June 2023, all NeoZoline Ventilation Tubes were \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cstrong>&nbsp;&nbsp;\u003C\u002Fstrong>Adept has failed to ensure that the conditions of the supplier agreement were adhered to by your supplier.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that there is no risk to the end users for products currently in supply and with distributors, based on the following considerations:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The post-market periodic safety update report (PSUR) on Ventilation Tubes supplied by \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>indicated no adverse events.\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Post market surveillance data indicated we have had no product safety or performance complaints since product launch.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>However, a lack of adverse events in post market safety signals does not provide assurance that the device meets its design specifications, in light of the fact that, Adept Medical was unaware that your supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;the NeoZoline Ventilation Tube \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>did not have any documentation that the \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>device was validated.\u003C\u002Fp>\n\n\u003Cp>Additionally, your firm has outlined a plan to be completed by June 1, 2025, which includes the following actions:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>However, based on your firm's response, it is unclear how you intend to evaluate suppliers' compliance with 21 CFR Part 820, the Quality System Regulation.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that the NeoZoline Ventilation Tubes are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PM_A) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, in that your firm did not notify FDA regarding a significant change or modification in the device that could significantly affect the safety or effectiveness of the device, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 C.F.R. 807.81 (a)(3)(i).\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has modified the NeoZoline Ventilation Tubes cleared under K061058. The modification involves the use of a \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;which was not cleared in the original submission and is a change that could significantly affect the safety or effectiveness of the device. This modification necessitates a comprehensive risk assessment to ensure the device remains safe and effective. A new biocompatibility evaluation is required to determine if \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cstrong>&nbsp;\u003C\u002Fstrong>Any \u003Cstrong>(b)(4)\u003C\u002Fstrong> may affect how the device can be safely and effectively sterilized. Thus, your sterilization processes must be validated for the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure that it can be properly sterilized without&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> becoming unsafe. The change in \u003Cstrong>(b)(4)\u003C\u002Fstrong> may alter the device's performance or specifications, so a thorough re-evaluation is necessary to ensure it still meets all necessary standards and functions as intended. Due to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> modification and its potential impact on the device's safety and performance, a new 510(k) submission is required before marketing the modified device in the United States.\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fd efault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm's response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #692226 when replying. If you have any questions about the contents of this letter, please contact: Shu-Chen Peng, Ph.D. at 301-796-6481.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Malvina B. Eydelman, M.D.\u003Cbr>\nDirector\u003Cbr>\nOHT1: Office of Ophthalmic, Anesthesia,\u003Cbr>\nRespiratory, ENT and Dental Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\n\u003Cstrong>(b)(4)\u003C\u002Fstrong>, Registrar Corp.,\u003Cbr>\n144 Research Drive,\u003Cbr>\nHampton, Virginia,\u003Cbr>\nUSA 23666\u003Cbr>\nPhone: Tel: 1-757-224-0177, Ext.&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\nEmail:\u003Cstrong>(b)(4)\u003C\u002Fstrong>@registrarcorp.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Murray Fenton\n\nRecipient Title\n\nFounder, CEO and Guiding Director\n\nAdept Medical Ltd.\n\n2-6 Mc Donald Street\n\nMorningside\n\nAuckland\n\nNew Zealand\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nOctober 11, 2024\n\nDear Mr. Fenton:\n\nDuring an inspection of your firm located in Auckland, New Zealand on May 13, 2024, through May 16, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Tympanostomy Tubes \"NeoZoline Ventilation Tubes\". Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. §351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Ms. Yi Huang, Quality and Regulatory Manager dated June 13, 2024, concerning our investigator's observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures for acceptance activities, which include inspections, tests, or other verification activities, as required by 21 CFR 820.80(a).\n\nFor example:\n\n1) Your firm's current incoming inspection and acceptance procedure for Biological Indicator (b)(4) (BI) is not adequately established. This inadequacy could compromise the sterilization process, potentially affecting the safety and effectiveness of the NeoZoline V ntilation Tubes. Your firm discards the Certificate of Conformance provided by (b)(4) with each BI batch, which was requested by the FDA investigator during the inspection. It appears that your firm failed to retain critical documents such as the reconciliation sheet, production batch record, or (b)(4) Certification of Conformance, which are required under your own WI22 \"Production QC and Release Product Register,\" specifically section 2.3, to demonstrate that the product was successfully sterilized. The inspection revealed that your firm does not perform BI Population verification tests on the received BI batches to ensure that the population has not changed during shipping or storage. This is a critical step is necessary to provide a high degree of assurance that the BIs are viable to support verification that finished product is successfully sterilized through the (b)(4) Sterilization process. Additionally, the inspection revealed that critical information such as the batch number and expiration date of the BI used in the sterile load is not documented on the post-sterilization B1 Test Reports, which are used as part of the finished device acceptance and release process.\n\n2) Your firm's incoming inspection and acceptance procedure for Sterile Potties (M1421, M1422) used for storing ultrasound cleaned NeoZoline Ventilation Tubes is not adequately established. The inspection revealed that your firm accepts incoming sterile pottle lots without a Certificate of Sterilization from the supplier. (b)(4). Your firm stated that no additional testing or verification is performed to ensure the sterility of the incoming potties. (b)(4)\n\nWe reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on June 1, 2024. Your firm concluded that a risk analysis of the specific observation indicates no risk to end users for products currently in distribution and manufacturing. That conclusion is based on the following factors:\n\nThe (b)(4) Biological Indicator is an off the shelf product from supplier where (b)(4) has claimed compliance with ISO 11138-1:2017 and ISO 11138-2:2017.\n\nThe BI is packaged in a foil pouch designed to protect the product from humidity excursions.\n\nThe potties are used to store non-sterile Ventilation Tubes hence the sterility of the pottle is not a requirement.\n\nAdditionally, your firm has outlined a plan with the following actions to be completed by December 1, 2024, which includes the following actions:\n\n(b)(4)\n\nBased on your firm's response there is an ambiguity in the definition of the term `pottle' and whether it is required to be sterile or not. (b)(4) your firm's response states that there is no risk for the stenle products manufactured at your facility because the BIs that they use conform to ISO 11138-1:2017 and ISO 11138-2:2017, and that they are in their sterile packaging until they are needed. However, the inspection demonstrated that your firm does not do any testing to verify that the BIs purchased for the purpose of demonstrating that terminal sterilization is achieved, are actually viable when they are used. Additionally, the inspection revealed that they do not capture key data such as BI batch number and expiration date, and thus if a BI falsely indicated that a sterilization was successful, there is no mechanism by which your firm can trace the lots of sterile products back to a failed BI.\n\nAdditionally, your firm did not include documentation or evidence of the corrections or corrective actions because they are in progress and have not been completed. Additionally, given the observations described above, your firm has not provided a commitment to conduct a retrospective assessment of all finished devices whose sterilization was verified using Biological Indicator (b)(4) to determine whether sterility was compromised.\n\n2. Failure to ensure that where the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a). For example:\n\n1) Your firm's ultrasonic cleaning process using the (b)(4) Cleaner (b)(4) is not adequately validated according to your firm's Manufacturing Process (b)(4). During the inspection, FDA's investigator revealed that the ultrasonic cleaning process was not adequately validated because critical details—such as the description of the NeoZoline Ventilation Tube (including part number, size, and shape), the number of validation batches (runs), validation batch size, and sample size used—were not documented.\n\n2) During the inspection, your firm stated that it had not validated the (b)(4) process for the NeoZoline Ventilation Tube (b)(4). Your firm stated that the (b)(4). Adept Medical also confirmed during the inspection that (b)(4) had not validated the NeoZoline Ventilation Tube (b)(4) and that prior to Spring 2023, (b)(4) the NeoZoline Ventilation Tube (b)(4) who also did not have a (b)(4) NeoZoline Ventilation Tube.\n\nWe reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates its Initial Action was completed on June 1, 2024. Your firm concluded that there is no risk to end users for products currently in supply and with distributors, based on the following factors:\n\nThere is an existing validated sterilization process indicating a sterility assurance level of (b)(4)\n\nAnnual bioburden results of pre-cleaned devices have bioburden levels below (b)(4) CFU.\n\nCurrent validation data, although not well documented in its sample selection and setting, still indicated the current setting provided adequate bioburden results, well within the capability of the sterilization process.\n\nAdditionally, your firm has outlined a plan to be completed by June 1, 2025, which includes the following actions:\n\n(b)(4)\n\nHowever, your firm has not provided any evidence to substantiate your claims that the (b)(4) sterility assurance level or the bioburden limits below (b)(4) CFU were consistently achievable. The inspection raised concerns about your firm sterilization process, as discussed in the above section regarding compliance with 21 CFR 820.80(a). It is noteworthy that FDA requested validation documents for the (b)(4) Cleaner during the May 2024 inspection and did not receive any documentation to indicate that this process was validated.\n\n3. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100. For example:\n\nYour firm's Corrective and Preventive Action (CAPA) procedure (M05-03) fails to ensure that:\n\n1) The quality data is adequately analyzed to identify potential and existing causes of nonconformances or other quality issues. Your firm stated to the FDA investigator that, although data is analyzed, they do not evaluate the results to determine whether any corrective or preventive actions are necessary, as required by 21 CFR 820.100(a)(3).\n\n2) Your firm failed to adequately verify the effectiveness of corrective actions for several CAPAs before closing them. Specifically, CAPAs CA-459, CA-438, and CA-437 were closed after implementing corrective actions, but your firm did not verify the effectiveness of these actions, as required by 21 CFR 820.100(a)(4).\n\n3) CA-429 was closed on February 16, 2023; at the time of the inspection, your firm stated that they had not started any of the corrective actions identified in the CAPA. As a result of the discussion during the inspection, your firm volunteered to mark the CAPA as 'open,' so that the corrective actions could be implemented.\n\nWe reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that although procedure (b)(4) the procedure did not instruct how to this data should be analyzed, and what subsequent actions should be taken once the data analysis is complete. However, your firm's procedure (b)(4)\n\nYour firm has outlined the following plan to be completed by April 1, 2025, which includes the following actions:\n\n(b)(4)\n\nHowever, your firm's response does not identify conducting a retrospective analysis for all past CAPAs, to determine the impact of the lack of data analysis, and whether the appropriate corrective and\u002For preventive action was taken to address each CAPA's root cause. Additionally, your firm did not identify what actions it would take to address the lack of implementation of identified corrective actions and whether that issue is a systemic problem.\n\n4. Failure to establish and maintain procedures to control product that does not conform to specified requirements, including the identification, documentation, evaluation, segregation, and disposition of nonconforming product; and failure to ensure that the evaluation includes a determination of the need for an investigation, as required by 21 CFR 820.90(a). For example:\n\nThe FDA investigator reviewed six NC records related to your firm's NeoZoline Ventilation Tubes. All six NC records were closed (NC-2516, NC-2767, NC-2641, NC-2640, NC-2738, NC-2523), but showed the following deficiencies in documentation:\n\nThe NC records did not adequately document the evaluation of the identified nonconformities.\n\nThe rationale for not conducting related investigations was inadequately documented in all six NC records.\n\nYour firm explained that incoming NeoZoline Ventilation Tubes (b)(4) are not inspected upon arrival. (b)(4). Your firm further stated that they (b)(4). This target achievement was cited as the reason for not taking further action.\n\nWe reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that there is no risk to end users for products currently in supply and with distributors. That conclusion is based on postmarket surveillance data, which shows no product safety or performance complaints since the product's launch. However, a lack of documented safety signals does not ensure that nonconforming product was controlled and not introduced into commerce.\n\nAdditionally, your firm has outlined a plan to be completed by April 1, 2025, which includes the following actions:\n\n(b)(4)\n\nHowever, your firm did not include documentation to demonstrate that it has evaluated or will evaluate all past non-conformances against your new procedure to determine whether additional corrective action was required to address the non-conformances identified in your NC Records.\n\n5. Failure to define the type and extent of control to be exercised over the product, services, suppliers, contractors, and consultants, based on the evaluation results, as required by 21 CFR 820.50(a)(2). For example:\n\nDuring the inspection, your firm was asked whether the (b)(4) for the NeoZoline ventilation tubes was validated (b)(4). Your firm stated you have no knowledge or documentation regarding whether the (b)(4) for the NeoZoline Ventilation Tubes had been properly validated. (b)(4) Adept Medical learned the (b)(4) Adept Medical received (b)(4) units of NeoZoline Ventilation Tubes in various types from (b)(4) between June 2023 and November 2023. They released (b)(4) units ((b)(4) boxes) of the NeoZoline Ventilation Tubes to the United States. Prior to June 2023, all NeoZoline Ventilation Tubes were (b)(4). Adept has failed to ensure that the conditions of the supplier agreement were adhered to by your supplier.\n\nWe reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that there is no risk to the end users for products currently in supply and with distributors, based on the following considerations:\n\nThe post-market periodic safety update report (PSUR) on Ventilation Tubes supplied by (b)(4) indicated no adverse events.\n\n(b)(4)\n\nPost market surveillance data indicated we have had no product safety or performance complaints since product launch.\n\nHowever, a lack of adverse events in post market safety signals does not provide assurance that the device meets its design specifications, in light of the fact that, Adept Medical was unaware that your supplier (b)(4) the NeoZoline Ventilation Tube (b)(4) did not have any documentation that the (b)(4) device was validated.\n\nAdditionally, your firm has outlined a plan to be completed by June 1, 2025, which includes the following actions:\n\n(b)(4)\n\nHowever, based on your firm's response, it is unclear how you intend to evaluate suppliers' compliance with 21 CFR Part 820, the Quality System Regulation.\n\nOur inspection also revealed that the NeoZoline Ventilation Tubes are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PM_A) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, in that your firm did not notify FDA regarding a significant change or modification in the device that could significantly affect the safety or effectiveness of the device, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 C.F.R. 807.81 (a)(3)(i).\n\nSpecifically, your firm has modified the NeoZoline Ventilation Tubes cleared under K061058. The modification involves the use of a (b)(4) which was not cleared in the original submission and is a change that could significantly affect the safety or effectiveness of the device. This modification necessitates a comprehensive risk assessment to ensure the device remains safe and effective. A new biocompatibility evaluation is required to determine if (b)(4). Any (b)(4) may affect how the device can be safely and effectively sterilized. Thus, your sterilization processes must be validated for the (b)(4) to ensure that it can be properly sterilized without (b)(4) becoming unsafe. The change in (b)(4) may alter the device's performance or specifications, so a thorough re-evaluation is necessary to ensure it still meets all necessary standards and functions as intended. Due to the (b)(4) modification and its potential impact on the device's safety and performance, a new 510(k) submission is required before marketing the modified device in the United States.\n\nFor a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fd efault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm's response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #692226 when replying. If you have any questions about the contents of this letter, please contact: Shu-Chen Peng, Ph.D. at 301-796-6481.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nMalvina B. Eydelman, M.D.\n\nDirector\n\nOHT1: Office of Ophthalmic, Anesthesia,\n\nRespiratory, ENT and Dental Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\n(b)(4), Registrar Corp.,\n\n144 Research Drive,\n\nHampton, Virginia,\n\nUSA 23666\n\nPhone: Tel: 1-757-224-0177, Ext. (b)(4)\n\nEmail:(b)(4)@registrarcorp.com","Adept Medical Ltd.","adept-medical-ltd-692226-10112024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadept-medical-ltd-692226-10112024","2026-10-26T08:07:50.120298+00:00","2024-11-26","692226","Mr. Murray Fenton","2026-08-19T17:57:49.713+00:00","2024-10-11",{"id":320,"raw":321,"subject":176,"body_html":325,"body_text":326,"firm_name":327,"letter_id":328,"created_at":18,"fei_number":19,"letter_url":329,"updated_at":330,"action_type":22,"case_status":23,"posted_date":331,"marcs_cms_no":332,"product_type":83,"closeout_date":19,"issuing_office":72,"recipient_name":333,"body_fetched_at":334,"delivery_method":105,"recipient_title":19,"reference_number":19,"action_taken_date":335,"medical_device_id":19,"response_letter_date":19},520,[322,323,324,72,176,13,13,13],"\u003Ctime datetime=\"2025-10-28T04:00:00Z\">10\u002F28\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-02T04:00:00Z\">10\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcontec-medical-systems-co-ltd-717941-10022025\">Contec Medical Systems Co., Ltd.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Kun “James” Hu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Contec Medical Systems Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 112 Qinhuang West Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Economic and Technical Development Zone\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Qinhuangdao Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hebei Sheng\u003C\u002Fspan>, \u003Cspan>066004\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>October 2, 2025\u003C\u002Fp>\u003Cp>Dear Kun “James” Hu:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Qinhuangdao, Hebei, China on June 9, 2025 through June 12, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures CMS 8000 Patient Monitor, CMS600P2PLUS B-Ultrasound Diagnostic System, CMS1700B Color Doppler Ultrasound Diagnostic System, CMS 9000 Patient Monitor, PO30 Pulse Oximeter, Pocket Fetal Doppler. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Kun “James” Hu, CEO dated July 1, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). For example,\u003C\u002Fp>\u003Cp>A. The cause of nonconformities identified are not adequately investigated.\u003C\u002Fp>\u003Cp>B. Corrective actions taken are not documented per your firm’s CAPA procedure.\u003C\u002Fp>\u003Cp>C. The preventive action of creating the procedure, “Cybersecurity Management Plan, Version 1, Effective 6\u002F5\u002F2025” was not documented as completed prior to closing CAPA number 20250227M on 3\u002F18\u002F2025.\u003C\u002Fp>\u003Cp>D. Verification activities performed to verify corrective and preventive actions were effective are not adequately documented. Specifically, you have not verified that customers are correctly interpreting actions to be taken in response to your open recall (Z-1764-2025).\u003C\u002Fp>\u003Cp>The response dated July 1, 2025, is not adequate. In \"FEI 3006979678,OBS1,WS2025061201-English\" you provided the revised procedures, training records, and reopened the cited CAPAs for further corrective actions. However, you have not performed a retroactive review of your CAPAs to ensure you have adequately investigated the cause of nonconformities, documented corrective actions taken per your updated CAPA procedure, and documented the verification activities performed to verify corrective and preventive actions were effective. Further, your responses do not address the verification of corrective and preventive action effectiveness for your open recall (Z-1764-2025). As such, you have not provided evidence to support the adequate systemic implementation of your revised procedures and adequate CAPA procedures in accordance with 21 CFR 820.100(a).\u003C\u002Fp>\u003Cp>2. Failure to adequately establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). For example:\u003C\u002Fp>\u003Cp>A. Test plans created to validate device software designs do not ensure validation testing is performed under adequately defined operating conditions. For example, test plans do not include established acceptance criteria prior to testing.\u003C\u002Fp>\u003Cp>B. Test reports do not confirm that design outputs meet design inputs. For example,\u003C\u002Fp>\u003Cp>i. Two security risks were found in the B-Ultrasound Diagnostic testing and your firm failed to document the patch created to shut down the function of the ports as a deviation from the test plan.\u003C\u002Fp>\u003Cp>ii. The Security Test Report for the Color Doppler Ultrasound Diagnostic System did not include Network Segmentation, Zone Boundary Protection, and General Purpose, person-to-person communication restriction testing as identified as required in the Test Plan.\u003C\u002Fp>\u003Cp>C. Software design validations are not documented in device DHFs. For example, your firm did not have the software Test Plans for the B-Ultrasound Diagnostic System cleared under K232895 or the software Test Plan for the Color Doppler Ultrasound Diagnostic System cleared under K232908 in the respective DHF.\u003C\u002Fp>\u003Cp>D. Your firm failed to adequately implement your risk management procedure for the CMS 8000 software.\u003C\u002Fp>\u003Cp>The adequacy of the response dated July 1, 2025, cannot be determined at this time.\u003C\u002Fp>\u003Cp>While your response provided updated procedures and test plans, it appears your response did not include complete test reports. Therefore, you have not provided evidence to support the adequate systemic implementation of your revised procedures and adequate design validation in accordance with 21 CFR 820.30(g).\u003C\u002Fp>\u003Cp>3. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). For example, complaints received via eCommerce sites and complaints received via international country officials are not reviewed and evaluated for reportability. Specifically, several complaints from eCommerce sites and one from Canada’s Medical Devices and Clinical Compliance Directorate were not logged in the complaint log for handling via your firm’s complaint handling procedure and were not evaluated for reportability to the FDA. Additionally, feedback associated with user error or known product quality degradation associated with component longevity (cables, power cord, USB cable, etc.) are not documented as complaints for trending or investigation.\u003C\u002Fp>\u003Cp>The response dated July 1, 2025, is not adequate. Your response included updated procedures and training records; however, you have not performed a retroactive review of complaints received through eCommerce sites or international country officials to ensure you have adequately received, reviewed, and evaluated these complaints. Further, you have not provided evidence to support the adequate systemic implementation of your revised procedures and adequate complaint receiving, reviewing, and evaluating in accordance with 21 CFR 820.198(a).\u003C\u002Fp>\u003Cp>4. Failure to adequately maintain records at a location that is reasonably accessible to responsible officials of the manufacturer and to employees of the FDA, as required by 21 CFR 820.180. For example: the inspector asked to be taken to the location where the software test plan for the B-Ultrasound Diagnostic System could be found and your firm's Deputy Vice Manager for Certification and Registration indicated that test plans are not maintained at your firm for validation testing performed by third party vendors.\u003C\u002Fp>\u003Cp>The adequacy of your response dated July 1, 2025, cannot be determined at this time. Your response revised the Product Certification and Registration Work Instruction and provided the training records on the revised instruction. However, you have not provided evidence to support the adequate systemic implementation of your revised work instruction and adequate records maintenance in accordance with 21 CFR 820.180.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violation\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s CMS8000 Patient Monitor devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to include a copy of all communications regarding the correction or removal in the report, as required by 21 CFR 806.10(c)(12). For example, you included a paragraph in the customer notification letter sent to consignees for an open recall (Z-1764-2025) that was omitted from the version of the letter sent to the FDA as part of the written report.\u003C\u002Fp>\u003Cp>Given the serious nature of the violations of the Act, all devices manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations are addressed. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violation(s) described in this letter. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Jennifer Kozen at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 675091 when replying. If you have any questions about the contents of this letter, please contact: Jennifer Kozen at 301-796-5813 or Jennifer.Kozen@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems.\u003C\u002Fp>\u003Cp>Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003Cbr>Bram Zuckerman&nbsp;&nbsp;\u003Cbr>Director Office of Cardiovascular Devices\u003Cbr>Office of Product Evaluation and Quality&nbsp;&nbsp;\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Marco Mu\u003Cbr>MID-LINK INTERNATIONAL CO., Ltd\u003Cbr>2219 Rimlang Drive, Suite 301\u003Cbr>Bellingham, Washington, US 98226\u003Cbr>Phone: 702-209-5185\u003Cbr>Fax: 360-925-3199\u003Cbr>Email: us.agent@mid-link.net\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nKun “James” Hu\n\nRecipient Title\n\nCEO\n\nContec Medical Systems Co., Ltd.\n\nNo. 112 Qinhuang West Street\n\nEconomic and Technical Development Zone\n\nQinhuangdao Shi\n\nHebei Sheng, 066004\n\nChina\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nOctober 2, 2025\nDear Kun “James” Hu:\nDuring an inspection of your firm located in Qinhuangdao, Hebei, China on June 9, 2025 through June 12, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures CMS 8000 Patient Monitor, CMS600P2PLUS B-Ultrasound Diagnostic System, CMS1700B Color Doppler Ultrasound Diagnostic System, CMS 9000 Patient Monitor, PO30 Pulse Oximeter, Pocket Fetal Doppler. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Kun “James” Hu, CEO dated July 1, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). For example,\nA. The cause of nonconformities identified are not adequately investigated.\nB. Corrective actions taken are not documented per your firm’s CAPA procedure.\nC. The preventive action of creating the procedure, “Cybersecurity Management Plan, Version 1, Effective 6\u002F5\u002F2025” was not documented as completed prior to closing CAPA number 20250227M on 3\u002F18\u002F2025.\nD. Verification activities performed to verify corrective and preventive actions were effective are not adequately documented. Specifically, you have not verified that customers are correctly interpreting actions to be taken in response to your open recall (Z-1764-2025).\nThe response dated July 1, 2025, is not adequate. In \"FEI 3006979678,OBS1,WS2025061201-English\" you provided the revised procedures, training records, and reopened the cited CAPAs for further corrective actions. However, you have not performed a retroactive review of your CAPAs to ensure you have adequately investigated the cause of nonconformities, documented corrective actions taken per your updated CAPA procedure, and documented the verification activities performed to verify corrective and preventive actions were effective. Further, your responses do not address the verification of corrective and preventive action effectiveness for your open recall (Z-1764-2025). As such, you have not provided evidence to support the adequate systemic implementation of your revised procedures and adequate CAPA procedures in accordance with 21 CFR 820.100(a).\n2. Failure to adequately establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). For example:\nA. Test plans created to validate device software designs do not ensure validation testing is performed under adequately defined operating conditions. For example, test plans do not include established acceptance criteria prior to testing.\nB. Test reports do not confirm that design outputs meet design inputs. For example,\ni. Two security risks were found in the B-Ultrasound Diagnostic testing and your firm failed to document the patch created to shut down the function of the ports as a deviation from the test plan.\nii. The Security Test Report for the Color Doppler Ultrasound Diagnostic System did not include Network Segmentation, Zone Boundary Protection, and General Purpose, person-to-person communication restriction testing as identified as required in the Test Plan.\nC. Software design validations are not documented in device DHFs. For example, your firm did not have the software Test Plans for the B-Ultrasound Diagnostic System cleared under K232895 or the software Test Plan for the Color Doppler Ultrasound Diagnostic System cleared under K232908 in the respective DHF.\nD. Your firm failed to adequately implement your risk management procedure for the CMS 8000 software.\nThe adequacy of the response dated July 1, 2025, cannot be determined at this time.\nWhile your response provided updated procedures and test plans, it appears your response did not include complete test reports. Therefore, you have not provided evidence to support the adequate systemic implementation of your revised procedures and adequate design validation in accordance with 21 CFR 820.30(g).\n3. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). For example, complaints received via eCommerce sites and complaints received via international country officials are not reviewed and evaluated for reportability. Specifically, several complaints from eCommerce sites and one from Canada’s Medical Devices and Clinical Compliance Directorate were not logged in the complaint log for handling via your firm’s complaint handling procedure and were not evaluated for reportability to the FDA. Additionally, feedback associated with user error or known product quality degradation associated with component longevity (cables, power cord, USB cable, etc.) are not documented as complaints for trending or investigation.\nThe response dated July 1, 2025, is not adequate. Your response included updated procedures and training records; however, you have not performed a retroactive review of complaints received through eCommerce sites or international country officials to ensure you have adequately received, reviewed, and evaluated these complaints. Further, you have not provided evidence to support the adequate systemic implementation of your revised procedures and adequate complaint receiving, reviewing, and evaluating in accordance with 21 CFR 820.198(a).\n4. Failure to adequately maintain records at a location that is reasonably accessible to responsible officials of the manufacturer and to employees of the FDA, as required by 21 CFR 820.180. For example: the inspector asked to be taken to the location where the software test plan for the B-Ultrasound Diagnostic System could be found and your firm's Deputy Vice Manager for Certification and Registration indicated that test plans are not maintained at your firm for validation testing performed by third party vendors.\nThe adequacy of your response dated July 1, 2025, cannot be determined at this time. Your response revised the Product Certification and Registration Work Instruction and provided the training records on the revised instruction. However, you have not provided evidence to support the adequate systemic implementation of your revised work instruction and adequate records maintenance in accordance with 21 CFR 820.180.\nCorrections and Removals Violation\nOur inspection also revealed that your firm’s CMS8000 Patient Monitor devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\nFailure to include a copy of all communications regarding the correction or removal in the report, as required by 21 CFR 806.10(c)(12). For example, you included a paragraph in the customer notification letter sent to consignees for an open recall (Z-1764-2025) that was omitted from the version of the letter sent to the FDA as part of the written report.\nGiven the serious nature of the violations of the Act, all devices manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations are addressed. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violation(s) described in this letter. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Jennifer Kozen at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 675091 when replying. If you have any questions about the contents of this letter, please contact: Jennifer Kozen at 301-796-5813 or Jennifer.Kozen@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems.\nYour firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nBram Zuckerman\nDirector Office of Cardiovascular Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\nMarco Mu\nMID-LINK INTERNATIONAL CO., Ltd\n2219 Rimlang Drive, Suite 301\nBellingham, Washington, US 98226\nPhone: 702-209-5185\nFax: 360-925-3199\nEmail: us.agent@mid-link.net","Contec Medical Systems Co., Ltd.","contec-medical-systems-co-ltd-717941-10022025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcontec-medical-systems-co-ltd-717941-10022025","2026-10-26T08:08:17.623451+00:00","2025-10-28","717941","Kun “James” Hu","2026-08-19T16:12:22.676+00:00","2025-10-02",{"id":337,"raw":338,"subject":342,"body_html":343,"body_text":344,"firm_name":345,"letter_id":346,"created_at":18,"fei_number":19,"letter_url":347,"updated_at":348,"action_type":22,"case_status":23,"posted_date":349,"marcs_cms_no":350,"product_type":63,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":351,"delivery_method":352,"recipient_title":19,"reference_number":19,"action_taken_date":353,"medical_device_id":19,"response_letter_date":19},637,[339,340,341,11,342,13,13,13],"\u003Ctime datetime=\"2025-09-16T04:00:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-09T04:00:00Z\">09\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcosmo-medical-spa-dba-cosmo-med-spa-715873-09092025\">Cosmo Medical Spa dba Cosmo Med Spa\u003C\u002Fa>","Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Delivery and Read Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Cosmo Medical Spa dba Cosmo Med Spa\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1068-8321 Kennedy Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Markham\u003C\u002Fspan> \u003Cspan>ON\u003C\u002Fspan> \u003Cspan>L3R5N4\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Canada\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@cosmomedspa.com\"> info@cosmomedspa.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 9, 2025\u003C\u002Fp>\u003Cp>Cosmo Med Spa:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fcosmomedspa.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your claims concerning compounded semaglutide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The following claims concerning compounded semaglutide products appear on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“Ozempic (semaglutide) injection (4 weeks supply)”\u003C\u002Fli>\u003Cli>“Ozempic (semaglutide) injection (10 weeks supply)”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded semaglutide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>George Tidmarsh, M.D., Ph.D. Director\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Delivery and Read Receipt Requested\n\nProduct:\n\nDrugs\n\nRecipient:\n\nCosmo Medical Spa dba Cosmo Med Spa\n\n1068-8321 Kennedy Rd\n\nMarkham ON L3R5N4\n\nCanada\n\ninfo@cosmomedspa.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nSeptember 9, 2025\nCosmo Med Spa:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fcosmomedspa.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.1 As described below, your claims concerning compounded semaglutide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe following claims concerning compounded semaglutide products appear on your website:\n“Ozempic (semaglutide) injection (4 weeks supply)”\n“Ozempic (semaglutide) injection (10 weeks supply)”\nCompounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.2\nFor the reasons discussed above, your compounded semaglutide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\nYou should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nGeorge Tidmarsh, M.D., Ph.D. Director\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n______________________\n1 The semaglutide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n2 Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.","Cosmo Medical Spa dba Cosmo Med Spa","cosmo-medical-spa-dba-cosmo-med-spa-715873-09092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcosmo-medical-spa-dba-cosmo-med-spa-715873-09092025","2026-10-26T08:08:18.730704+00:00","2025-09-16","715873","2026-08-19T16:19:52.144+00:00","Via Electronic Mail - Delivery and Read Receipt Requested","2025-09-09",{"id":355,"raw":356,"subject":176,"body_html":361,"body_text":362,"firm_name":363,"letter_id":364,"created_at":365,"fei_number":19,"letter_url":366,"updated_at":367,"action_type":22,"case_status":140,"posted_date":368,"marcs_cms_no":369,"product_type":83,"closeout_date":370,"issuing_office":72,"recipient_name":371,"body_fetched_at":372,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":373,"medical_device_id":19,"response_letter_date":19},1671,[357,358,359,72,176,13,360,13],"\u003Ctime datetime=\"2023-12-26T14:20:00Z\">12\u002F26\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-22T04:00:00Z\">09\u002F22\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsonesta-medical-ab-667325-09222023\">Sonesta Medical AB\u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsonesta-medical-ab-667325-12042023\">\u003Ctime datetime=\"2024-02-28T05:00:00Z\">02\u002F28\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Pelin Sari\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sonesta Medical AB\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Industrivagen 7\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>171 48\u003C\u002Fspan> \u003Cspan>Solna\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sweden\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@sonestamedical.se\"> (b)(6)@sonestamedical.se\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 22, 2023\u003Cbr>\n\u003Cbr>\nDear Ms. Sari:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Solna, Sweden on June 5, 2023, through June 7, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Model 6210 radiographic table and Model S2 and S3 cystometric tables. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from you dated June 1, 2023, August 11, 2023, and September 1, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specific requirements, as required by 21 CFR 820.50(a). Specifically, your firm’s current purchasing controls procedure, Supplier Evaluation, Rev 2, dated April 7, 2021, fails to define the frequency, type, and extent of control to exercise over suppliers, contractors, and consultants, based on the results of periodic evaluation. Additionally, your firm has not evaluated your contract repair\u002Fservicer, and the current contract Quality Assurance &amp; Regulatory Affairs consultant. Further, your firm failed to maintain records covering evaluation of the current contract Quality Assurance &amp; Regulatory Affairs consultant, who has been assisting your firm in overseeing and maintaining their Quality System procedures since the year 2020.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses dated June 1, 2023, August 11, 2023, and September 1, 2023, and conclude that they are not adequate. Your firm’s responses state that you have revised the Supplier Evaluation SOP 1) to include the frequency and\u002For period for evaluation of suppliers, contractors, and consultants, 2) to include the type and extent of control to exercise over suppliers, contractors and consultants based on the results of the periodic evaluation, 3) to include evaluation of the contract repair\u002Fservicer for the Model 6210 radiographic table and Model S2 and S3 cystometric tables, and 4) to include requirements for assessment of contractors, consultants, and evaluation of the current contract QA\u002FRA consultant. You state that appropriate staff has received training on the revised SOPs and forms. You have not completed the assessment and evaluation of the contract repair\u002Fservicer and your current contract Quality Assurance &amp; Regulatory Affairs consultant. Additionally, you have not conducted a retrospective review of related documentation to ensure compliance with updated procedures. Although your firm’s responses state that you have updated the Supplier Evaluation procedures, the revised procedures were not included for our evaluation.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically, your firm’s procedure, Process description deviation management, Rev 1, dated November 25, 2020, fails to define requirements for review of complaints to determine if they should be evaluated for Medical Device Reporting. Additionally, your firm’s complaint records do not consistently include the dates and results of investigation (e.g., covering failures involving welding breakages and safety switches). Further, a review of a sampling of complaint records found five of five records do not list the Unique Device Identification (UDI) code for the subject devices.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses dated June 1, 2023, August 11, 2023, and September 1, 2023, and conclude that they are not adequate. Your firm’s responses state that you have revised the complaint handling SOP to require dates and results of investigations and UDI code for subject devices. You also state that you have revised several forms including CAPA form and Non-Conformance Report form and trained the staff on the revised SOPs and forms. Also, you have not completed a review of complaints per the revised procedure to evaluate reportability for Medical Device Reporting and have not conducted a retrospective review of related documentation to ensure compliance with updated procedures. Although your responses state that you have updated the complaint handling procedures, the revised procedures were not included for our evaluation.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain procedures to ensure that the design requirements relating to a device are appropriate and address the intended use of the device, including the needs of the user and patient, as required by 21 CFR 820.30(c). Specifically, your firm does not have procedures for defining a mechanism to resolve incomplete, ambiguous, or conflicting design requirements.\u003C\u002Fp>\n\n\u003Cp>As of September 13, 2023, you have not provided a response to this observation.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish and maintain procedures for validating the device design under defined operating conditions on initial production units, lots, or batches, or their equivalents, as required by 21 CFR 820.30(g). Specifically, your firm’s design validation procedure, Rev 1, dated January 22, 2021, does not fully define requirements to ensure devices are designed to meet user needs and intended uses. For example, the procedure fails to a) require the evaluation to be carried out on initial production units or their equivalents; b) require the evaluation to be carried out under actual or simulated use conditions.\u003C\u002Fp>\n\n\u003Cp>As of September 13, 2023, you have not provided a response to this observation.\u003C\u002Fp>\n\n\u003Cp>5. Failure to establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i). Specifically, your firm does not have procedures for defining control for changes to existing device design requirements and design results, to include a) describing the changes and the reason for the changes; b) determining the need to verify and\u002For validate the changes; c) determining impact on the design risk analysis; d) determine any new regulatory requirements, such as premarket clearance or approval, as needed.\u003C\u002Fp>\n\n\u003Cp>As of September 13, 2023, you have not provided a response to this observation.\u003C\u002Fp>\n\n\u003Cp>6. Failure to establish and maintain procedures to control all documents, as required by 21 CFR 820.40. Specifically, your firm’s document controls procedure, Rev 1, dated December 15, 2020, does not require the approval of quality system documents to include the signature of the approving personnel and the date of that signature. Additionally, your firm has not fully implemented the current document controls procedure, which requires that you assign a unique document number to each quality system document, as multiple procedures do not feature a unique document number.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses dated June 1, 2023, August 11, 2023, and September 1, 2023, and conclude that they are not adequate. Your firm’s responses state that you have revised the document controls SOP to implement Acrobat sign and included the requirement of signature of approving personnel and date on the approval of quality system documents, as well as to include a unique document number to each quality system document. However, you have not conducted a retrospective review of related documentation to ensure compliance with updated procedures. Although your response states that you have updated the document controls procedures, the revised procedures were not included for our evaluation.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case #667325 when replying. If you have any questions about the contents of this letter, please contact: Lu Jiang at +1(240)402-5779.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Robert Ochs, Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT8: Office of Radiological Health\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>Cc:\u003Cbr>\nGreg Swanson\u003Cbr>\nUS Agent\u003Cbr>\nEmergo Global Representation LLC\u003Cbr>\n2500 Bee Cave Road, Building 1, Suite 300\u003Cbr>\nAustin, Texas 78746\u003Cbr>\nUSAgent@UL.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nPelin Sari\n\nRecipient Title\n\nChief Executive Officer\n\nSonesta Medical AB\n\nIndustrivagen 7\n\n171 48 Solna\n\nSweden\n\n(b)(6)@sonestamedical.se\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nSeptember 22, 2023\n\nDear Ms. Sari:\n\nDuring an inspection of your firm located in Solna, Sweden on June 5, 2023, through June 7, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Model 6210 radiographic table and Model S2 and S3 cystometric tables. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from you dated June 1, 2023, August 11, 2023, and September 1, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specific requirements, as required by 21 CFR 820.50(a). Specifically, your firm’s current purchasing controls procedure, Supplier Evaluation, Rev 2, dated April 7, 2021, fails to define the frequency, type, and extent of control to exercise over suppliers, contractors, and consultants, based on the results of periodic evaluation. Additionally, your firm has not evaluated your contract repair\u002Fservicer, and the current contract Quality Assurance & Regulatory Affairs consultant. Further, your firm failed to maintain records covering evaluation of the current contract Quality Assurance & Regulatory Affairs consultant, who has been assisting your firm in overseeing and maintaining their Quality System procedures since the year 2020.\n\nWe reviewed your firm’s responses dated June 1, 2023, August 11, 2023, and September 1, 2023, and conclude that they are not adequate. Your firm’s responses state that you have revised the Supplier Evaluation SOP 1) to include the frequency and\u002For period for evaluation of suppliers, contractors, and consultants, 2) to include the type and extent of control to exercise over suppliers, contractors and consultants based on the results of the periodic evaluation, 3) to include evaluation of the contract repair\u002Fservicer for the Model 6210 radiographic table and Model S2 and S3 cystometric tables, and 4) to include requirements for assessment of contractors, consultants, and evaluation of the current contract QA\u002FRA consultant. You state that appropriate staff has received training on the revised SOPs and forms. You have not completed the assessment and evaluation of the contract repair\u002Fservicer and your current contract Quality Assurance & Regulatory Affairs consultant. Additionally, you have not conducted a retrospective review of related documentation to ensure compliance with updated procedures. Although your firm’s responses state that you have updated the Supplier Evaluation procedures, the revised procedures were not included for our evaluation.\n\n2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically, your firm’s procedure, Process description deviation management, Rev 1, dated November 25, 2020, fails to define requirements for review of complaints to determine if they should be evaluated for Medical Device Reporting. Additionally, your firm’s complaint records do not consistently include the dates and results of investigation (e.g., covering failures involving welding breakages and safety switches). Further, a review of a sampling of complaint records found five of five records do not list the Unique Device Identification (UDI) code for the subject devices.\n\nWe reviewed your firm’s responses dated June 1, 2023, August 11, 2023, and September 1, 2023, and conclude that they are not adequate. Your firm’s responses state that you have revised the complaint handling SOP to require dates and results of investigations and UDI code for subject devices. You also state that you have revised several forms including CAPA form and Non-Conformance Report form and trained the staff on the revised SOPs and forms. Also, you have not completed a review of complaints per the revised procedure to evaluate reportability for Medical Device Reporting and have not conducted a retrospective review of related documentation to ensure compliance with updated procedures. Although your responses state that you have updated the complaint handling procedures, the revised procedures were not included for our evaluation.\n\n3. Failure to establish and maintain procedures to ensure that the design requirements relating to a device are appropriate and address the intended use of the device, including the needs of the user and patient, as required by 21 CFR 820.30(c). Specifically, your firm does not have procedures for defining a mechanism to resolve incomplete, ambiguous, or conflicting design requirements.\n\nAs of September 13, 2023, you have not provided a response to this observation.\n\n4. Failure to establish and maintain procedures for validating the device design under defined operating conditions on initial production units, lots, or batches, or their equivalents, as required by 21 CFR 820.30(g). Specifically, your firm’s design validation procedure, Rev 1, dated January 22, 2021, does not fully define requirements to ensure devices are designed to meet user needs and intended uses. For example, the procedure fails to a) require the evaluation to be carried out on initial production units or their equivalents; b) require the evaluation to be carried out under actual or simulated use conditions.\n\nAs of September 13, 2023, you have not provided a response to this observation.\n\n5. Failure to establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i). Specifically, your firm does not have procedures for defining control for changes to existing device design requirements and design results, to include a) describing the changes and the reason for the changes; b) determining the need to verify and\u002For validate the changes; c) determining impact on the design risk analysis; d) determine any new regulatory requirements, such as premarket clearance or approval, as needed.\n\nAs of September 13, 2023, you have not provided a response to this observation.\n\n6. Failure to establish and maintain procedures to control all documents, as required by 21 CFR 820.40. Specifically, your firm’s document controls procedure, Rev 1, dated December 15, 2020, does not require the approval of quality system documents to include the signature of the approving personnel and the date of that signature. Additionally, your firm has not fully implemented the current document controls procedure, which requires that you assign a unique document number to each quality system document, as multiple procedures do not feature a unique document number.\n\nWe reviewed your firm’s responses dated June 1, 2023, August 11, 2023, and September 1, 2023, and conclude that they are not adequate. Your firm’s responses state that you have revised the document controls SOP to implement Acrobat sign and included the requirement of signature of approving personnel and date on the approval of quality system documents, as well as to include a unique document number to each quality system document. However, you have not conducted a retrospective review of related documentation to ensure compliance with updated procedures. Although your response states that you have updated the document controls procedures, the revised procedures were not included for our evaluation.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case #667325 when replying. If you have any questions about the contents of this letter, please contact: Lu Jiang at +1(240)402-5779.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nRobert Ochs, Ph.D.\n\nDirector\n\nOHT8: Office of Radiological Health\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCc:\n\nGreg Swanson\n\nUS Agent\n\nEmergo Global Representation LLC\n\n2500 Bee Cave Road, Building 1, Suite 300\n\nAustin, Texas 78746\n\nUSAgent@UL.com","Sonesta Medical AB","sonesta-medical-ab-667325-09222023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsonesta-medical-ab-667325-09222023","2026-10-26T08:10:01.487143+00:00","2023-12-26","667325","2024-02-28","Pelin Sari","2026-08-20T00:25:09.984+00:00","2023-09-22",19,{"510k":376,"classification":377,"enforcement":378,"event":379,"event_backfill":380,"pma":381,"warning_letter":382},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]